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Abstract 
Discovery and effects of pharmacological inhibition of the E3 ligase Skp2 by 
small molecule protein-protein interaction disruptors 
By John Kenneth Morrow, M.S. 
Advisor: Shuxing Zhang, Ph.D. 
 
Skp2 (S-phase kinase-associated protein 2), one component of the SCF E3 
ubiquitin ligase complex, directly interacts with Skp1 and indirectly associates with 
Cullin1 and Rbx1 to bridge the E2 conjugating enzyme with its protein substrate to 
execute its E3 ligase activity. Skp2 is an Fbox protein (due to it containing an Fbox 
domain) and it is the rate-limiting component of the SCF complex. Skp2 targets 
several cell-cycle regulatory proteins for ubiquitination and degradation; most notable 
and significant for cancer are the cyclin-dependent kinase inhibitor, p27. Skp2 is an 
oncogene and studies have shown that over-expression of Skp2 leads to increased 
degradation of p27 and increased proliferation in several tumor types. Additionally, 
Skp2 is over-expressed in multiple human cancers. Clearly, Skp2 represents an 
attractive target for attenuating p27 ubiquitination and subsequent cell cycle 
progression. However, Skp2 does not have an easily identifiable and druggable 
“pocket” on which small molecules can bind; it interacts with Skp1 through the Fbox 
domain and binds to an accessory protein called Cks1 to bind to p27. Despite this 
hurdle, in this study, two selective small molecule inhibitors of the Skp2 SCF 
complex were discovered via an in silico screen that disrupt two places: the 
Skp1/Skp2 interaction site and the p27 binding site via targeting hot-spot residues. 
vi 
 
The Skp1/Skp2 inhibitor disruption resulted in restoring p27 levels in the nucleus and 
blocks cancer progression and cancer stem cell traits. Additionally, the inhibitors 
phenocopy the effects of genetic Skp2 deficiency. Two specific residues on Skp2 
were predicted to bind to this Skp1/Skp2 inhibitor: Trp97 and Asp98.  When these 
residues were mutated to alanine, the inhibitor lost its ability to bind to Skp2. To 
investigate the flexibility and understand the conformational change upon inhibitor 
binding and dynamics of the SCF complex, molecular dynamics simulations, 
homology models, and structural analysis was carried out on the complex with and 
without the inhibitors. These simulations showed that the contributions of the N-
terminal tail region of Skp2 does not contribute directly to the binding of these 
inhibitors; but its conformation is important in the context of the other members of the 
SCF complex. Further dynamics analysis validated the mutagenesis results, showing 
that the two Skp2 mutants (Trp97Ala, Asp98Ala) that retained Skp1 binding but 
blocked inhibitor binding were stable, whereas the mutant that was unable to retain 
Skp1 binding (Trp127Ala) showed destabilization in the Fbox domain. Finally, active 
recruitment events after post-translational modifications are shown to be possible by 
the interaction of phosphorylated Ser256 on Skp2 with Lys104 loop region on Cul1 
The model shows that this is due to the significant flexibility in the F-box domain of 
Skp2, making this interaction very likely. These results show that Skp2 is a promising 
target on which protein-protein interaction disruptors can be designed, and 
consideration of the dynamics of protein complexes is required to understand ligand 
binding. 
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Chapter 1: Introduction 
1.1 Targeting Protein-Protein Interactions to Expand the Drug-Target Space 
1.1.1 Current state of Small Molecule Cancer Therapies 
 Despite a reported spending of $50 billion on research in the pharmaceutical 
industry into small molecule therapeutics (reported in 2006), there is a surprising lack 
of information on the known universe on which these therapeutics act upon. It has 
been proposed in 2006 that the consensus number of drug targets for all classes of 
therapies that have been FDA approved numbers only 324 (1). This estimate is rather 
liberal when compared to other studies that use slightly different metrics and at a 
higher but still modest count of 667 (2). When one breaks down the approved drugs 
based on the target type, the overwhelming majority of them target very few major 
classes: G-protein coupled receptors (GPCRs), nuclear receptors, ion channels or 
enzymes (most prominent of the enzyme category are the kinases) (1, 3) (Figure 1. 
Distribution of Approved drugs sorted by target type. Enzymes and GPCRs make up 
over 2/3 of all targets.. More recent and comprehensive studies in the last year place 
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the human-genome derived practical target count pathway analysis that put the 
number at 273 (4), or even 218 (3).  
 
         
Figure 1. Distribution of Approved drugs sorted by target type. Enzymes and GPCRs 
make up over 2/3 of all targets. 
The breakdown of the ChEMBL database conducted as of writing shows that 
out of 7,610 total targets, 3983 or 52% are in the “enzyme” category (5). This 
paradigm follows the classic drug-target model of considering a target druggable by 
targeting the active-site of the protein and blocking natural ligands of these 
receptors/enzymes. This becomes problematic when one considers that the non-
enzyme classification of proteins expressed in the proteome make up the majority of 
proteins involved in signaling pathways, transport, transcription, translation and other 
Enzymes - 47%
GPCRs - 30%
Ion Channels 7%
Nuclear Receptors and Transporters - 8%
Other Receptors - 4%
Integrins - 1%
DNA - 1%
Micellaneous - 2%
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vital cellular functions. Clearly then the state of small molecules remains very 
narrowly focused on archetypes and models that can be argued as outdated especially 
when one considers that many diseases, most notably cancer, remain best described as 
a disease “at best, minimally controlled by modern medicine” (6). 
 
1.1.2 PPIs and Their Potential as a Therapeutic Target 
The inherent complexity of cancer (and other diseases that have multiple 
pathways involved in their phenotype and have poor prognoses) leads us to the 
conclusion that the paradigm of “one drug, for one target, for one disease” (also 
sometimes referred to as “low-hanging fruit” is not capable of reducing the disease 
burden. One must expand the drug-target space and consider unconventional target 
types. 
To expand this drug-target space and take into account the functions of proteins 
in their relevant pathways, it is critical to consider that most cellular proteins do not act 
as isolated units; they often form complexes with other proteins (7). Formation of these 
protein complexes require specific interactions that become the foundation for almost 
all biological processes, especially signal transduction. The complexity of these 
protein-protein interactions (PPIs) is what primarily provides them with their diversity 
in functions. From this complexity, distinctions can be made in the shape, size and 
surface complementarity of protein-protein interactions (8-12). These interactions can 
be described as locally optimized, with the clustered, networked, densely packed 
residues contributing mainly and cooperatively to the stability of the complex (13). The 
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sites by which proteins interact with their partners are formed by surfaces with adequate 
electrostatic complementarity and shape (14-17). Other major factors that influence 
protein-protein interactions are hydrophobicity (9, 18) and electrostatic interactions 
(16), and flexibility (14-16). While interfaces with an area as small as 1150-1200 Å2 
have been described in low-stability and short-lived complexes, “standard-size” 
interfaces (19) are roughly 1600 Å2 (+/- 400 Å2) and involve only small changes in 
conformation (12) and approximately 750-1500 Å2 of the surface area buried in each 
protein (20). The “large” interfaces bury 2000-4660 Å2 and occur mostly between G-
protein and other components of signal transducers, and between proteases and one 
class of their inhibitors (17, 19). Understanding the connection between structure and 
function of molecular systems can be achieved through examination of the protein-
protein associations, and enables the characterization of their energetic properties (21, 
22). When one considers that there are over 45,000 protein-protein pairs in yeasts, it 
should become apparent that the number of potential, druggable targets in humans is 
enormous (23).  
Cellular dysfunctions from faulty protein-protein interactions are the underlying 
cause of a variety of diseases, including cancer and neurological disorders (24, 25). 
Despite the critical importance and relative abundance of protein-protein interactions, 
very few small-molecule PPI inhibitors have made the difficult transition from hits to 
marketed drugs. While peptide-based inhibitors derived from 5-50 amino acids of a 
single member of an interacting protein pair are easy to construct, conversion of these 
peptides to “drug-like” molecules has proved to be the biggest hurdle (26, 27). One 
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significant part of this problem is the nature of the PPIs; classic protein inhibitors 
primarily target well-defined grooves and pockets (28, 29), whereas PPIs are usually 
large and relatively planar surfaces that were originally considered not conducive to 
druggability by “drug-like” molecules (16, 30). Advancements in two areas: the 
understanding of the physical nature of PPIs as well as the increasing diversity and 
quality of small, lead-like compounds have allowed PPIs into the realm of valid targets, 
thereby greatly expanding the available target space for a plethora of diseases (31, 32).  
 
1.2 Hot spots as a Basis for Drug Discovery Efforts 
Used with explicit permission from Bentham Science Publishers in the article: 
Current Pharmaceutical Design. 2012;18(9):1255-65. 
 
1.2.1 Introduction to hot spots 
It has been well established that for all proteins, the energy distribution is not 
uniform across a given protein-protein interaction; that a small subset of residues will 
have a more significant contribution to the binding free energy than other residues (13, 
33-40). Clackson and Wells’ pioneering study of the binding of human growth hormone 
to its receptor discovered these important residues and coined the term ‘hot spots’ (33). 
Later work revealed that hot spots occupy only a fraction of the larger interface area 
(34), and proclaimed a more precise definition of a hot spot as a residue whose mutation 
to alanine results in a decrease of at least 2.0 kcal/mol in binding free energy 
(ΔΔGbinding) (41).  Binding free energy, or ΔΔG, is defined as ΔGmut – ΔGwt, where ΔGwt 
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and ΔGmut are the binding free energies upon complex formation of the wild-type and 
alanine-mutated proteins, respectively. It has been calculated that 9.5% of interfacial 
residues are hot spots (42).  
The composition of hot spots is distinctive and not random, with tryptophan 
(21%), arginine (13.3%), and tyrosine (12.3%) being the only three fundamental amino 
acids having more than 10% frequency (34, 43). The complex formed by human growth 
hormone and its receptor is shown with its dominating tryptophan residues (Figure 2). 
Out of the 29 interfacial residues in this complex, only four hot spots have ΔΔGbinding 
greater than 4.5kcal/mol, and two of them are tryptophan. Tryptophan’s unique function 
can be partially explained by its large and aromatic π-interactive nature (44) as well as 
its large hydrophobic surface and protective effects from water (45). When the bulky 
tryptophan residue is mutated to alanine, the difference in size generates a large cavity 
that creates a highly complex destabilization (34). 
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Figure 2. Example of typical hot spot residues of human growth hormone (green 
cartoon) and its receptor (blue sticks) (PDB Code 1a22). Three of the four hot spot 
residues of the receptor are represented in sticks, hydrogen bonds are shown in dashes. 
This result was displayed using PyMOL (46). 
Consideration of the structural aspects of hot spots (47, 48) reveals that they are 
cooperative and structurally conserved (13, 36, 49, 50). This structural conservation is 
also apparent when examining the rate of mutation of surface residues; protein 
interfaces (51) and functional sites (52) mutate at a relatively slower rate when 
compared to other surface residues. Mutations of the interactions between proteins may 
occur largely by coevolution, where substitutions in one protein trigger reciprocal 
changes in the other protein (51). Numerous studies of protein-protein interfaces have 
revealed the presence of hot spots where binding affinity and specificity can be resolved 
by an epitope that is consisting of only a small portion of interfacial residues (34, 35, 
53-55). Clearly, the structural conservation of hot spots and their correlating binding 
affinity make them attractive drug targets for small molecule inhibition. It is not 
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surprising then, that hot spots have been considered in the design of small molecule 
inhibitors of unwanted protein-protein interactions, and several potential drugs show 
great promise in targeting hot spots (20, 25, 42, 56-63). 
 
1.2.2 Hot spots as potential drug targets 
Hot spots can facilitate drug design in two ways. First, the binding site can be 
predicted by the presence of hot spots, and this binding site can be considered a starting 
point to perform docking and/or screening of ligands (64). Second, rigid docking could 
exploit the relatively less flexible hot spots, and improvements in protein docking 
would be achieved by choosing dominant conformation of the hot spot side chains 
resulting from molecular dynamics (MD) simulations rather than the unbound X-ray 
conformation (65, 66). Initial studies have shown that hot spots have physico-chemical 
properties that may be predictive (42, 53), and this prediction goes a long way to 
decipher the functional mechanism of proteins. From the mechanisms, valuable 
information can be used for a wide range of purposes: mutant proteins can be designed 
that will validate the interactions, drugs can be developed that target the protein-protein 
interactions, and molecular recognition can be expanded to help us understand complex 
signaling pathways.  
Successful identification of hot spots involved in protein interfaces is crucial in 
determining potential active sites, and the corresponding druggability of a protein 
target. It is only after the completion of this step that rational, structural based drug 
design can begin. Systematic mutagenesis of protein-protein interactions has yielded a 
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wealth of information on the hot spots themselves, but there are significant inroads that 
can be made as to the general nature of these hot spots.  Unfortunately, no general 
patterns of shape, charge or hydrophobicity exist that can be used to predict which 
residues form hot spots (12, 16). Additionally, residue conservation is rarely sufficient 
for accurate prediction of protein interfaces (50). Further potential pitfalls become 
apparent when considering the inherent plasticity and expansive diversity of PPIs.  
Despite these challenges, the increasing use of computational methods holds 
high potential to provide accurate analysis in prediction of hot spots at a fraction of the 
time and cost for conventional, experimental techniques. Advancement in both 
hardware processing power as well as software predictive models will increase the 
speed and the accuracy of hot spot predictions. The increasing rate of both 
crystallographically resolved protein-protein complexes as well as experimental alanine 
mutagenesis studies will provide a more comprehensive dataset from which to further 
increase the accuracy of computational prediction of hot spots. Composite approaches 
that incorporate initial computational predictions, and are then validated against 
experimental means provide the most comprehensive understanding of the nature of hot 
spots.  These validations will vastly improve the predictive power of in silico techniques 
by continually evolving from the increasing pool of data from which they are built upon. 
 
1.2.3 Current Experimental Methods to predict hot spots 
Experimental identification of hot spot residues is primarily performed by 
alanine scanning. This process involves mutation of a residue of interest to alanine, and 
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recording the resulting binding energy changes. If this mutation results in a marked 
drop in the binding constant (typically tenfold or higher), the residue is considered a 
hot spot (53). Substitution with alanine removes all atoms in the side chain past the β-
carbon. Alanine is used because of its relatively inert methyl functional group without 
contributing additional flexibility (67-69). Mutation to glycine would also remove the 
side chain, but is not used since it can introduce unwanted conformational flexibility in 
the protein backbone (70).  
In the context of protein folding, a mutation on a hot spot residue can be considered to 
destabilize the bound ensemble state relative to the unbound one (71, 72). It follows 
then that alanine scanning determines the specific contribution of residues to the 
ensemble’s stability, and resulting protein function.  
 If we are to consider the plasticity of protein interfaces, alanine scanning 
mutations affect free energy surfaces that can lead to differential effects of the bound, 
unbound state, or both (Figure 3). It becomes advisable then to interpret both the 
structure and energetic properties of each ensemble to rather than a specific residue 
interactions (53). Initially, alanine scanning was applied towards human growth 
hormone and the growth hormone binding protein (33), and this technique has proved 
invaluable in PPI analysis and hot spot detection (12, 34, 39, 53, 61). The resulting data 
from alanine scanning can be deposited in the Alanine Scanning Energetics Database 
(ASEdb), and verified experimental hot spots from the literature are found in the 
Binding Interface Database (BID) (41, 73). These repositories, while useful, have two 
drawbacks. First, hot spot information from experimental studies is limited to very few 
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complexes. Secondly, it is not recommended to interpret this data to specific residue 
interactions (53).   
 
Figure 3. Mutations from alanine scanning can affect free energies of bound and 
unbound states. Mutant A is an ideal result where only the complex is destabilized, and 
the binding free energy with respect to the wildtype (ΔΔG) can be attributed to specific 
changes in the PPI contacts. Mutant C affects both states simultaneously. The measured 
binding free energy difference from B and C mutants must be interpreted cautiously. 
(Figure adapted from (53): “Unraveling hot spots in binding interfaces: progress and 
challenges”, used with explicit permission from Current Opinion in Structural Biology). 
Experimental mutagenesis of target proteins for elucidation of hot spots is not 
applicable on a large scale since individual mutants must be purified and analyzed 
separately (53). Systematic analysis requires each alanine-mutated protein to be 
constructed, placed in an expression system sometimes refolded, then the resulting 
protein activity is assessed in an in vitro assay (70). While techniques such as 
reflectometric interference spectroscopy (74) and “shotgun scanning” (75) have 
alleviated some of the labor involved, experimental hot spot analysis is still very time 
consuming and expensive. The theoretical and computational prediction of hot spots 
has become one of the most attractive and challenging topics in biochemistry, 
12 
 
biophysics, and bioinformatics, and each of these disciplines offer unique strategies to 
confront this challenge.  Next, we will outline the methods and tools available for 
computational hot spot prediction (Table 1). 
Hotspot 
prediction 
Properties Used Availability Technique Reference 
FoldX Energy-based 
Tool & 
Server 
Computational 
alanine scanning 
(76) 
Robetta Energy-based Server 
Computational 
alanine scanning 
(77) 
PP_Site 
Energy, structure-
based 
Tool Simple algorithm (78) 
FTMap Energy –based 
Tool & 
Server 
Probe based rigid 
body docking 
with fast Fourier 
transform 
correlation 
(79, 80) 
PCRPi, 
PCRPi-W 
Energy, structure, 
evolutionary 
Tool & 
Server 
Bayesian 
Network 
(81, 82) 
Guhary & 
Chakrabarti 
H-bonding, 
interface location 
Tool Simple algorithm (83) 
KFC2 
ASA, various 
structural features 
Server 
Support Vector 
Machine (SVM) 
(84) 
MINERVA 
Structure, 
sequence, 
Tool 
Descision Tree, 
SVM 
(85) 
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molecular 
interaction 
HSPred Energy-based Tool 
SVM (Residue 
specific) 
(86, 87) 
Rajamani Side chain ΔASA Tool 
Molecular 
Dynamics 
(65) 
Higa & Tozzi 
Structural, 
evolutionary 
Tool SVM (88) 
Grosdidier & 
Recio 
Energy-based 
(Docking) 
Tool 
Normalized 
interface 
propensity 
(89) 
HotPoint & 
HotSprint 
Conservation, 
accessibility, 
residue propensity 
Server & 
Database 
Empirical 
formula 
(46, 90) 
Table 1. Summary of Hot Spot Prediction Methods 
 
1.2.4 Current Computational Methods to predict hot spots 
1.2.4.1 Energy-based Computational Methods 
Computational alanine scanning estimates the energetic contribution of each 
residue to the total binding energy via virtual alanine scanning. The process for 
computational alanine scanning is briefly described as follows: Using a side chain 
repacking algorithm, mutation of each interface residue to alanine is performed. Then, 
a numeric energy function is used to evaluate the bound and unbound states of the 
original and mutant proteins. Finally, the change in the binding energy (ΔΔG) of each 
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mutation is calculated thermodynamically. This approach requires the complex 
structure as input and is best for providing an accurate estimation of free energy charges 
(91).  
One such algorithm is FOLDEF, available as the FoldX web server. It was 
developed by Guerois et al., and was used to predict the energetic effect of mutations 
on protein complexes. FOLDEF was built on the FoldX complex energy function, 
which systematically truncates side chains between two proteins (or protein-peptide) to 
alanine, then calculates change in the binding energy after relaxation (76). The complex 
energy function contains terms for: implicit and explicit desolvation, van der Walls 
forces, hydrogen bonding, Coulombic electrostatics, changes in entropy, and dipole 
interactions. FOLDEF was trained on a database of 339 mutants and gave a global 
correlation of 0.83 and a standard deviation of 0.81kcal/mol when tested on a database 
of 1,030 mutants. FoldX predictions have a linear correlation with experimental binding 
energies, and the standard deviation of predictions from a linear regression of the data 
is 0.88 kcal/mol (92).  
Similarly, Kortemme and Baker used a simple physical model (named Robetta) 
that includes various parameters including: Lennard Jones interactions, solvation 
interactions, packing interactions, implicit solvation and hydrogen bonding to calculate 
free energy (77). Similar to FoldX, the Robetta energy function was parameterized from 
protein stability data. Robetta mutates side chains to alanine and locally repacks the 
structure within 5Å of the mutant residue, while keeping the rest of the protein 
unchanged. The predicted changes in binding energies form the basis for hot spot 
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predictions (93). When tested on a database of 743 mutations in the interface of each 
protein (from the ASEdb), Robetta was able to correctly predict 79% of hot spot 
residues with a 1.0 kcal/mol cutoff, and an average error of 1.06 kcal/mol (93, 94). The 
implicit solvation model has two potential errors: Robetta cannot identify hot spots that 
are involved in water-mediated hydrogen bonds, and when waters can compensate for 
a mutation, it will incorrectly predict mutations as hot spots.  
Gao et al. developed a structure-based method, called PP_SITE, based only on 
three properties: H-Bond, hydrophobic and van der Walls interactions. PP_SITE is 
developed based on POCKET, which is a module of the multi-purpose program 
LigBuilder (95). PP_SITE creates a box with regularly spaced grids to cover interfacial 
residues and uses probes for each structural property to screen those grids. The probes 
include a positively charged sp3 nitrogen (ammonium cation), a negatively charged sp2 
oxygen (as in a carboxyl group), and a neutral sp3 carbon atom (methane). For each 
grid, the scores are calculated and a grid label is assigned to it. This method then offers 
the ability to analyze the decomposition of the contributions of regions in the predicted 
hot spots, enabling comprehensive exploration of the properties of the protein-protein 
interface. PP_SITE was tested on 13 complexes with 250 alanine mutations on 
interfacial residues. For the 75 hot spot residues in this set, 66 were predicted correctly, 
giving an 88% success rate (ΔΔG > 1.5 kcal/mol) (78).  
FTMap (79) is a recent approach that uses docking results of small organic 
probes to discover hot spots. It was originally conceived as a computational equivalent 
of the experimental multiple solvent crystal structures (MSCS) technique, where a 
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target protein is co-crystallized in the presence of a diverse set of organic solvent probe 
molecules. It has been shown that molecular probe distribution on the protein surface 
allows for discovery and characterization of potential ligand interaction sites (96). The 
FTMap algorithm samples billions of positions from 16 small molecule probes (with 
varying hydrophobicity and hydrogen-bonding capacity) globally across the total 
protein surface using a fast Fourier transform correlation approach. The poses are 
evaluated with an empirical scoring function that includes van der Waals terms, 
electrostatic interaction energy, a cavity term to represent the effect of nonpolar 
enclosures, and a structure-based pair-wise interaction potential. The 2000 most 
favorable docked conformations are energetically minimized and clustered. The lowest 
energy clusters from different and overlapping probe types are clustered again into 
consensus sites; the largest consensus site is generally located at the most important 
sub-site of the protein binding site. FTMap is available as a publically-available server, 
where only the PDB file or a PDB code of the protein is required. The output shows the 
six lowest energy cluster representatives as well as the number of non-bonded and 
hydrogen bonds between the probes and each residue in the protein (Figure 4). 
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Figure 4. FTMap results for carbonic anhydrase I (PDB 2CAB) displayed in PyMOL.  
The pocket nearest to the center contains 19 docked probes, and is the binding site for 
drugs acetazolamide, methazolamide, and foscarnet 
 
Another recent method called PCRPi (Presaging Critical Residues in Protein 
interfaces) is based on the integration of three main sources: energetic, structural, and 
evolutionary determinants by using Bayesian networks to unify them into a common 
probabilistic framework (81). Specifically, the attributes are: interaction engagement 
index, topographical index, four separate conservation indexes (ANCCON, 
ANC3DCON, CON, and 3DCON), and the BE index. The BE index is an in silico 
alanine scan using FoldX (76). This method has been developed as a web server (called 
PCRPi-W) where users can enter a PDB code or upload a complex, as well as select the 
type of Bayesian network architecture (naïve or expert) (82). Two different types of 
training sets are available for users: Ab+, which contains entire dataset of 636 interface 
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residues, including antigen-antibody complexes, and Ab-, which does not include these 
antigen-antibody complexes. Using a BID dataset derived in Tuncbag et al. (97), the 
PCRPi-W method recorded a precision of 0.79 and recall of 0.64 when compared in a 
head-to-head comparison with other computational methods (82). Also of note, the 
PCRPi-DB is the result of annotating and archiving the entire Protein DataBank (98) 
using PCRPi (99). 
Finally, Guharoy and Chakrabarti used only the two criteria: hydrogen bonding 
across the interface, and location in the interface core to predict more than 80% of hot 
spots with experimental contribution of core residues to the energy of binding (ΔΔG > 
2 kcal/mol) (83). An experimental database of 462 mutants from 28 interfaces was used, 
out of which 143 form hydrogen bonds. The average unsigned error (calculated as | 
ΔΔGcalc - ΔΔGexp|) for all mutations was 1.04 kcal/mol. This technique is 
computationally inexpensive due to its small number of parameters, and is hence 
potentially applicable across a large set of complexes. One limitation of this technique 
is that coupling and indirect effects cannot be considered explicitly. 
 
1.2.4.2 Molecular Dynamics-Based Methods 
These types of methods are also energy-based, but use more intensive molecular 
dynamics computations to provide an atomic level of hot spot prediction. Therefore we 
grouped them separately. One particular study using MD techniques looked at anchor 
residues, which are residues that have limited mobility and strongly correlate with 
conserved hot spot residues (100). The study of anchor residues was conducted by 
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Rajamani et al. on 11 different proteins and concluded that these residues have side 
chains that experience the largest decrease in solvent-accessible surface area (>100 Å2) 
when in a complex (65). From their analysis of 39 complexes, they concluded that 
anchor residues have high structural conservation across different homologs. They also 
found that the anchor residue (primarily from the smaller of the two proteins) binds to 
a structurally constrained binding groove of the other protein that stabilizes the bound 
intermediate state, and the larger the buried surface area of the main anchor residue, the 
fewer secondary anchors are required for complex formation (65). This work was based 
on another group’s nanosecond explicit solvent MD simulations of three complexes and 
the observation that key side chains frequently display the rotamer conformations of 
the complex before any receptor-ligand interaction (101). 
Huo et al. applied a MM-PBSA (molecular mechanics-Poisson-Boltzmann 
surface area) approach to the human growth hormone-receptor complex (hGHpb). 
Here, protein-protein interfaces are probed with explicit molecular mechanical 
energies, continuum implicit solvation free energies, and approximations of vibrational 
entropy changes. All of these terms are then averaged over each conformation provided 
by the MD simulation. Using free energy calculations of snapshots equally spaced along 
a single dynamical trajectory, they were able to predict the experimental ΔΔG of 
binding with an average error of ±1kcal/mol for the alanine mutations of hydrophobic 
and polar/charged residues without buried salt bridges (102). The full structural and 
energetic consequences of a mutation of a bound and unbound state can be adequately 
described when the proper thermodynamic cycle is employed (102). This 
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comprehensive analysis requires repeated sampling of the mutant in both bound and 
unbound forms, which is computationally expensive when compared to other methods, 
especially on a large scale. To circumvent this potential computational roadblock, 
approximations to generate the mutant ensembles can be used which simulate first the 
un-mutated protein, then are post-processed to introduce mutations to alanine (64, 103). 
 
1.2.4.3 Machine Learning-based Methods 
The third method uses learning based methods (commonly called machine 
learning, or ML). This method is very novel, considers a diverse series of factors, and 
will be used in future drug discovery efforts. The KFC (Knowledge-based FADE and 
Contacts) uses a rule-based model created by a machine learning algorithm to elucidate 
structural patterns that are indicative of hot spots. The KFC model is actually a 
combination of two learned decision tree models: K-FADE uses the residue size and 
radial distribution of shape specificity and interface points calculated by Fast Atomic 
Density Evaluation (FADE) (104), and K-CON uses the residue’s intermolecular 
atomic contacts, hydrogen bonds, interface points, and chemical types (105). These 
structural features return a binary answer as to whether a residue is a hot spot or not, 
and a confidence score with each prediction. Alone KFC predicted 58% of alanine 
scanning hot spots with precision of 49% and recall of 58% when a hot spot is 
associated with ΔΔG > 2kcal/mol. When KFC was combined with Robetta’s 
computational alanine scanning technique described previously, (the combined model 
called KFC+Robetta-Ala, or KFCA) (93), the predictive accuracy jumps to 72%. The 
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KFCA analysis was applied to two complexes: the calmodulin (CaM)/smooth muscle 
myosin light chain kinase (smMLCK) and to the bone morphogenetic protein-2 (BMP-
2)/BMP receptor-type I (BMPR-IA) complex. Both complexes had strong correlation 
between KFC hot spot predictions and experimental mutations, and in the case of 
BMP2, KFC was able to highlight a region where alanine mutation of two key residues 
(Phe49 and Pro50) are more disruptive than the sum of the individual mutations (106). 
A more recent study also used the KFC method in the study of the interaction of the 
antibody, called 19D9D6, and the hepatitis C virus (HCV). Comparison of MD 
simulation results matched three residues that were predicted as hot spots in KFC that 
are important for the interaction between the virus and antibody (107). The KFC 
method is now available via an interactive, public web server, where users can submit 
complexes (via uploaded file, or providing the PDB code) and view results for each job, 
as well as upload scores from Robetta’s alanine scanning, ConSurf sequence 
conservation, or experimental data (105).  
The KFC method has been recently improved, with two new models trained 
using a support vector machine (SVM) (108): KFC2a and KFC2b. KFC2a is composed 
of eight features primarily related to solvent accessibility, interface position, packing 
density, and local plasticity. This KFC2a model showed a true positive rate of 0.85, 
outperforming HotPoint, KFC, Robetta, and FOLDEF, despite having a slightly higher 
false positive rate than the other models. KFC2b uses seven features (two of which are 
found in KFC2a), and boasts a higher specificity (84). 
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Cho et al. applied a SVM that initially incorporates 54 multifaceted features 
from structure, sequence, and molecular interaction. The model is named MINERVA, 
an acronym of MINE, Residue VAlue. From these 54 features, decision tree selection 
is performed to identify the best feature subset. Atomic packing density, relative surface 
area burial and weighted hydrophobicity are the top three features for picking hot spots 
that were selected from the decision tree, with the weighted atomic packing density 
displaying the highest effectiveness (85). Previous hot spot and conservation analysis 
has shown that local packing density around conserved residues and hot spots is higher 
than anticipated, and a good correlation exists between local packing density and 
experimental ΔΔG (109). MINERVA displays better sensitivity, specificity, precision 
and F1 score than Robetta, FOLDEF, and KFC when tested on two different training 
sets; the best performance occurred when the model was trained on the 2 kcal/mol set 
rather than the 1 kcal/mol set (85). Their work also revealed that residue conservation 
is not ideal for correctly identifying hot spots, and that hot spots are closely related to 
π- π interactions.  
Another group that has successfully used SVM is Lise et al., who previously 
described a hybrid method in which energy terms are used as input features of a SVM 
classifier and is called HSPred (86). Their method considers basic energy terms (van 
der Waals, H-bond, electrostatic and desolvation potentials, hydrogen bonds, and 
Coulomb electrostatics) calculated from the complex structure. In a later study, this 
model was improved by 10% in overall precision and recall by creating separate SVM 
classifier predictions specifically optimized for arginine or glutamic acid residues, as 
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these amino acid types did not perform well in the original model (87). The method is 
also available as a web server and is free to non-commercial users (87). 
A set of 43 structural and evolutionary parameters were used with an SVM 
classifier in the work by Higa and Tozzi. These parameters can be grouped into the 
following types: amino acid type, evolutionary profile, conservation score, surface area, 
solvation energy, and geometry (88). When using the dataset compiled by Darnell et 
al.(106), this method had a performance of 60.4% (measured by F-Measure) that 
corresponded to a recall of 78.1% and a precision of 49.5% (88). This work is 
significant in that it does not require the complex; it can be used with only knowledge 
of the monomer. As a result, this method can be used when the interface region is 
unknown, and can prove useful for discovery of novel protein interfaces. 
Another method that does not require prior knowledge of the complex structure 
is the work from Grosdidier and Recio, whereby the analysis of rigid-body docking 
ensembles provides normalized interface propensity (NIP) values. This NIP parameter 
is obtained from rigid-body docking simulations and calculates the propensity of a 
given residue to be located at the interface. It includes electrostatics and desolvation 
scoring in its calculations for predictions (89). The NIP method was developed from 
their previous findings that highly populated low-energy regions consistently 
corresponded to proven binding sites (110). Their method has up to a 80% positive 
predictive value, but it is not exhaustive and will miss hot spots that are not directly 
involved in the interface or arise from highly specific interactions (89). 
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While machine learning methods hold great promise, it is worth mentioning that 
simple empirical models can provide better predictive power. Tuncbag et al. presented 
an empirical model based on conservation, accessible surface area (ASA), and 
knowledge-based  pairwise residue potentials of the interface residues This model 
provides 70% accuracy, higher than machine learning based methods when using 150 
residues from ASEdb as the training set (97). Later, this method was incorporated into 
a web server, called HotPoint, where users can upload a protein complex and quickly 
visualize results (46). The relative residue solvent accessibilities are calculated in the 
complex and monomer states, and the solvent mediated potentials are taken from 
Keskin et al (111). If the following two qualifications for a residue are met: the relative 
ASA in complex is less than or equal to 20%, and the total pair potential is greater or 
equal to 18.0, then that residue is labeled a hot spot (46). Change of solvent accessible 
surface area (ΔASA) upon the formation of a complex is strongly related to the 
solvation energy, which has been shown previously to be one of the most significant 
factors involved in protein-protein binding (112). This technique was also used to 
correctly identify the hot spots on Mdm2. Another database named HotSprint was 
developed by the same group. It was the first database to exploit sequence conservation 
and incorporates solvent accessibility of residues. This method gives an accuracy of 
76% that performs better than several machine-learning based methods (90). 
1.3 The Ubiquitination Pathway 
Sections reproduced from Future Medicinal Chemistry. (2015) 7(17), 2333-
2350 with implicit permission of Future Science Group 
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1.3.1 Introduction 
Ubiquitination, a step in the non-lysosomal degradation of proteins, is a 
crucial post-translational modification in eukaryotic organisms. Rapid and timely 
degradation of transcriptional regulators and other proteins by the ubiquitin-
proteasome system (UPS) regulates a wide variety of cellular processes(113). 
Ubiquitination involves covalent attachment of ubiquitin, a small 8-kDa protein, to a 
substrate and results in recognition and shuttling of the substrate to the 26S 
proteasome complex for degradation (114). It is important to note that the 
ubiquitination process combined with the proteasome complex step is also referred to 
as the ubiquitin-proteasome system (UPS) or ubiquitin proteasome pathway (UPP).  
The ubiquitination process is tightly controlled by three families of enzymes: 
ubiquitin-activating enzymes (E1s), ubiquitin-conjugating enzymes (E2s), and finally 
ubiquitin-protein enzymes (E3s). There exists two E1 enzymes with ubiquitin-
activating capability : UBA1 being the primary E1 and the recently discovered UBA6 
with unclear functions and uncharacterized regulations (115, 116) In contrast to the 
small number of E1s, there are approximately 40 E2s (117, 118) and 500-1,000 
human E3 ligases, providing both specificity and versatility (119). The three steps of 
the ubiquitination process (Figure 5) have been reviewed previously (120, 121).  
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Figure 5. General structural outline of ubiquitin/proteasome pathway. E1s (Blue) are 
activated by ATP and bind to ubiquitin (orange). They then transfer ubiquitin to E2 
(blue) and the E3 enzyme transfers ubiquitin to the substrate, which is then shuttled to 
the proteasome for degradation.  
 
Briefly, the activation step requires binding of both ATP and ubiquitin and 
links the α-carboxyl group of the C-terminal glycine residue of ubiquitin to a cysteine 
residue on E1, and a thioester linkage is formed between the ubiquitin and E1. Then 
the E2 binds to both activated ubiquitin and the E1 enzyme and thus transfers the 
ubiquitin from E1 to the active site cysteine of the E2 via a trans(thio)esterification 
reaction. Finally, the E3 catalyzes the linking of ubiquitin to a lysine residue on the 
substrate. Repetitions of these sequential steps results in long chains of ubiquitin 
(polyubiquitin) on the protein to be degraded, and the specific lysine residue on 
ubiquitin used for linking (e.g., K48, K63, etc.) results in different topologies (122). 
Ubiquitination was originally described as a mechanism by which cells dispose of 
short-lived, damaged, or abnormal proteins, but more recent studies have revealed that 
it also plays a significant role in post translational modification. Ubiquitination can 
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result in the addition of a single ubiquitin moiety, called monoubiquitination, rather 
than polyubiquitination. Generally, polyubiquitination reactions are formed on the 
K48 residue, and this process tags substrates for proteasomal degradation and 
recycling (123). On the other hand, the K63-linked non-proteolytic ubiquitination 
spares proteins from degradation and regulates localization and activity of multiple 
kinases and pathways, such as PKB/Akt, TAK1, IKKγ/NEMO, TNFR, IRAK1, 
MLK3, IGF-1R, T cell receptor (TCR), NOD-like receptor (NLR), and RIG-I-like 
receptor pathways. This type of ubiquitination can cooperate with other linkage types 
to achieve the physiologically required output of a signaling pathway (122, 124, 125) 
and therefore has been crucially implicated in diverse biological processes including 
signal transduction, transcriptional regulation, growth response, innate immune 
response, and DNA repair and replication (124-126). 
Mitotic cell cycle progression through each stage is tightly controlled by 
cyclin-dependent kinases (CDKs), and their relative interactions with members of the 
cyclin and CDK inhibitor (CKIs) families.  The relative amounts of these signal 
factors fluctuate within and between each stage of the cell cycle occurs via the result 
of periodic proteolysis(127); the ubiquitin-proteasome scheme is responsible for the 
degradation of these mitotic regulatory proteins, which results in the control of their 
intracellular concentrations(128, 129). 
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1.3.2 Ubiquitination in Cancer 
Ubiquitination can affect cancer development and progression in many ways. 
Both tumor suppressing and promoting pathways have elements that are tightly 
regulated by the process. One fundamental aspect of cancer is the deregulation of the 
cell cycle and checkpoint control (127). which is highly regulated through constant 
synthesis coupled to a particular timeframe of specific proteolysis of cyclins, cyclin-
dependent kinases (CDKs) as well as CDK inhibitors (CKIs) executed by the UPS 
(130).  Other cell cycle regulatory proteins that may contribute to cancer progression 
include cyclin E, p57, p130, FoxO1, c-Myc and E2F1 (131, 132). 
Another well-known example is the E3 ligase MDM2 which bind to the tumor 
suppressor protein p53 that is inactivated in more than 50% of human cancers. Also, 
mutations and alterations in ubiquitin ligases are found in a wide variety of tumor 
types and tremendously impact clinical outcomes (133-136).  
In addition to the above proteolytic polyubiquitination, which may contribute 
to cancer development, it is worth mentioning that monoubiquitination has unique 
effects on cancer as well (125). Monoubiquitin can serve as a recruitment signal to 
proteins that contain ubiquitin binding domains, and the functions of such non-
proteolytic ubiquitination include, but not limited to: altered protein activity, 
subcellular localization, enzyme activation, DNA repair, chromatin dynamics (124, 
137-139), and transcriptional regulation(140, 141). These facts underscore the 
importance of ubiquitination in tumorigenesis and the resulting interest as a clinical 
target. 
29 
 
1.3 Existing Small Molecules Targeting Ubiquitin/Proteasome Pathway 
1.3.1 Targeting the Proteasome   
The first therapeutic proteasome inhibitor tested in humans was bortezomib 
(Velcade), which was first synthesized in 1995, entered clinical trials in 1998, and 
approved by the FDA for use in multiple myeloma (MM) in 2003 (142) (Table 2). 
The clinical antitumor activity of bortezomib is well established as both a single-use 
agent and combination in the treatment of MM and other hematological malignancies. 
Bortezomib also exhibits efficacy in non-small cell lung cancer and pancreatic cancer 
(143, 144), and more recently it was expanded for use in patients with mantle cell 
lymphoma (MCL). High affinity and specificity of binding of bortezomib is achieved 
partly through the boron atom to the 26S proteasome’s catalytic site (145-147). 
Consequently, proteasome inhibition alters the balance of all intracellular peptides, 
increasing those that require cleavage at acidic and hydrophobic sites and causing side 
effects such as neuropathy and autophagy in certain conditions (148-151). As is an 
issue with many cancer therapeutics, resistance can develop quickly and this occurs 
with bortezomib on average in about one year (140, 152, 153). Another notable 
proteasome inhibitor approved recently by the FDA is carfilzomib (marketed under 
the trade name Kyprolis), and is used for relapsed and refractory MM who have been 
previously treated with bortezomib (154, 155).  Carfilzomib is also approved for MM 
and was derived from epoxomicin, a natural product that was shown to contain potent 
anti-inflammatory activity and proteasome inhibition (156).  
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Class Drug Name Target Status Structure Ref. 
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lymphoma 
N
N N
H
O
O
H
N
B
HO OH
 
(142) 
Carfilzomib 
20S 
Proteaso
me 
FDA 
approved 
for 
relapsed 
and 
refractory 
MM 
O
O
O
O
O
OO
H
N
N
H
H
N
N
H
N
 
(154, 
155) 
Marizomib 
20S 
Proteaso
me 
Phase I 
O
NH
OH
H
O
O
Cl
 
(157) 
Ixazomib 
(MLN-9708) 
20S 
Proteaso
me 
Phase I 
N
H
O
H
N
O B
Cl
Cl
OHHO
 
(158) 
CEP-18770 
20S 
Proteaso
me 
Phase II 
N
H
N
O
N
H
O B
OH
HO OH
 
(159) 
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E2 
Leucettamol 
A 
Ubc13-
Uev1A 
interactio
n 
Preclinical/ 
Research 
NH2OH
H2N
OH
 
(160, 
161) 
CC0651 Cdc34 
Preclinical/ 
Research 
NH
O
O
HO
O
HO OH
Cl
Cl
 
(162) 
E3 – 
immuno-
modulators 
Thalidomide CRBN 
FDA 
approved 
for 
treatment 
of MM 
N
O
O
NH
O
O
 
(163) 
Lenalidomide CRBN 
FDA 
approved 
for 
treatment 
of MM 
N
O
NH
O
O
NH2
 
(164) 
Pomalidomid
e 
CRBN 
FDA 
approved 
for 
refractory 
MM 
N
O
O
NH
O
O
NH2
 
(165) 
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E3 - p53 
potentiators 
Nutlin-3a 
MDM2/
MDMX 
antagonis
t 
Multiple 
Phase I 
trials 
Cl
N
N
Cl
O
O
N
O
HN
O
 
(166, 
167) 
RG7112 
MDM2/
MDMX 
Phase I 
Cl
N
N
Cl
O
N
O
N
S
OO
 
(168) 
ATSP-7041 
Dual 
inhibitio
n of 
MDM2 
and 
MDMX 
Preclinical/ 
Research 
 
(169, 
170) 
NSC207895 
Dual 
inhibitio
n of 
MDM2 
and 
MDMX 
Preclinical/ 
Research 
NH
O
N+
N NO2
-
O
N
 
(171) 
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E3 - F-box 
protein 
antagonists 
NSC689857 Skp2 
Preclinical/ 
Research 
N
H
O
O
OH
OH
 
(172) 
NSC681152 Skp2 
Preclinical/ 
Research 
O
O
OH
OH
 
(172) 
SCF-I2 Cdc4 
Preclinical/ 
Research 
O
OH
O
HO
 
(173) 
C1, C2, C16, 
C20 
Skp2 
Preclinical/ 
Research 
O
S
N
N
Br
O OH
O
S
(C1)
 
(174) 
Compound A Skp2  
Preclinical/ 
Research 
N
H
N
O
 
(175) 
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Compound 
ZL-25 
Skp2  
Preclinical/ 
Research 
O
O
HO
N
N
S
 
(176) 
GS143 βTrCP 
Preclinical/ 
Research 
O
OH
N
N
OO
F
 
(177) 
Erioflorin βTrCP 
Preclinical/ 
Research 
O
O
O
O
O
H
H
H
OH
 
(178) 
BC-1215 Fbxo3 
Preclinical/ 
Research N
N
H
H
N
N
 
[77] 
SMER3 Met30 
Preclinical/ 
Research 
O
N
N
N
N
O
 
[75] 
Table 2. Selected compounds targeting elements of the ubiquitin–proteasome system 
and their current status in the drug development pipeline. 
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Other next generation proteasome inhibitors are in clinical trials and have the 
potential to achieve a better therapeutic ratio and reduced probability of inherent and 
acquired resistance. An example is the structurally and pharmacologically unique 
marizomib (also called salinosporamide A) currently in Phase I trials (157). It is a 
natural product produced from marine bacteria, and its mechanism of action is unique 
in that it irreversibly and covalently modifies the active site threonine residues of the 
20S proteasome (179, 180). Moreover, a Phase Ib clinical study of the combination of 
marizomib with vorinostat has just completed but the results have not yet been posted 
with non-small lung cancer patients (Clinical Trial NCT00667082).  
Finally, two other reversible peptide boronic acid-based proteasome inhibitors 
in different stages of development are CEP-18770 and MLN-9708 (181, 182). CEP-
18770 has been tested in Phase I trials for solid tumors and non-Hodgkin’s 
lymphoma, and entered Phase II trials for relapsed and refractory MM by itself and in 
combination with lenalidomide (a thalidomide derivative) and dexamethasone 
(Clinical Trials NCT00572637, NCT01023880, and NCT01348919). It has shown in 
vitro antiangiogenic activity and potently represses RANKL-induced 
osteoclastogenesis, and is not cytotoxic to normal human epithelial cells and bone 
marrow-derived stromal cells (159). MLN-9708 (also called Ixazomib) has shown 
great promise and advanced to Phase III trials; it is also being considered in 
combination with lenalidomide and dexamethasone (Clinical Trial NCT01564537). In 
Phase II trials, while showing adverse side effects, it was generally well tolerated and 
the majority of patients (58%) had a very good partial response or better (158). 
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1.3.2 Targeting E2 Enzymes 
While few therapies targeting the E2 enzymes are in development (relative to 
proteasome and E3 inhibition), there are some recent examples worth mentioning that 
are in preclinical stages (Table 1). Leucettamol A, which was isolated from the sea 
sponge Leucetta aff. Microrhaphis, was shown to inhibit the Ubc13-Uev1A interaction, 
blocking the E1-E2 complex formation (160). It was determined that, contrary to an 
earlier assessment that this was a racemic compound, it is in fact a chiral and optically 
active compound (161). Another marine sponge, Lissodendryx fibrosa was the source 
for manadosterols A and B which inhibited the same Ubc13-Uev1A interaction with 
higher potency than leucettamol A (183). CC0651 was found to allosterically inhibit 
the E2 enzyme Cdc34 and cause accumulation of p27 by inserting itself into a cryptic 
pocket distant from the catalytic site, causing displacement of secondary structural 
elements (162). However, targeting the E2 is still lacking sufficient specificity 
compared to E3 inhibitors as described in the following sections. 
 
1.3.3 Targeting E3 Ligases 
E3 ubiquitin ligases represent a diverse set of enzymes and provide the 
specificity of the ubiquitination reaction, and have significant roles in many different 
diseases, especially cancer. The E3 ligases are currently broadly classified into two 
major families from their structural motifs: HECT-type (Homologous to the E6-AP 
Carboxyl Terminus) and RING type (Really Interesting New Gene); RING domain 
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ligases are the most common (184). There are also two RING-finger derivative 
domains: U-box (UFD2-homology domain) and PHD (plant homeo domain) E3 types, 
but RING-finger types are the largest groups of E3 ligases. 
E3 elements in the UPS are considered to be primarily responsible for the 
specific recognition of a large number of target proteins, acting as the substrate 
recognition component of the UPS pathway (114). This specificity is crucial when 
considering the prospect of designing drugs for the entire ubiquitination pathway, as 
they can be designed to target specific substrates of the E3 ligase without affecting 
other substrates. As a result, the E3 ubiquitin ligases are drug targets with the most 
potential for cancer therapies as they have fewer targets and offer a higher specificity 
of the system (185, 186). There are several notable E3 ligase targeting agents that are 
worthy of mentioning, and there have been many recent developments that show 
promising results in preclinical testing. 
 
1.3.3.1 Thalidomide and its Derivatives 
Thalidomide was originally developed as a sedative and an agent to cure 
hyperemesis gravidarum in pregnant women, and became infamous for its limb 
formation birth defects. Although banned after discovery of these effects in 1962, it 
had off-label use for patients of erythema nodosum leprosum (ENL); it was this use 
that led to clinical trials of its assessment and characterization of its 
immunomodulatory effects. Its primary target has been identified to be cereblon 
(CRBN), which forms an E3 ligase complex with damaged DNA binding protein 1 
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(DDB1) and Cul4A that is important for limb development, and binding of 
thalidomide to this complex appears to be the mechanism for the teratogenic effects in 
embryonic development (163). Two optimized second-generation derivatives of 
thalidomide, lenalidomide and pomalidomide (164, 165), are also used for MM by 
targeting CRBN and modulate its specificity as a substrate receptor, not by inhibition, 
rather by selective enhancement of the ubiquitination and degradation of Ikaros 1 and 
3 (IKZF1 and IKZF3) zinc finger transcription factors (187).  A crystal structure of 
lenalidomide in complex with CBRN shows the binding mode and that it binds to the 
substrate binding domain of CRBN and blocks ubiquitination (188-190).  
 
1.3.3.2 MDM2/p53 
The tumor suppressor protein p53 has been called the “guardian of the 
genome” due to its critical role in inducing cell cycle arrest and apoptosis in response 
to DNA damage. There exist over ten E3s associated with the regulation of p53, but 
the one with the most unquestionable importance has been MDM2 (murine double 
minute 2)(191).  The p53-binding domain of MDM2 is at the N-terminus, and the 
RING domain in the C-terminus acts as the ubiquitin ligase to promote rapid 
degradation of p53 after its export from the nucleus (192-194). Inhibition of the 
MDM2/p53 interaction has been achieved by the small molecule nutlins, which have 
completed Phase I clinical trials and  (166, 167). Nutlins are the general name given 
to compounds based on a cis-imidazoline scaffold, and their derivatives offer better 
activities but still retain elements of the core structure. Serdemetan was tested in a 
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Phase I trial and showed good p53 induction, but cardiac construction effects were 
observed (195-197). Nutlin-3a (a more promising agent) was optimized for better 
pharmacological properties to become RG7112 (also known as RO5045337); it 
stabilized p53 and activated the p53 pathway in cancer cells, and is being tested both 
as a monotherapy and in combination and some Phase I trials are still ongoing 
(NCT01677780) (168, 198). Nutlins and their derivatives are competitive inhibitors 
and structural mimics of p53 (via Phe19, Trp23 and Leu26) (166). MDMX (murine 
double minute X – also known as HDMX in humans, or also MDM4 or HDM4) 
shares significant homology with MDM2 and is also a negative regulator of p53, but 
nutlin-3 has shown decreased effectiveness in inhibiting MDMX-p53 interactions due 
to its differential binding (199). This highlights one limitation of MDM2-targeting 
agents such as nutlins: tumors with high MDMX and low MDM2 expression respond 
poorly to MDM2 inhibition (170). To combat this problem, a dual inhibitor of MDM2 
and MDMX (ATSP-7041) was discovered and activates the p53 pathway in vitro and 
in vivo (169, 170). Another compound overcoming the limitation, NSC207895, was 
found to target MDMX specifically and acted additively with nutlin-3a to activate p53 
and decrease cancer cell viability (171). 
 
1.3.3.3 SCF E3 Ligases (Excluding Skp2) 
 The RING-finger type SCF (Skp1/cullin/F-box) E3 ligases are the largest 
family of E3 ubiquitin ligases, and they consist primarily of three core subunits: an F-
box protein that contributes to the specificity of the SCF, Skp1 (S-phase-kinase-
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associated protein-1) that acts as a bridging protein and binds to the F-box, and Cul1 
(One of the seven family members in the Cullin family) that forms the major 
structural scaffold of the SCF. The majority of the substrates of SCF E3 ligases are 
involved in regulating cell cycle progression, gene transcription, DNA replication, 
and signal transduction (119, 200, 201). A growing body of evidence suggests that 
phenotypes such as genomic instability, uncontrolled proliferation, and cancer result 
from the dysregulation of these E3s (119), and more than a couple E3 ligases have 
been proposed to be drug targets and prognostic biomarkers in cancers such as 
melanoma (202). Their potential as drug targets has been only been uncovered very 
recently, and as the F-box proteins provide the specificity of the SCF complex, many 
small molecules have been designed to target specific members (Table 1).  
SMER3 was discovered from a yeast-based screen of rapamycin enhancers, 
and blocks the SCFMet30 in vivo and in vitro but not the closely related SCFCdc4. 
SMER3 was also demonstrated to directly bind to Met30 and prevents degradation of 
Met4, an antiproliferative transcriptional activator (203). Small molecule screens 
identified SCF-I2, which inhibits the F-box protein Cdc4 in yeast but not its human 
ortholog Fbxw7 (173). Its specificity can be explained by an allosteric mechanism: it 
binds between two beta strands in the WD40 domain of Cdc4 that is 25Å away from 
the substrate binding site. While SCF-I2 failed to inhibit Cdc4 activity in vivo, it did 
show the potential of using allosteric inhibition of the WD40 domain.  
Another example is BC-1215 which was recently synthesized to inhibit Fbxo3 and 
blocks degradation of another F-box protein (Fbx12), which in turn degrades the TNF 
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receptor-associated factor (TRAF) adaptor proteins that are responsible for cytokine 
secretion (204). This resulting TRAF inhibition by BC-1215 dampens NF-κB 
activation through the TNF signaling cascade (205).  
βTrCP (b- transducin repeats-containing proteins) is an E3 ligase that binds to 
Skp1 and promotes degradation of a breadth of key regulatory protein elements in 
cancer biogenesis, including: Pro-caspase-3, WEE1, MCL1, p100, p105 and CD4. In 
most cases, it functions as an oncoprotein and has been found with upregulated 
mRNA levels in many cancer types (202, 206).  GS143 and Erioflorin both block 
interaction between βTrCP and their targets: phospho-IκBα (nuclear factor of kappa 
light polypeptide gene enhancer in B-cells inhibitor, alpha) and Pdcd4 (Programmed 
cell death protein 4), respectively (177, 178). Inhibition of βTrCP can result in tumor 
cell arrest at multiple points in the cell cycle at nanomolar concentrations and the 
inhibitors show promising results in vitro (207, 208) 
 
1.4 Skp2 in the Ubiquitination Pathway and its Role in Cancer 
1.4.1 Basic Information of Skp2 and structural features 
One well characterized E3 ligase is the SCF (Skp1/Cul1/F-box) complex, 
which are RING-type (Really Interesting New Gene) E3s and these target a broad 
range of proteins involved in the progression of the cell cycle, transcription, and 
signal transduction proteins (209, 210). The Cul1 protein joins with Rbx1 to form the 
RING domain, and this forms the catalytic core complex that recruits the E2 portion, 
and the Skp1 acts as an adapter protein that is responsible to bind to the variable F-
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box protein; this F-box protein is the variable portion of the SCF complex that binds 
to the substrate, and its consensus sequence is about 50 residues long with the most 
commonly repeated residue being leucine.  
The most well characterized mammalian F-box protein is Skp2 (S-phase 
kinase-associated protein 2; also known as FBXL1, FBL1, and p45) (Figure 6). Skp2 
acts as the substrate-recruiting element of the SCF and together with Skp1, Cul1, and 
Cks1 forms an E3 ligase to form the functional SCF complex. The most prominent 
and arguably significant protein that is ubiquitinated by Skp2 is the CDK p27. The 
protein p27 is periodically expressed in the cell cycle. Its specific phase of high 
expression are at the G1 phase and it decreases at the S phase. As the levels of p27 
mRNA remain stable throughout the cell cycle, it is widely considered that its protein 
levels are controlled means of a posttranscriptional mechanism. Skp2/SCF primarily 
targets p27 in the nucleus in the S and G2 phases. As p27 is ubiquitinated by Skp2, 
there is an inverse relationship between Skp2 expression and p27 levels in multiple 
tumor types as well as normal tissues (211-213). 
 
Figure 6. Linear representation of full length sequence of human Skp2 showing 
significant domains and features. 
 The Skp2 protein is 424 residues in length, with the F-box domain lying closer 
to the N-terminal region at the 94-140 position, and the C-terminal region forming a 
concave surface comprised of ten leucine-rich repeats (LRR) (Figure 7)  Skp2 also 
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contains a putative nuclear localization signal (NLS) within the region where Skp2 
phosphorylation occurs at by Akt at Ser72, triggering Skp2 cytosolic localization 
(214).  The three LRRs closest to the F-box are non-canonical, while the other seven 
are canonical.  After the tenth LRR, the ~30 residue C-terminal tail turns back 
towards the first LRR, forming what has been referred to as a ‘safety-belt’ that might 
aid to pin down substrates into the concave surface formed by the LRRs (215) 
(Figure 8). It is this C-terminal tail and the LRRs farthest from the F-box (repeats 6-
10) that bind the Cks1 accessory protein, which in turn is required for the recognition 
and ubiquitination of the p27Kip1 (216, 217). 
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Figure 7. General structural of Skp2 colored from N-terminus (purple) to C-terminus 
(red). 2AST structure with N-terminal purple region is a homology model and 
prediction of tail in unbound Skp2. 
 
1.4.2 Functions of Skp2 Interacting proteins and Roles in Cancer 
 Skp2, due to its role in degrading a significant cell cycle control element, is 
considered an oncogene and has been implicated in many different and diverse 
cancers, including: lung carcinomas (218), neuroblastoma and gliomas (219, 220), 
renal cell carcinoma (221), colon carcinoma and rectal cancer (222, 223), gallbladder 
carcinoma (224), gastrointestinal stromal tumors (225), esophageal and oral squamous 
cell carcinoma (226, 227), osteosarcoma (228), and cervical (229). In breast cancer, it 
has been shown that Skp2 expression is associated with acquisition of epithelial- 
mesenchymal transition (EMT) in paclitaxel-resistant breast cancer cells (230), and is 
a potential biomarker for Luminal A breast cancer (231). One recent meta-analysis of 
Skp2 expression that represented 5,514 patients (a large amount of which were Asian) 
showed Skp2 overexpression is associated with poor overall survival as well as 
disease-free survival/relapse-free survival (DFS/RFS) in all patients as well as in the 
analysis of subgroups. Analysis of multiple datasets indicate that these effects are due 
to amplification, and not mutation/deletion, of Skp2. Multiple studies support this 
notion, showing that copy number gain is the contributing mechanism of Skp2 
overexpression (232) (Figure 8).  
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Figure 8. Skp2 is commonly amplified and not mutated in many cancers. Source: 
cBioPortal.com(233) 
Recently some novel biological functions of Skp2 were identified and it can 
activate Akt through non-proteolytic K63-linked ubiquitination for glycolysis (via 
activating Glut1 expression) (234). A connection to tumor epithelial-mesenchymal 
transition (EMT) has been shown to function in Skp2 also via the increased Akt1 
phosphorylation and the accumulation of c-Myc during EMT by TGF-β1 signaling to 
Skp2 via Akt1. Also, a recent report shows that Skp2 activates LKB1 (via K-63 
ubiquitination) for cancer cell survival under energy stress via oncogenic Ras 
upstream of Skp2 (235). 
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It is well understood that for p27 to have its cyclin-dependent kinase inhibition 
(CKI) activity in negatively regulate the cell cycle progression, it must be present in 
the nucleus, and its activity is not present in the cytosol. Researchers have shown that 
the inverse correlation between Skp2 and p27 is clinically associated with poorer 
patient survival and increasing malignancy (213). Also significant is the fact that 
multiple cancers show that p27 is frequently lost or mislocalized (and not often 
mutated) to the cytoplasm, including cancers such as endometrial carcinoma 
(EndoCa), renal cell carcinoma (RCC) and breast cancer (236). In fact mutations in 
the p27 gene across all cancers are exceedingly rare, at a rate of only 3% (237). The 
ability of p27 to block cell cycle progression is regulated predominantly by post-
translational modifications; these determine the subcellular localization and the 
stability of p27. The ubiquitination of p27 is readily and quickly achieved in the 
nucleus specifically by the Skp2 SCF complex when p27 phosphorylated on Thr187, 
but when it is phosphorylated on Ser10, it is able to bind to CRM1 and be exported to 
the cytoplasm, where there it is targeted for degradation by another E3 ligase: the 
Cul1-KPC1/2 complex (238, 239).  
The localization of p27 has multiple, startling effects on a cell. In the 
cytoplasm, p27 can repress RhoA, which leads to: diminished focal adhesion 
formation, reorganization of the actin cytoskeleton, and promotion of cell motility in 
addition to promoting autophagy and inhibiting apoptosis (240). Additionally, loss of 
nuclear p27 results in increased CDK2 activity and this increase results in 
phosphorylation of the estrogen receptor (ER), thereby elevating ER activity and 
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promoting growth of hormone-dependent tumors. These facts taken together indicate 
that p27 is a tumor suppressor in the nucleus, but an oncogene in the cytoplasm.  
Therefore, there are two potential targets on Skp2 that might be exploited: the 
first is the Skp1/Skp2 interface. It could be disrupted, removing the rate limiting 
component (Skp2) from the SCF. The other is the p27 binding site. The specificity for 
p27 binding to the Skp2 SCF complex in the nucleus is made available by a pocket 
formed by Skp2 and an accessory protein named cyclin-dependent kinase subunit 1 
(Cks1). This pocket provides an interface on which to target specifically that could 
result in the rescue of p27. 
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Chapter 2: Skp2 Hot Spots and Virtual Screening for Inhibitors of Skp2 
  Skp2 is clearly an oncogene and acts as the rate-limiting component of the 
SCF complex, and provides the specificity towards the substrate (most notably p27). 
Despite its role in transferring ubiquitin to a substrate, it has no prototypical “catalytic 
residue” that could be targeted like other enzymes. Skp2 also acts as an intermediate 
adapter between Skp1 and the accessory protein Cks1, and the PPI interfaces formed 
between both proteins is large, so conventional virtual screening techniques are likely 
to fail. To circumvent this problem and to design small molecules towards Skp2, we 
must target areas of the PPI interfaces in exactly the right region to disrupt the 
proteins, and the consideration of hot spots have the potential to find this region.  
 The main thrust of this study is to combine the theory of targeting PPIs 
(focusing on the theory of hot spots) and use a variety of computational techniques to 
predict the hot spots that exist on Skp2. If the hot spots cluster in a specific region that 
appears to be druggable (i.e., a pocket or groove), than this region will be selected as 
the center region on which to conduct a virtual screen. A successful screen in which a 
small molecule can disrupt the PPI and result in Skp2 unable to bind to the remaining 
members of the SCF complex. This chapter describes how the hot spot analysis was 
carried out, how the hot spots were selected, how the screens were conducted, and 
how a small list of molecules were selected for biological testing. Finally, this chapter 
shows the biological effects of the top hits. 
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2.1 Materials and Methods: Development and Application 
2.1.1 Selection of Compound Libraries for Virtual Screening 
There were multiple iterations and multiple sources that were used for the 
compound libraries. For the ligand set used in the initial Skp1/Skp2 virtual screens, 
we selected the chemical library DiverSet (241) from ChemBridge. DiverSet has a 
unique set of 50,080 handcrafted compounds that are derived from the Express-Pick 
collection of 450,000+ compounds. The majority of these compounds have good 
drug-like and lead-like molecules, with most compounds having molecular weights 
below 500 and logP values less than 5, in keeping with Lipinski rules of 5 (Figure 9). 
 
 
Figure 9. Distribution of molecular weight and logP of Diverset compound library 
used in Skp1/Skp2 screen 
 
For the Cks1/Skp2/p27 screening, we used a chemical library that was first 
filtered so that it only contained drug-like and lead-like compounds then additional 
filters using our in-house protocol to remove PAINS (pan-assay interference 
compounds) to keep compounds that had logP within 1.0 to 4.0 and molecular 
weights between 100 and 400 were applied. This lead-molecule like library of 
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approximately 52 thousand compounds was then used as the basis for the virtual 
screening using our in-house HiPCDock program. 
 
2.1.2 Virtual Screening Methodology for Cks1/Skp2/p27 binding site 
Sections of this methodology were adapted from the following publication: 
“Targeting TRAF6 for Cancer Therapeutical Development”, published by the 
University Of Texas Graduate School Of Biomedical Sciences at Houston in August 
2012. 
For the in silico high-throughput (HTS) virtual screening on the 
Cks1/Skp2/p27 binding site, the 2AST structure was obtained from the PDB (242), 
and the structure was prepared using the MOE software package from CCG. It is 
known that Cks1 is required for Skp2-mediated ubiquitination of p27, so the Cks1 
protein was included along with p27 and Skp2 (216). Previous studies of p27 and its 
interactions demonstrated that mutation of Glu185 dramatically reduced the binding 
of p27 to the complex while T187A mutation completely abolished the 
phosphorylation of p27 (242, 243). We also found that in this structure, p27 shows 
two potential regions that were pocket-like that corresponded to these two residues. 
To further define the key residues to be included for virtual screening, we performed 
rigorous “hot spot” predictions using routine approaches in an ensemble manner(244), 
combined with molecular visualization of multiple SCF complex structures(206, 242, 
243, 245).  
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Instead of performing one screen that covered both pockets, we performed 
three screens; two separate and exhaustive jobs were carried out on only the two 
individual pockets, and a final larger screen that covered both pockets together. The 
resulting hits from these screens were biased towards those that were present in both 
pockets. However, the majority of the top selected hits were found to occupy the 
Glu185 pocket. The top performing results from GOLD were visualized and 
examined for their ability to cohabitate both of these regions. 
The resulting top 5,000 hits (based on docking scores and docking poses) were 
then docked using GOLD by CCDC. The top scoring 500 ligands (by GoldScore) 
were visualized individually (using PyMOL) in their docked conformation with the 
original submitted Skp2 2AST structure. Three main criterions were considered in the 
final selection of 500 hits. The first criterion was the degree to which the ligands’ 
conformation occupied the interaction site between p27 and Skp2/Cks1. Second, the 
conformation, binding affinity, and resulting “fit” within the p27 binding site 
compared to the corresponding Skp2 residues was considered. Each ligand, given its 
orientation in the docked position, was evaluated on its ability to potentially block the 
binding of p27 protein by considering hydrogen bonds, electrostatic and aromatic 
interactions. The third and final consideration was the distinctiveness in the 
chemotypes when compared to other ligands. We placed the ligands into “classes” 
based upon the individuality of their underlying scaffold and how this scaffold was 
oriented in the binding site. Ligands that shared a similar scaffold and orientation 
were considered to be in the same class, and would then share the same chemotypes. 
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Also for the selected 500 hits, we assigned a “priority” to each molecule which was an 
aggregate of the second and third factors (conformation in the pocket and 
distinctiveness). This priority was defined as: low, medium or high. The priority then 
became similar to a degree of confidence for each ligand. Compounds with “high” 
priority were regarded as most likely to yield good biological activity, and should be 
tested over the other low and medium confidence ligands. Eventually from the 500 
hits, we selected 123 unique compounds with high priority that were recommended to 
be tested for biological activity. In addition to these 123 unique compounds, based on 
the core scaffold of compound 405, a search of structurally similar compounds (also 
called a SAR by catalog) was carried out and identified 41 compounds that were 
analogues of compound 405. 
 
2.1.3 Virtual Screening Methodology for Skp1/Skp2 binding site 
The high-quality and most comprehensive crystal structure of Skp2 was 
obtained from the Protein Data Bank(246) (2AST) and the B chain (Skp2) was 
analyzed in complex with the A chain (Skp1)(242). The N-terminal tail has not been 
crystalized on this structure, but the rest of the protein (the F-box, the LRR domain, 
and the seatbelt region) is present in this structure. In fact, the N-terminus has never 
been crystallized on Skp2. Water molecules along with the C and D chains were 
removed from this 2AST crystal structure via PyMOL (247). From the literature, the 
19 residues on Skp2 in contact with Skp1 formed the basis for detecting druggable 
sites in the F-box region of Skp2 (243). The first region (pocket 1) was close to the N-
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terminus of Skp2, and the second region (pocket 2) had close proximity to the 
corresponding C-terminus of Skp1. The software MOE(248) and its site finder 
function validated the second pocket region on Skp2 within the F-box for which to 
dock small molecules to. Since the two regions (referred to as pocket 1 and pocket 2 
henceforth) appear to have distinct differences in their surface area, size and location 
on Skp2, the two pockets were treated as separate virtual screens, each with a unique 
center and size. 
The broad methodology for the virtual HTS on this region of Skp2 was similar 
to that for the Skp2/Cks1/p27 binding site. The docking program used, HiPCDock 
(249), is based upon DOVIS (250).  The program considers a 3-dimensional cubic 
region with user defined coordinates, and the centers of these cubes were placed in the 
binding sites for each docking study. Pocket1 was centered at AutoDock coordinates 
1.134, -114.378, -1.751 (x,y,z) and grid points of 80 in each dimension. Pocket2 had a 
center of -1.962, -100.846, 10.708, grid points of 48 in each dimension. Both virtual 
screens had genetic algorithm parameters of 100 runs, a population size of 100, and 
rate of crossover at 0.8. Further details (configuration files) of HiPCDock and the 
docking parameters used are available in the appendix.  
After the initial docking of DiverSet, the 2000 compounds with the best 
HiPCDock scores for each pocket were then docked again into the same receptor 
(Skp2) using the GOLD (Genetic Optimization for Ligand Docking) software 
suite(251) to further narrow down the top binders using a scoring method different 
from HiPCDock.  GoldScore was chosen as the fitness function, and a radius of 10Å 
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was used. The centroids were defined in the same manner as the HiPCDock, and a 
cavity file was generated from the selection. Further specific parameters used in the 
GOLD docking are available upon request.  
The resulting top scoring 200 ligands from each pocket on Skp2 with the 
highest GOLD fitness values were then structurally clustered based on structural 
MACCS (Molecular ACCess System) fingerprints using MOE fingerprint clustering. 
The metric used was the Tanimoto coefficient, and the similarity and overlap were set 
to 60%. After clustering based on these fingerprints, the cluster center ligands from a 
given cluster are retained. The resulting 120 ligands from this clustering (70 ligands 
for pocket1, 50 ligands for pocket2) were then individually visualized (using PyMOL) 
in their docked conformation. Three main criterions were considered in the final 
selection process. The first criterion was the degree to which the ligands’ 
conformation occupied the interaction site between Skp1 and Skp2. If the 
conformation primarily existed outside of the interaction site, it was no longer 
considered a candidate. Second, the conformation, binding affinity, and resulting “fit” 
within the Skp2 binding site compared to the corresponding Skp1 residues was 
considered. Each ligand, given its orientation in the docked position, was evaluated on 
its ability to potentially block the binding of the Skp1 residues. Along with these 
potential blocking effects, we also considered the binding affinity of the ligand in its 
pocket. This included qualities such as hydrogen bonds, static and aromatic effects. 
The third and final consideration was the distinctiveness in the molecular scaffold 
when compared to other ligands for each pocket. We placed the ligands into “classes” 
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based upon the individuality of their underlying scaffold and how this scaffold was 
oriented in the binding site. Ligands that shared a similar scaffold and orientation 
were considered to be in the same class, and would then share the same class number. 
We then assigned a “priority” to each molecule which was an aggregate of the second 
and third factors (conformation in the pocket and distinctiveness). This priority was 
listed as: low, medium or high. The priority then became similar to a degree of 
confidence for each ligand. Compounds with “high” priority were regarded as most 
likely to yield good biological activity, and should be tested over the other low and 
medium confidence ligands. The result from this visual selection process was that 57 
ligands in total were recommended to be tested for biological activity; 41 total ligands 
were chosen as compounds to be tested for pocket1 with 16 compounds listed as high 
priority. For pocket2, 16 total compounds were selected, and 11 of these were high 
priority. Only the high priority compounds were actually tested biologically, and two 
of the ligands (7957666 and 9040817) were included in both of the pocket 1/pocket 2 
lists; this lead to a final total of 25 compounds ordered for biological testing. 
 
2.1.4 Biological testing by Collaborators 
Cell culture and reagents 
293T, PC3, A549, H460, H1299, Hep3B and U2OS cells were cultured in 
DMEM containing 10% FBS while LNCaP and H3255 were cultured in RPMI-1640 
medium containing 10% FBS. (His)6-ubiquitin, GST-Akt, and HA-Akt constructs 
was described previously. (252) Flag-Skp2 was a gift from Dr. W. Wei. GST-Skp2 
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Trp97Ala (W97A) and GST-Skp2 Asp98Ala (D98A) mutants were generated in 
pGEXSkp2ΔN-Skp1Δ, a gift from Dr. B.A. Schulman, by site-directed mutagenesis 
assay according to manufacturers’ standard procedures (Stratagene). ZL-25 and its 
analytical data including 1H, 13C NMR and LC-MS/MS analysis were obtained from 
ChemBridge. LY294002 was purchased from Cell signaling. 
 
LC-MS/MS analysis of the in vitro binding between Skp2 and Skp2 inhibitor. 
GST-Skp2 W97A and GST-Skp2 D98A mutants used for demonstrating #25-
Skp2 interaction were generated in pGEXSkp2ΔN-Skp1Δ bicistronic co-expression 
constructs. Subsequently, the GST-Skp2 WT, GST-Skp2 W97A and GST-Skp2 
D98A mutants were co-expressed, purified and formed complex with Skp1 (Δ38–44 
aa.) as described previously (253). The purified proteins were incubated with ZL-25 
for overnight at 4°C, and the GST tags were thrombin-cleaved and pulled-down by 
glutathione sepharose beads (Invitrogen). The untagged protein samples were pH-
adjusted by adding 50mM ammonium bicarbonate and digested by adding 200 ng 
modified trypsin (sequencing grade, Promega) for 18hrs at 37°C. The resulting 
peptides and compound were analyzed by LC-MS/MS on an Orbitrap-Elite mass 
spectrometer (Thermo Scientific, Waltham MA). Proteins were identified by database 
searching of the fragment spectra against the SwissProt (EBI) protein database using 
Mascot (v 2.3, Matrix Science, London, UK). Typical search settings were: mass 
tolerances, 10 ppm precursor, 0.8d fragments; variable modifications, methionine 
sulfoxide, pyro-glutamate formation; up to 2 missed cleavages. The extracted ion 
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chromatograms (XICs) for the bound compounds were examined and peak heights 
were analyzed and quantified by using Qual Browser (Thermo). 
 
2.2 Results: Predicted Hot Spot Residues for Virtual Screening 
2.2.1 Hot Spots on Skp1/Skp2 interface 
The Skp1-Skp2 interface is interdigitated, with alternate structural elements from 
protein interlocking with the other. The middle F-box domain of Skp2 and Skp1 C-
terminal helix (H8 helix) are sandwiched between the other Skp1 helices on one side 
and the first LRR and C-terminal safety-belt on the other side. This interface has been 
described as having a variable and a core interface from the F-box perspective. In the 
core interface, the F-box packs with the H5, H6, and H7 helices of Skp1. It is referred 
to as the core interface because it accounts for two-thirds of the surface area buried, 
(2,050 Å2) and contains residues conserved in all Skp1 and F-box protein 
members(243). The variable interface was defined as the opposite face of the F-box 
packing with the H8 helix of Skp1 and also with the first LRR and C-terminal end of 
the safety-belt (an area of 930Å2). The structural elements in the variable interface are 
conserved in Skp1 and Skp2 orthologues, but not in other F-box and Skp1 family 
members, particularly in the H8 helix (243). This is not to say that the variable region 
does not contribute to binding. An in vitro assay that compared dissociation of the 
Skp1-Skp2 complex with that of a F-box-Skp1ΔH8 complex, which has a core 
interface structure similar to the original but lacks all of the elements unique to the 
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variable interface, showed half-lives of greater than 9 hours and less than 30 minutes, 
respectively(243).  
The SiteFinder program in MOE (Chemical computing group) was used on the 
2AST crystal structure, this program does not consider hot spots but uses simple 
proximity-based rules of connectivity. Also, the HotPoint, FTMap, as well as KFC2A 
and KFC2B models were used on the same structures. For each of these jobs, the 
2AST structure was stripped of all other proteins/solvent molecules/waters, leaving 
only the Skp2 protein. Default parameters were used for the HotPoint models, and 
KFC2 was submitted the refined PDB structure, as the entry of the PDB code on the 
web server gave an error. KFC predictions were showing highly inconsistent results 
with the HotPoint and MOE site finder predictions, including suggestions on both 
Skp1 and Skp2 where residues had their side chains slightly buried and predictions of 
residues with smaller sidechains where it was not obvious as to how these residues 
interactions between Skp1 and Skp2 were possible. The KFC results were not 
discarded, just given less weight in the final ensemble consideration. Also, FTMap’s 
prediction was biased towards pockets of the Cks1 binding site, but did find regions 
that were closer to Skp1. The top ranked cluster centers (the areas with the most 
docked pharmacophores) were corresponding to the Cks1 binding site (Figure 10). 
The top ranked cluster centers that were not in the Cks1 binding site region (in the 
LRR domain) actually corresponded to areas where HotPoint and SiteFinder both 
predicted there were concentrations of hot spot residues. These regions were close to 
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the Skp1-facing H1 helix on Skp2, and the region just behind the H2 and H3 helixes 
of Skp2, facing the beginning of the LRR domain.  
To bolster the predictions, structural analysis was carried out on the contacts 
between Skp1 and Skp2 based on distance and hydrophobic interactions. Overall, 
HotPoint faired the best in predicting the contacting residues, but was biased towards 
residues that were larger and bulkier.  
          
Figure 10. FTMap results of Skp1/Skp2 (blue/green) hot spot predictions. Top 
scoring cluster centers were in the Cks1 binding site, but centers 3, 5, as well as 6/7 
showed good consensus to other hot spot predictions and residues contacting Skp2. 
 
Based on visualization analysis as well as literature reports(242) there are 19 
residues on Skp2 in contact with Skp1 and they form the basis for detecting druggable 
sites in the F-box region of Skp2 (206, 242, 243). The consensus of the hot spot 
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prediction tools as well as the SiteFinder results suggested we group Skp1/Skp2 
contact sites into two pocket-like and distinct regions (Table 3).  
Residue 
Number Name Chain RelCompASA RelMonomerASA Potential Prediction 
95 V B 62.3 115.13 12.39   
96 S B 58.17 73.11 2.13   
97 W B 3.16 61.76 32.59 Hotspot 
99 S B 69.61 80.8 8.13   
100 L B 0.13 23.79 41.47 Hotspot 
101 P B 30.39 44.78 7.19   
104 L B 2.83 49.91 31.55 Hotspot 
107 G B 30.84 48.2 10.65   
108 I B 0.87 47.88 39.69 Hotspot 
111 C B 30.5 82.75 20.49   
112 L B 2.32 24.76 32.47 Hotspot 
114 L B 0.08 5.13 61.89 Hotspot 
116 E B 16.96 37.81 8.76   
118 L B 11.62 54.47 37.19 Hotspot 
119 K B 25.6 66.17 4.7   
121 S B 6.27 19.42 13.14   
122 G B 25.04 87.07 5.36   
123 V B 2.78 60.03 17.75   
124 C B 12.56 43.95 12.65   
125 K B 53.92 91.3 8   
127 W B 4.73 26.39 33.1 Hotspot 
128 Y B 35.12 65.45 18.64   
142 L B 0.58 4.03 47.82 Hotspot 
145 K B 18.99 39.77 8.64   
154 R B 27.56 52.86 19.44   
155 L B 0.85 9.75 54.63 Hotspot 
Table 3. Consensus of HotPoint prediction of hot spot residues on Skp2 based on 
2AST structure. Two pockets were selected based on the two groups of the hotspots. 
 
Trp97, Leu100, Ile108, and Val120 were predicted by all three methods to be hot 
spots, and Trp127 was predicted to be a hot spot by KFC2B and HotPoint. The first 
region (referred to henceforth as pocket 1) is close to the N-terminus of Skp2 and is 
actually within the F-box motif, including Trp97, Phe109, Glu116, Lys119, and 
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Trp127. The second region (referred to henceforth as pocket 2) has proximity to the 
corresponding C-terminus of Skp1, formed by the first and second LRR as well as 
some residues from the F-box, essentially around the variable interface of the F-box 
region of Skp2 (Figure 11). 
                
Figure 11. Identified binding pockets on the Skp12/Skp2 complex. Skp2 (molecular 
surface: gray for carbon, blue for nitrogen, and red for oxygen atoms). Skp1 (purple 
ribbon). Cyan (Skp1 residues interacting with Skp2). 
 
2.2.2 Hot Spots on Cks1/Skp2/p27 interface 
After the consensus analysis of the KFCA, KFCB, PCRPi, and HotPoint 
programs, the residues determined to be the most significant for binding were found 
to center around the PhosphoThreonine187 (TPO187) and Glu185 residues of the p27 
peptide (Figure 12). We selected the residues for which to do virtual screening (using 
the GOLD software) based on these two regions (calling the region around Glu185 
“Pocket1” and the region around T187 “Pocket2”) and, applying techniques similar to 
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those in de novo drug design, we biased our results towards hits that showed similar 
properties and positions to that of the residues in those areas.  
        
Figure 12. Cks1/Skp2/p27 binding site. TPO187 and Glu185 are both significant for 
binding. Virtual screens were centered on these two points separately, and one screen 
included both points together.  
The residues that were selected on Cks1 were: Tyr8, Ser9, Lys11, Arg20, 
Glu40, Arg44, Gln49, Gln50, Ser51, Gln52, Trp54, and Arg71. For Skp2, the residues 
were: Arg294, Asp319, Arg344, and Tyr346 (Table 4. Consensus of 4 hot spot 
predictions on the Skp2/Cks1/p27 interaction site. Residues selected as hot spots 
highlighted in orange or red.) (Figure 13).  
Essentially, this was a more straight forward hot spot prediction, as the p27 
surface area residues that are contacting Skp2 and Cks1 are much smaller and less 
intricate than the Skp1/Skp2 interaction site. Most of these residues closely resembled 
the ones that are in contact with p27 peptide, and, as was mentioned previously, it is 
known that mutations on the Thr187 and Glu185 residues abolish or significantly 
impact the ubiquitination of p27(242). Residues with at least two programs reaching a 
consensus were considered “mild” hot spots (highlighted in orange), while more than 
63 
 
two consensus predictions were considered “strong” hot spots (highlighted in red).  
The number of polar contacts were also calculated by MOE and PyMOL, and these 
also had good agreement with the PCRPi and KFC2 models. HotPoint was perhaps 
overly sensitive in this prediction space with many potential false positives, but it had 
no false negatives. 
              
Figure 13. Hot spot residues for Cks1 (blue)/Skp2 (green) interface. 
 
Chain Res# Res Hotpoint KFC2A KFC2B PCRPi Rank 
Polar 
Cntacts 
B 265 Trp H H H 3 1 
B 291 Ser H       1 
B 294 Arg H     8 1 
B 318 Ser H     9   
B 319 Asp H     7 1 
B 343 Ser H         
B 344 Arg H H H 1 4 
B 368 Phe H     13   
B 393 Trp   H H 2   
B 398 Arg H   H 4 3 
  
C 35 Thr   H   9   
C 36 His     H     
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C 37 Leu H H H 10 2 
C 38 Met H         
C 40 Glu H     2   
C 41 Ser H H   1 3 
C 42 Glu H H H 3 3 
C 44 Arg H     5   
C 45 Asn H H   6   
Table 4. Consensus of 4 hot spot predictions on the Skp2/Cks1/p27 interaction site. 
Residues selected as hot spots highlighted in orange or red. 
 In conclusion, HotPoint and KFC models appeared to have the best predictive 
capacity for the two interaction sites on Skp2, but the use of a larger consensus 
(programs such as FTMap and PCRPi), as well as a visual and robust structural 
analysis was needed to increase the confidence in the predictions.  HotPoint appear to 
perform better for larger and more elaborate surface area interactions (the Skp1/Skp2 
interaction), and its potential bias towards larger residues is a means by which it can 
have this strength, but it hinders for smaller interactions. Other studies have shown it 
to be highly sensitive when compared to other methods (254). FTMap and KFC (and 
to a lesser extent, PCRPi) showed their strength in the smaller sites, but performed 
poorly on the larger complexes. The performance of KFC on smaller sites is likely 
due to their use of a training set that primarily involves hormones, inhibitors and 
small fragment proteins, and not many large complexes (84). 
 These predictions formed the basis for the sites (the general area as well as 
which specific residues to focus on) on which to perform the virtual screening. The 
centroid of the screen was selected such that the area encapsulated by the docking 
program (GOLD uses a radius, HiPCDock uses a cubic unit) contained all the residues 
selected as hot spots.  
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2.3 Results: Evaluation of Skp2 Virtual Screening  
2.3.1 Ligands Submitted for Testing for Skp1/Skp2 interface 
For the Skp1/Skp2 virtual screen, 41 total ligands were chosen as compounds 
to be tested for pocket 1 with 16 compounds listed as high priority. For pocket 2, 16 
total compounds were selected, and 11 of these were high priority. Again, we 
assigned high priority to the compounds in which we had the highest confidence in 
these being active biologically based on their pose and diversity in the virtual screen. 
Only the high priority compounds were ordered for testing in the thought that if none 
of the high priority compounds were active, the medium and low priority compounds 
would be selected for a second round of testing.  
HiPCDock Results: The HiPCDock docking scores of the 50,080 compound 
DiverSet library into pocket 1 and pocket 2 are summarized below (Table 5). The 
histograms of the energies are close to extreme value distribution, and are displayed 
below (Figure 14), (Figure 15). 
 Pocket 1 Pocket 2 
Mean -5.43 -4.12 
Median -5.39 -4.14 
Mode -5.55 -4.23 
Maximum -0.83 -0.00026 
Minimum -12.31 -10.95 
Standard Deviation 1.138 1.18 
Table 5. HiPCDock docking sores of DiverSet into Pocket 1 and Pocket 2 
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Figure 14. Histogram of energies of Pocket 1 HiPCDock docking results. 
 
 
Figure 15. Histogram of energies of Pocket 2 HiPCDock docking results. 
 
Gold Results 
In GOLD, the default scoring function is the GoldScore; this is comprised of 
four components from the equation: 
int_int___ vdwhbextvdwexthb SSSSf +++=  
Where Shb_ext is the protein-ligand hydrogen bonding score and Shb_int is the internal 
hydrogen bonding of the ligand. Svdw_ext and Svdw_int are the scores arising from weak 
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external and internal Van der Waals forces, respectively. The top Gold fitness scores 
for the 4,000 compounds (2000 for pocket 1, 2,000 for pocket 2) are summarized 
below in table form (Table 6), and histograms (Figure 16), (Figure 17). 
 
 Pocket 1 Pocket 2 
Mean 37.76 35.65 
Median 37.93 35.91 
Mode 42.01 36.84 
Maximum 62.55 56.15 
Minimum -44.99 8.29 
Standard Deviation 8.59 5.54 
Table 6. Gold docking sores of DiverSet into Pocket 1 and Pocket 2 
 
              
Figure 16. Histogram of energies of Pocket 1 Gold docking. 
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Figure 17. Histogram of energies of Pocket 2 Gold docking. 
 
 The biological testing of the Pocket 2 compounds revealed almost all 
compounds were poor binders except for one: 9040817. However, investigation of the 
mechanism revealed it was not acting in the mechanism we proposed. Also, secondary 
screens were showing that 9040817 was not effective (Table 7. Top 16 Compounds 
selected for biological testing for Pocket 2. Ligands marked as “High” priority were 
tested biologically. Most of these compounds were not active except for 9040817. 
). 
# Structure ID 
Gold 
Fitness 
Auto 
Dock 
Score 
Class Priority 
In vitro 
binding 
1 
N N
S
N
HN
O
O
N
H
 
7974443 56.15 -6.47 1 High 
>100 
µM 
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2 
N
N
H
N
N N
H
O
S
Cl 
7694040 52.21 -8.35 2 High 
>100 
µM 
3 
N
N
S
N
N
N
 
9043923 51.75 -7.05 3 High 
>100 
µM 
4 NN
H
N
H
N
S
Cl Cl
Cl
Cl
Cl
 
7839261 50.81 -6.31 4 Med 
Not 
tested 
5 
N N
N
N NH
O Cl 
9043648 50.12 -6.89 3 Med 
Not 
tested 
6 N
N
N
N OH
 
9037036 47.94 -6.5 5 High 
>100 
µM 
7 S N
N
O
O
 
5570289 47.31 -6.2 6 Med 
Not 
tested 
8 N HN
N
S
F 
7818158 47.28 -6.4 7 High 
>100 
µM 
9 Redacted Redacted 47.27 -6.68 8 High 5 µM 
10 N
N
O
N
H
 
7740910 46.89 -6.7 9 High 
>100 
µM 
11 
N
N
N
O
N
Cl
F
Cl
 
7739449 46.79 -6.91 3 Med 
Not 
tested 
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12 N
N
N N
O
O OH
 
9062916 46.43 -6.42 10 High 
>100 
µM 
13 N N
HN N
O
O  
7957666 46.39 -6.51 11 High 100 µM 
14 N
N
N N
N
H
N
NH2
Cl
O
 
7726220 46.27 -8.56 3 Low 
Not 
tested 
15 N
NHBr
O
 
7631104 46.11 -8.01 12 High 100 µM 
16 
SN
N
H
N
O
O
Cl
 
6037495 45.64 -6.18 7 High 
>100 
µM 
 
Table 7. Top 16 Compounds selected for biological testing for Pocket 2. Ligands 
marked as “High” priority were tested biologically. Most of these compounds were 
not active except for 9040817. 
 
 Structure ID 
Gold 
Fitness 
Auto 
Dock 
Score 
Class Priority 
In Vitro 
Binding 
Cell 
Sensitivity 
(IC50) 
8 
N
N
N
NH
O
N
S  
9040817 57.31 -8.19 3 High 5 µM >20 µM 
19 Redacted Redacted 54.47 -8.04 10 High 5 µM 5 µM 
35 Redacted Redacted 51.46 -8.52 14 High 5 µM 5-10 µM 
39 Redacted Redacted 51.17 -8.03 17 High 5 µM 10-20 µM 
41 N
SON
O
HO
 
5572358 
(ZL-25) 
50.71 -7.95 18 High 5 µM 5-10 µM 
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Table 8. Results of cell sensitivity (secondary screen) studies. Ligands #35 (which 
has its structure redacted) and #41 (5572358) were found to be the most sensitive and 
fit the mechanism of action. 
The top performing compounds from both pocket 1 and pocket 2 were 
submitted to cell sensitivity studies. The Cell sensitivity studies showed that 
compounds Redacted and 5851912 did not fit the mechanism proposed. These likely 
were achieving the sensitivity values due to another, off-target mechanism of action 
(not via targeting Skp2 and p27 ubiquitination) and were not pursued further. The 
compounds that were found to be most active and fit the mechanism were 5572358 
(which became the lead, ZL-25), and a second compound (which was also known 
internally as ZL-22). ZL-22 was only slightly less active than ZL-25, so ZL-25 
became our primary lead. 
 
2.3.2 Ligands Submitted for Testing for Cks1/Skp2/p27 interface 
In regards to the Cks1/Skp2/p27 site, the unique features of this particular 
target required a more unconventional approach in regard to the virtual screening 
methods. The crystal structure shows that Cks1 binds to the concave leucine-rich 
repeat (LRR) domain on Skp2 (the interface buries ~ 1850Å2 of solvent accessible 
surface), and p27 forms contacts with both Cks1 and Skp2, with interface sizes of 
~740Å2 and ~400Å2, respectively. These interfaces form what is essentially an 
atypical, three-part protein complex on which we focused our inhibitor design efforts. 
The use of three screens covering the two pockets individually and then both taken 
simultaneously was used to maximize the possibility of discovering a ligand large 
enough that could hit both pockets together, (such that might have a stronger potential 
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to block p27 binding) but still retaining the potential of finding a ligand that had a 
high affinity for only one pocket. The top hits from the two smaller targeted screens 
were merged into only 5 compounds with high priority that were tested (Table 9). 
 
# Structure ID 
Gold 
Score 
MolWt logP 
1 
S
O
O
HN O
N
O
O
 
ST02940
5 
65.9258 438.50 
3.03
3 
2 
S
N S
N
H
N
O
O
O O
-
 
ST04175
6 
65.8194 376.43 
2.72
9 
3 
N
N
O OH
HO OH
-
O
 
R732486 62.0391 283.30 
2.33
3 
4 N
NNN H
N
S
S
O
O
-
O
 
R549606 61.2877 312.35 
0.53
4 
5 
N
NN
N
S
H
N
O
O
F
F
F
 
ST02735
5 
60.3729 395.36 
3.45
1 
Table 9. Top hits from two small targeted screens with high priority that were 
biologically tested. #1 (ST029405, referred to later as ZM-405) was found to be active 
and fit the mechanism. 
73 
 
 From the wide screen that incorporated both pockets, there were 14 
compounds selected, five were considered high priority. Due to the low number of 
compounds listed here, all were ordered and all were tested (Table 10).  
 
# Structure ID 
Gold 
Score 
MolWt logP 
1 
N
N+
HN
-
O
O
O
O
O
-
O
Cl
OH
 
ST01693
9 
75.95 454.80 3.372 
2 NNH
O
O
O
O
-
O
O
 
ST03131
2 
74.82 415.38 3.506 
3 
O
N
N
H
O
O
O
O
-
Cl
 
ST02463
4 
73.99 395.77 2.737 
4 N
S
O
O
O
O
O
O
-
O
O
-
 
ST03137
8 
73.44 463.42 3.543 
5 
N
NSS
O
O
H
N
OO
-
O
O
 
ST04003
3 
73.057 482.51 1.92 
6 
S
N
H
N
N
H
N
O
O
O
O O
-
O
 
ST01190
8 
72.54 427.41 3.176 
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7 
S
NH
O
O
HN
O
O
S
O
 
R508276 72.09 407.48 2.381 
8 S
N
H
N
O
O
O
O
OO
Br
 
ST00433
8 
72.06 533.39 3.759 
9 
S
N+
O
O
O
-
O
H2N
O
N
H
 
ST03189
7 
71.68 375.40 2.125 
10 
N+
NH
HN
-
O
O
O
O
O
O
O
 
ST01692
1 
71.29 451.43 3.476 
11 S N
H
O O
-
O
O
 
ST02409
1 
71.26 354.40 2.375 
12 
S
H
N
N
H
O
O
O
O
-
O
O
 
ST04018
6 
71.24 431.48 2.708 
13 
N
N+
N
NHN
H
O
O
O
O
-
Cl
O
 
ST02117
3 
71.19 428.81 3.674 
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14 
H
N
N
H
H
N
O
O
O
O
-
O O
 
L440442 70.76 398.39 1.78 
Table 10. Selected compounds for testing from broad based screen covering both 
T187 and Glu185 pockets. #14 (L440442, later known as ZM-442) was originally 
considered active in initial screens but was not confirmed in secondary assays. 
 
2.3.4 Discussion of findings from Virtual Screens 
The 2AST crystal structure was chosen for its high resolution and its inclusion 
of the p27 and Cks1 peptides. Consideration of the residues that contacted Skp2 from 
Skp1 was a crucial step in understanding which sites would lead to the disruption of 
this complex, and the site finder in MOE helped to validate pocket 2 as a reasonable 
location to perform one of the virtual screens. The choice of the DiverSet library as 
the primary screening ligand set ensured that adequate chemical diversity was present 
in the virtual screening. The diversity stems partially from the more than 260,000 
unique 3-point pharmacophores present within DiverSet. It has high diversity in drug-
like compounds, and applied filters remove unsuitable compounds such as: 
undesirable chemical groups (e.g. Michael acceptors, crown-ethers & analogs, 
disulfides, epoxides), structural, salt and tautomeric duplicates (241).  
Using HiPCDock as the first High-Throughput Docking (HTD) tool for 
screening because of its, speed, efficiency and ease of use in a High-Performance 
Computing, multiple-CPU cluster environment. Its basis on the AutoDock framework 
allows for easy automation and high levels of control over the parameters involved, 
and its statistical-based bioinformatics model towards structure-based HTD gives it an 
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advantage over other docking tools. The binding free energy distribution is very close 
to extreme value distribution, which allows us to calculate the probability and 
expectation of the binding free energy of the ligand-receptor complex; from these 
calculations, a statistical significance of the prediction can be evaluated.  
By docking the top results from HiPCDock into GOLD, we were able to 
utilize a consensus method to enhance the probability of finding active compounds. 
GOLD has been shown in multiple studies to have high accuracy in the prediction of 
binding modes of ligands and it is a more than acceptable program for its use in 
various techniques when compared with other docking or virtual screening programs 
(255-257). The clustering of the GOLD results based on MACCS fingerprints 
increases the relative diversity of the pool of molecules selected for biological testing 
and removes structurally similar compounds.  
The top scoring 130 compounds cluster centers were visualized individually 
by hand in PyMOL to maximize the potential of finding ligands that would prove to 
be active biologically. This higher scrutiny at this stage not only ensured that there 
was more than adequate diversity in the final compounds; it confirmed that the 
compounds resided in the desired interaction site and therefore had a high potential of 
inhibiting the interaction with Skp1. Also of note, our analysis was independent of the 
two docking scores that we obtained; this made for our analysis to be more qualitative 
than quantitative.  
Skp2, when in complex with the different bound forms of each ligand, gives 
us insight as to what features lead to this good activity. The ligand 5572358 (the 41st 
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entry in the above table, referred to as ZL-25 in the remainder of this study), when 
docked to Skp2, is indicative of the structures of other ligands that showed high 
docking scores, and good biological activity. Also of note is the pi stacking occurring 
towards Trp97, with an average distance of 3.27Å to this residue. The ligand ZL-22, 
which also shows good biological activity, also shows a single hydrogen bond, but 
occupies a lipophilic region bound by Ile108, Trp127, Phe109, and Leu105.  Again, 
the pi stacking appears to be strong between the ZL-22 ligand and the Trp97 residue, 
with an average distance of 3.1Å. 
 
2.3.4 Summary of findings from Virtual Screens 
In total, from the initial virtual screens there were two compounds initially 
considered leads for both Skp2 regions. ZL-25 and ZL-22 for the Skp1/Skp2 interface 
(Figure 19), and ZM-405 with ZM-442 for the Cks1/Skp2/p27 project (Figure 18). 
From these, ZL-25 and ZM-405 were considered the primary leads on which lead 
optimization would be performed (Figure 20). 
 
Figure 18. Top two p27 inhibitors discovered via virtual screen (left) and proposed 
binding poses (right).  Compound ZM-442 (blue sticks) covers both pockets (Thr187 
and Glu185), whereas compound ZM-405 (purple sticks) is predicted to bind to just 
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the Glu185 pocket. Both compounds are capable to block p27 binding (shown in 
yellow sticks).  
 
 
Figure 19. ZL-25 in proposed docked position on Skp2. Significant residues for 
binding circled.  
 
  
Figure 20. Structures of the two Skp2 inhibitor leads: ZL-25 (left), ZM-405 (right). 
 
2.4 Results: Biological Effects of Virtual Screening Results 
2.4.1 In Vitro and In Vivo Data of Skp1/Skp2 inhibitor ZL-25 
 Portions of this data used with permission from the journal Cell, in the article: 
“Pharmacological Inactivation of Skp2 SCF Ubiquitin Ligase Restricts Cancer Stem 
Cell Traits and Cancer Progression” Cell. 2013 Aug 1;154(3):556-68. (176) 
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 Our collaborators performed the biological testing of the suggested 
compounds, the effects of the compounds are presented here. The initial in vitro 
binding assay/screen that identified ZL-22 and ZL-25 was a simple GST-Skp1 pull-
down assay at 5µM showing that it was able to completely prevent Skp1-Skp2 
interactions (Figure 21A.) and do so in a dose dependent manner in PC3 cells 
(Figure 21B). Next, our collaborators tested the ability of ZL-25 to reduce the levels 
of ubiquitinated p27 in vitro with a Skp2-mediated ubiquitination assay, and again it 
was able to achieve these effects in the sub-10µM range resulting in their stabilization 
(Figure 22). 
 
Figure 21. A. In vitro binding assay of Skp1-Skp2 with our without ZL-25 (far right 
lane).  B. In vivo dose dependent Skp1-Skp2 binding assay in PC3 cells. 
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Figure 22. ZL-25 is able to inhibit Skp2-mediated p27 ubiquitination in vitro.  
 
 Additionally, consistent with the ubiquitination assay of p27, a dose-
dependent induction in the fold change of p21 (another substrate of Skp2) and p27 
was seen in PC3 (prostate cancer) cells is apparent with ZL-25. It is not readily 
apparent as to why the 1µM dose seems to result in a small decrease in the fold 
change of p21 and p27 (Figure 23). 
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Figure 23. Induction of p21 and p27 via ZL-25. PC3 cells were treated with DMSO 
or ZL-25 at different doses for 24hrs and harvested for immunoblotting (IB) assay. 
 
As Akt is a substrate of Skp2 for K63-linked ubiquitination and Skp2 is 
responsible for its activation via this mechanism, ZL-25 was also shown to inhibit 
Skp2-mediated ubiquitination both in vivo (293T cells) and in vitro (Figure 24). 
 
Figure 24. ZL-25 also affects other Skp2 substrates, such as Akt. A. In vivo Akt 
ubiquitination assay showing dose dependent inhibition. B. In vitro Skp2-mediated 
Akt ubiquitination assay.  
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2.4.2 Confirmation of Binding Mechanism of ZL-25 
The predicted binding mode of ZL-25 shows several primary interactions with the 
F-box domain on Skp2. Most notable are the Trp97, Asp98, Arg126, and Trp127 
residues (Figure 25). Other nearby residues that contribute to Skp1 binding but not 
ZL-25 binding include Pro101, Leu105, Ile108, and Phe109.  
     
Figure 25. Proposed docking mode of ZL-25 to Skp2 F-box domain. Highlighted 
residues contribute significantly for ZL-25 binding. 
To determine the residues responsible for binding to both Skp1 and to ZL-25, site-
directed mutagenesis was carried out on all the above residues. The mutant proteins 
had their residues mutated to alanine (since it is the least reactive amino acid that does 
not introduce torsional freedom). Of the mutants Skp2 proteins, only the Skp2 
Trp97Ala, Asp98Ala, and Trp127Ala retained their Skp1 binding ability, the others 
lost their Skp1 binding capacity, but it is worth noting that Ile108 retained 50% of its 
binding affinity to Skp1 (Figure 26). Among the proteins that retained all their Skp1 
binding ability the biological activity of Trp97A, Asp98A, and Trp127A were tested 
for their capacity to bind to ZL-25. It was demonstrated that Trp97A and Asp98A are 
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resistant to the effects of the inhibitor, which confirms that these residues are 
responsible for binding ZL-25 to Skp2 and that the predicted binding mode of ZL-25 
from the virtual screen is accurate (Figure 27). 
            
Figure 26. 293T cell Skp1-Skp2 binding assay. W97A, D98A, and W127A all 
retained their ability to bind to Skp1. 
 
                   
Figure 27. 293T cell ubiquitin binding assay transfected with different mutant 
constructs and in the presence or absence of ZL-25. 
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 In addition to this mutant data, cell survival was examined of WT Skp2 versus 
the W97A and D98A mutants. The effect of ZL-25 was examined on survival in two 
types of prostate cancer cells: Skp2-knockdown and control mutants dosed with ZL-
25. The inhibitor had capable effect on the viability of control-knockdown cells in a 
manner that was dose-dependent, its effects were compromised when compared to the 
Skp2-silenced cells (Figure 28). 
 
Figure 28. PC3 cells with or without Skp2 knockdown (A) or PC3 cells stably 
expressed with Skp2 WT, W97A, or D98A mutants (B) treated with various doses of 
ZL-25, followed by cell survival assay. Cell survival percentage of each stable cell 
lines treated with various doses of ZL-25 was normalized to that treated with DMSO. 
Results are presented as mean values ± SD. ∗p < 0.05; ∗∗p < 0.01. 
 
 Next, to determine the specificity of ZL-25, two other highly similar F-box 
proteins (specifically Fbw7 and β-TrCP) were selected for their potential binding to 
ZL-25. Despite the drastic effects of ZL-25 on Skp2-mediated ubiquitination of p27 
and Akt by Skp2 (shown above), the inhibitor showed no appreciable effects on β-
TrCP-mediated ubiquitination of Snail and IκBα (two of the targets of β-TrCP) (258), 
as well as Fbw7-mediated ubiquitination of c-Jun and MCL-1 (two well described 
targets of Fbx7) (reviewed in (259)) (Figure 29). 
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Figure 29. ZL-25 is specific towards diminishing E3 activity of Skp2, but not other F-
box complexes such as β-TrCP and Fbw7. 293T cells transfected with various 
constructs with DMSO or ZL-25 was treated with MG132 for 6hr followed by in vivo 
ubiquitination assay. 
 
The mutagenesis data shows that ZL-25 binds to the Trp97 and Asp98 
residues on Skp2, and this compound is specific for Skp2 and no other highly similar 
F-box proteins. This prompted a further sequence analysis of the F-box domains of 
Skp2 compared to other F-box proteins. When the consensus sequence of all 69 
human F-box proteins are analyzed, the ZL-25 binding site occurs in a region of the 
F-box where consensus is low (N = 4,5 in below figure), and Skp2 contains residues 
not shared by other F-box proteins (Figure 30).  
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Figure 30. Consensus sequence of first 31 residues of F-box domain shows ZL-25 
binding site in region of low commonality to other proteins (residues 4 and 5 in this 
image, corresponding to Trp97 and Asp98, respectively). The consensus is much 
higher in the key leucine and proline at residues 7 and 8. Taken from Prosite (260). 
There have been other natural products that have been shown to interact with 
F-box proteins that show similar structures to ZL-25, (which is structurally an 
isoflavone, which is a natural product based on the flavonoid scaffold) although their 
specific mechanism of actions and modes/regions of binding have not been 
confirmed. 1,2,3,4,6-penta-O-galloyl-β-D-glucose (5GG), curcumin, quercetin as well 
as lycopene all cause downregulation of Skp2 protein in two different breast cancer 
cell lines, despite the fact that this downregulation did not always correlate with a 
corresponding p27 upregulation, but when 5GG is used in combination with chrysin, 
tumor growth was suppressed in xenograft mice (261). The isoflavone wogonin was 
shown to have anti-cancer effects and was able to down-regulate c-Myc and Skp2 at 
the protein level and also FBW7 levels were decreased in A549 cells (262). However, 
as wogonin also has potential to inhibit kinases involved in Ras pathways in 
melanoma cell lines and has affinity to matrix metalloproteinase-9 (MMP-9) in HCC 
(263, 264), it is possible there might be an underlying mechanism of which Skp2 is a 
minor player. 
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One issue with flavonoids as treatments is that they are readily and easily 
metabolized by phase II enzymes such as glucuronosyltransferases (UGTs) and 
sulfotransferases (SULTs), reducing their half-life drastically. Isoflavones such as 
genistein (ZL-25 is an isoflavone) however have been shown to not be metabolized by 
SULT1A3 (the major SULT in humans), but by SULT1A1, which is expressed in 
much lower amounts (265). Genistein, when compared to other isoflavone analogs, 
has also been shown that the formation of the genistein metabolite did not have 
comparable excretion and formation rates, showing that the intestinal disposition of 
isoflavone compounds was structurally dependent (266). 
 
2.4.3 In Vitro and In Vivo data of Cks1/Skp2/p27 inhibitor ZM-405 
 Our collaborators examined the effects of ST029405 (which was renamed to 
ZM-405) and found it to be the most active compound. As similar to the initial screen 
of ZL-25 via Co-IP of Skp1 and Skp2, this screen used Skp2 and p27. ZM-405 was 
able to disrupt p27-Skp2 interactions (specifically, binding to the SCF complex, as 
Cks1 accessory protein is required to bind to p27) and inhibit the ubiquitination of 
p27. Immunoprecipitated p27 and Normal Ig (NIg) blotted with anti-Ub antibody 
show disrupted p27 binding to Skp2 and decreased p27 (Figure 31). 
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Figure 31. Initial activity discovery of ZM-405. A. ZM-405 disrupts p27-Skp2 
interactions via Co-IP. B. ZM-405 also inhibits p27 ubiquitination. NIg: Normal Ig 
 To check the specificity of ZM-405, it was tested on a downstream target of 
Skp2 E3 ubiquitin ligase, the retinoblastoma member p130, which is another target of 
Skp2 (although not as significant as p27) (132). ZM-405 did not disrupt p130 as much 
as it did p27 at 10µM doses, indicating it also has good specificity towards its target 
of p27 (Figure 32). 
 
Figure 32. ZM-405 does not target p130 for ubiquitination. At 10µM doses, ZM-405 
shows it is specific for p27. 
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 In light of the knowledge that p27 is only effective when in the nucleus and is 
targeted for ubiquitination by Skp2 primarily in the nucleus (after it is phosphorylated 
on Thr187 (267) in this study, an attempt was made to look at the endpoint of restore 
nuclear p27 localization so that Skp2 and the SCF complex will be inhibited in the 
nucleus, and not the cytoplasm. ZL-405 was able, in a dose-dependent manner to 
restore nuclear localization of p27 and did not increase cytosolic levels. Again, 
consistent with the selectivity that was predicted for targeting the Cks1/Skp2 binding 
site, our collaborators found that it had these effects on restoring nuclear p27 while 
not having an effect on p130 in the nucleus or in the cytoplasm (Figure 33).   
 
Figure 33. Results of ZM-405 testing on restoring nuclear p27 levels. A. Western 
analysis shows selective p27 (but not other targets such as p130) levels increase. B. 
Total p27 increase is associated with increased nuclear and decreased cytoplasmic. 
 Another structural analysis of the Cks1/Skp2 interaction site in comparison to 
other F-box proteins shows that the region of Cks1/p27 binding does not share 
homology with other proteins, indicating that the specificity of Cks1/p27 binding 
90 
 
might be due to the differing sequence and explains why p130 is not affected in 
inhibitor treatment (Figure 34). 
 
 
Figure 34. Conservation of residues of seat-belt region of Skp2 (top row) compared 
to other F-box proteins. Warmer colors indicate higher conservation.  
 
2.5 Summary of Results and key Conclusions from Hot Spot study and Virtual 
Screening Data 
 After a rigorous study of the structure of Skp2 on two key regions (the 
Skp1/Skp2 interface and the Cks1/Skp2/p27 interface), an ensemble of computational 
hot spot prediction techniques were used on these two regions and the key residues 
that were suggested to be hot spots became the basis on which to perform multiple in 
silico high-throughput virtual screens using multiple large datasets of drug-like and 
lead-like compound libraries. Two lead compounds were discovered and tested in 
various biological systems and found to have good initial activity and good specificity 
for different areas of Skp2 (ZL-25 and ZM-405). In the next chapter, multiple 
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techniques will be used to analyze their binding and study their effects upon binding 
in order to suggest modifications to increase their potency and specificity. 
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Chapter 3: Binding Analysis and Pre-Clinical Development of Inhibitors 
3.1 Introduction 
 From the hot spot analysis of Skp2 (both in the Fbox/Skp1 region and the 
Cks1/p27 region, we identified two distinct (but yet distant and with differing effects) 
regions on which to conduct virtual screens. The subsequent virtual screens gave 
compounds that showed biological activity in both regions on Skp2.  
 Here our aims are to build off of the initial biological results obtained from 
both the Skp1/Skp2 and Cks1/Skp2/p27 inhibitors and develop them for future 
clinical use. This involves many steps, including: increasing the binding affinity of the 
inhibitors to their targets, maintain specificity of inhibitors to the targets, and 
minimize off-target effects, evaluate potential overt toxicity events, and maximize 
inhibitor’s ability to stay in tumor cells and maximize half-life and minimize 
metabolism. A major question that we also hope to answer is how are the inhibitors 
binding specifically to their targets, and how are the targets responding to ligand 
binding. This is especially important and difficult, as all the inhibitors presented here 
are PPIs, so there will be an interplay of not just two elements in the investigation of 
the ligand binding.  
 A concern with the Skp1/Skp2 inhibitor (ZL-25) is that, as was confirmed by 
the mutagenesis, it binds to Trp97 and Asp98, which are residues that are two away 
from the end of the Skp2 crystal structure in the 2AST PDB entry (242). The concern 
here is that the remaining 95 residues on the N-terminus tail of Skp2 very well might 
be significant for our study of ZL-25 binding, and certainly the N-terminal tail of 
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Skp2 must have significant interactions with Skp1 as well. Indeed, it was shown, 
when a mutant Skp2 was created without the 95 residue tail, the in vitro binding to 
Skp1 was greatly enhanced (data not shown), therefore it also must be oriented in 
such a way that would prevent its binding. Additionally, the nuclear localization 
signal is a motif in the region of residues 67-73.  
Therefore, to address this concern, before conducting binding analysis, a 
homology model was built that recreated the 95 residue N-terminal tail of Skp2. 
Homology modeling is a method that is well established and has been documented 
widely(268), and it is based on the assumption that proteins that possess similar 
sequences must also share similar three dimensional structures, and the number of 
protein folds that exist in nature must be relatively limited (269, 270). This technique 
has been widely utilized by many drug discovery which are based on the structural 
elements of the protein and has been proclaimed as the best prediction method of 
structural homologous protein (271).  
 
3.2 Materials and Methods: Development and Application 
 Multiple in silico techniques are discussed here that are widely used to 
streamline and rationalize drug discovery efforts and aid in decisions of the drug 
discovery pipeline.  Briefly they will be introduced before the specifics of the 
materials and methods are mentioned below.  
 Homology modeling involves the generation of a novel structure based on two 
primary elements: the sequence of a target protein and the model of an existing 
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structure with a similar sequence. It is widely used when x-ray or NMR structures are 
not available of certain protein but other family/species member proteins are 
available. Molecular dynamics (MD) simulations is an all-atom computer simulation 
of a system to study the physical movements of systems of atoms. Usually the atoms 
have their forces and potential energies modeled in a trajectory and the system is 
allowed to progress in small movements and the energies and potentials (force fields) 
are re-evaluated after each step. Both these programs are widely used in 
computational drug discovery efforts (268, 272). 
This is a computationally expensive process, to simulations were carried out 
via the Texas Advanced Computing Cluster (TACC) in Austin. In order to determine 
what settings would yield the best performance on the TACC, a series of identical 
jobs were run to determine the optimal number of CPUs and nodes to utilize that 
would provide the longest simulation in a 24 hour time period (Table 11. Influence of 
Number of CPUs utilized on length of MD simulation).  
 
Number of Nodes 
Utilized on TACC 
Number of CPUs 
Utilized on TACC 
Length of 24hr simulation 
(picoseconds) 
1 144 36590 
2 288 9649 
10 1440 886 
11.6 1680 831 
Table 11. Influence of Number of CPUs utilized on length of MD simulation 
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 Here we can see that the cross-talk between even just two nodes is a limiting 
factor, and therefore 144 CPUs is the optimal environment for this system to yield the 
best results before the simulation reaches the 24 hour wall time in the TACC 
environment. 
  
3.2.1 Skp2 N-terminal Tail Homology Modeling 
 The initial coordinates of Skp2 was obtained from the Protein Data Bank 
(PDB code: 2AST) (239). The Skp2 N-terminal tail used PDB code 2OVP (273) as 
the template, which is based on FBXW7, a similar F-box protein. This structure has 
not the entire tail, but residues 65-95. Additionally, when these structures are aligned, 
the extra residues on 2OVP form a well-structured helix behind the H2 and H3 helixes 
of the F-box domain of Skp2. The alignment was performed using the UCSD Biology 
Workbench with the default parameters, and MODELLER (version 9.17) was used to 
build the homology model (274) and perform loop refinement. 10 models were 
generated and evaluated based on their molpdf and DOPE scores as well as refined 
and validated visually (no obvious structural clashes/error). 
 
3.2.2 SCF Complex Homology Modeling 
Similar to the N-terminal tail modeling, the initial coordinates of the SCF 
complex was obtained from the Protein Data Bank (PDB codes: 2AST, 1LDK)(242, 
245). The gaps that are missing are as follows: Cul1 is missing the N-terminal 
residues 1-16, a large loop region with residues 55-84, and a second loop region 
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between residues 148-157. For Skp1, a loop is missing between residues 70-91. 
Finally, and again similar to the above modeling, the Skp2 N-terminal tail used PDB 
code 2OVP (273) as the template, which is based on FBXW7. This structure has not 
the entire tail, but residues 65-95. The residues were added based on the H. sapiens 
Skp1, Skp2, and Cul1 sequence (Uniprot IDs: P63208, Q13309, and Q13616, 
respectively. MODELLER (v. 9.17) was used to generate templates, and the best 
models were selected based on molpdf DOPE scores. 10 models were generated for 
each “run” and 10 runs were created, resulting in 100 overall models. From each run, 
a different random seed was selected to ensure that each run was independent of the 
previous ones. They were then inspected for obvious clashes/errors/improper angles. 
The top 2-3 candidates from each run were selected that had both the best molpdf 
DOPE scores and did not have any improper chains being inserted inappropriately 
into other elements of the SCF complex (e.g. MODELLER occasionally inserted the 
N-terminal loop region of Cul1 in between the H2 and H3 helixes of Skp2). These top 
2-3 models from 10 runs were then compared and the top model was selected. 
 
3.2.3 Skp2 Mutants Molecular Dynamics 
 The 2AST structure was used and stripped of all non-Skp2 atoms (Skp1, Cks1, 
p27, waters, and benzamidine groups. Three structures were generated: Wild type (no 
changes), a Trp97Ala mutant, and an Asp98Ala mutant. PyMOL was used to perform 
the mutations, and MOE performed a small minimization step on the side chain to 
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relax the mutants. AMBER software package was used as the software for the MD 
and the analysis (275).  
 
3.2.4 Skp2 N-terminal Tail and the SCF Complex Molecular Dynamics 
All molecular dynamics simulations were performed by the AMBER14 software 
package(275). For Skp1-Skp2, Skp2, Skp2-ZL-25 simulations, the 2AST structure 
was again selected. For the complete SCF complex with loop and tail regions, the 
model from the work done in the above section was used. The ff14SB force field 
(276) was induced to outline the atomic interactions between the protein elements. 
Structures were inserted in the centroid of a cubic water box using TIP3P (277). The 
system was energy minimized using steepest descent algorithm. After minimization 
step, the system was heated with water at 300K, and a density step was performed. 
After the density step, the production simulation was submitted. MMPBSA was used 
to analyze the energy of the ligand binding. RMSD and other AMBER analysis and 
processing of results was performed by the PTRAJ and CPPTRAJ packages (278). 
All simulations were performed remotely on the Lonestar HPC cluster at the Texas 
Advanced Computing Center (TACC) in the University of Texas at Austin. 
 
3.2.5 Cks1/Skp2/p27 interface Molecular Dynamics 
 The 2AST structure was used, but only Skp1, p27 and the benzamidine groups 
were removed, keeping Cks1 and Skp2. All other settings used were same as previous 
MD runs described above. 
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3.3 Structure Activity Relationship (SAR) Results 
 Next, a search was conducted for both lead ligands to find compounds with the 
same core scaffold, but had small modifications to uncover changes that would lead to 
better activity, namely, a structure activity relationship (SAR). A similarity search 
was carried out on each lead structure in the PubChem chemical database (279) 
(starting with 95% similarity) and structures that were commercially available were 
selected.  
 
3.3.1 SAR results of ZL-25 
For ZL-25, 14 structures were found and tested first as an in vitro Skp1-Skp2 
binding assay similar to the primary assay used to discover ZL-25’s activity (Figure 
35). 
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Figure 35. Structure-activity relationship (SAR) of ZL-25 and its derivatives. #25-5 is 
illustrated separately due to its unique core structure. 
The testing of these 14 revealed only two compounds with similar activity to 
the lead, listed as 25-5 and 25-9 (Figure 36). These were also tested in an in vivo 
ubiquitination assay and a multi-dose cell survival assay, and these two also 
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performed just as well as the lead, but not significantly better than the lead compound 
(Figure 37). 
 
Figure 36. In vitro Skp2-Skp1 binding assay in the presence of DMSO, ZL-25, or its 
derivatives. Only 25-5 and 25-9 were as active as the lead, ZL-25. 
 
 
Figure 37. 25-5 and 25-9 results matched lead, but no better. 293T p27 ubiquitination 
assay with various constructs in the presence of DMSO or ZL-25 (Left).  PC3 cells 
with various doses of ZL-25 or three other derivatives (25-6 is less effective) (Right).  
 
 Even though there were only two active compounds, the inactive compounds 
tell us about the structural features that are required and not required. Looking at 
Figure 35 at the chromone core structure and consider the different R groups, at the R0 
position the benzothiazole group (upper right side) seems needed; the 25-13 and 25-
14 4-Me-thiazole lost their activity. The double ringed benzomidazole (25-9) and 
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benzothiazole (all other compounds) groups are very similar and are able to more 
readily form pi-stacking interactions with Trp97 on Skp2. This also matches what we 
know about the mutagenesis efforts on the Trp97 group. 
 On the R1 group (upper left), the ethyl group possibly is required, but at the 
same time 25-5, (that has a chromen-2-one core), was able to bind without an ethyl 
group, but this might be due to the hydroxyl group’s interaction with the 
benzothiazole group in forcing it to not lie perpendicular to the chromen-2-one group. 
This also can be considered viable when one compares the structures with methyl or 
other large groups in the R2 position (25-12, 25-10, 25-6, 25-2, and 25-3). The R3 
position appears to benefit from a large ring group. 
 There have been additional rounds of SAR testing were carried out by three 
different sets of collaborators (the second round had 12 compounds, the third round 
had 11 compounds, the last one had six) and unfortunately the results often conflict 
with the previous group’s work. The second round of testing used a similar pull-down 
assay to what was used in the first assay, but most of these results were inconsistent 
with the first round of testing. Additionally, compounds that appeared to perform well 
actually failed in secondary screens. However, the one conclusion that was definitive 
across both SAR tests is that a large R3 group is required and cannot be hydrogen 
while there is no large group also on the 7’ position (where the hydroxyl group lies on 
ZL-25).  
The results are shown below, all the tested compounds from the first two SAR 
studies were docked using three different scoring functions and the molecular weight 
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and logP displayed. The values are color coded relative to all the others. More 
favorable values are greener and less red. The column “Norm. w/ vehicle” indicates 
the activity in two ways: either a percentage value showing % of Skp2 binding to 
Skp1 (lower number is better), or a value of 5 through 1. This is a scoring system that 
was used to rank the ligands. Five is comparable to ZL-25, 4 is about 50% as good, 3 
is even less as active as a 4 and was inconsistent in activity (experiments were 
performed in duplicate), 2 is even lower and inconsistent, and a value of 1 had 
absolutely no effect (Table 12). 
ID# Structure 
Gold 
Score 
ASP 
Chem 
Score 
Mol 
Wt 
logP Norm. w/  
vehicle 
Notes 
5572358 
N
S
O
N
O
HO
 
56.71 11.68 9.906 420.5 4.58 10% 
Original 
#25 
5141378 
 
N
S
O
O
HO
 
53.89 14.42 13.68 323.4 3.6 
100% 
(no 
effect) 
No 
piperidin 
(R3) 
5262653 
 
N
S
O
O
N
HO
 
57.85 13.51 14.49 380.5 3.61 8% 
di-
methyl 
R3 
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5363684 
 
N
S
O
O
HO
 
50.71 9.75 11.05 295.3 2.79 75% 
No R1, 
R2 
6942649 
N
O
SO
NH2HO
 
49.72 11.76 7.55 310.3 2.88 8% 
amine 
R2, no 
R3 
 
7354837 
N
S
OO
O
OO
 
59.36 4.474 7.008 429.4 4.65 8% 
replaced 
OH 
6944343 
N
N
O
N
OHO
 
54.32 17.53 16.16 375.4 3.95 35% 
pyrrolidi 
R3 
 
5575354 
 
N
S
O
N
O
O
HO
 
56.38 11.96 11.53 422.5 3.17 10% 
Morpho 
R3 
 
6942719 
 
N
O
S
O
N
HO
OH
OH
 
55.89 19.24 9.964 412.5 2.52 80% 
di-ethyl 
amine 
R2 
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6944820 
N
O
O
O
N
HO
 
55.68 22.53 19.92 336.4 3.1 10% 
di-
methyl 
R3 
 
6942580 N
N
O
N
OHO
 
56.69 18.13 16.04 403.5 4.84 8% 
azepane 
R3 
 
6241435 N
N
O
N
OHO
 
49.04 9.965 12.11 389.5 4.4 40% 
positive 
control 
5568376 N
N
O
N
O
HO
 
53.66 10.41 7.553 417.2 4.09 
Good_
5 
 
6238284 N
O
S
N
OHO
 
53.47 13.85 17.16 392.1 4.89 
Good_
5 
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5564702 
O
N
S
N
O
HO
 
54.8 9.776 7.612 434.2 5.31 Mild_4  
6239123 
O
N
S
N
O
HO
 
54.65 11.62 11.37 420.1 4.94 Mild_4  
6944596 
O
N
S
N
O
O
HO
O
 
55.6 8.116 9.606 492.2 5.29 Mild_4  
6240475 
 
O
N
S
N
O
HO
 
55.06 9.865 11.15 392.1 4.06 Mild_4  
9225029 
 N
O
S
N
O
HO
 
49.37 16.75 14.57 370.1 2.75 Mild_4  
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5359138 
 
N
S
O
O
N
HO
 
58.63 16.95 19.05 408.1 4.29 
Cmpra
bl_3 
 
5540697 
 
N
S
O
N
O
HO
 
52.71 17.68 16.4 392.1 3.77 
Cmpra
ble_3 
 
6942706 N
S
O
N
N
O
HO
OH
 
58.45 10.4 11.92 465.2 2.44 
Half-
Incnsist
nt_2 
 
9242229 
HO
N
O
N
S
O
N
 
57.59 16.66 13.6 461.2 3.25 
Half-
Incnsist
nt_2 
 
6944692 
O
N
S
N
N
O
HO
 
56.62 17.33 12.44 463.2 4.3 
No 
Effect 1 
 
6238459 
O
N
S
N
O
HO
 
56.03 14.55 13.82 420.1 4.96 
No 
Effect 1 
 
107 
 
6239814 
O
N
S
N
N
O
HO
 
55.25 12.98 12.24 421.1 3.05 
No 
Effect 1 
 
Table 12. Combined results of first two SAR studies. Values are color coded to have 
more favorable values in green. 5: comparable to ZL-25, 4 is about 50% as good, 3 is 
even less as active as a 4 and was inconsistent in activity (experiments were 
performed in duplicate), 2 is even lower and inconsistent, and a value of 1 had 
absolutely no effect. 
 
The third round of SAR testing was a viability assay and actually used ZL-25 
from two different vendors. The far right lane (#25) is ZL-25 from a primary vendor, 
#7 is from a secondary vendor and appeared to have slightly different activities. Two 
compounds were repeated across the two studies from the first round of SAR testing 
(data from Figure 35) and were consistently inactive: #6 is 25-5 from the previous 
study, as is #10 identical to 25-10. #12 is 25-13 from the previous study (Figure 38). 
Compounds from this study are in (Figure 39). 
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Figure 38. Second SAR study comparing viability. #7 is a batch of ZL-25 from a 
newer vendor, #25 is ZL-25 from a more previous vendor. Structures are visible 
inFigure 39.  
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Figure 39. Compounds used in 2nd SAR study (results on Figure 38). 
 
Compiling the results of all three group’s work into one table has been 
performed, and the best understanding of the compilation of the work is presented 
here (Figure 40). 
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Figure 40. Compilation consensus of conclusions of all SAR studies. On a per-
position basis. 
 
3.3.2 SAR results of ZM-405 
 ZM-405 has only had one primary SAR study, with only three compounds 
with one change on the benzene ring resulting in any activity (R3 group) (Figure 41). 
The hits were tested in ECC1 cells for 24hrs with shown doses and after 24hrs, total 
protein levels were determined by western with specific antibodies and it was 
determined that 9276 and 8243 were considered better performers than  ZM-405 
(Figure 42). A new compound (which has its info redacted) became then the new lead 
compound candidate for this project and was renamed ZM-276. 
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Figure 41. SAR study of ZL-405 inhibitor. #2 (redacted) was shown to be more 
effective than ZL-405. Modifications to R3 group highlighted.  
 
 
Figure 42. ECC1 cells treated with 3 ZM-405 analogs (last three digits indicate IDs). 
243 (redacted) and 276 (redacted) performed better than ZM-405.  
 
 An additional 76 compounds were selected with high similarity to ZM-405 
and were tested in a high-throughput assay for their ability to restore nuclear p27 
levels. Unfortunately only the compounds with modifications on the R3 group were 
active. There was great sensitivity on this group, and even other aromatic rings were 
completely inactive when compared to groups with large bulky modifications at the 
end of the R3 ring (Figure 43). 
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Figure 43. ZM-276 (left, redacted) was highly active in restoring nuclear p27, but 
SKT823113 (right) was almost completely inactive. 
 
3.4 Homology Modeling of Skp2 N-terminus Tail Results 
The original discovery of ZL-25 used the 2AST structure and the virtual 
screening took place on two regions of the Skp1/Skp2 interface. Originally, this 
project was to examine only the interaction between Skp2 and the ZL-25 ligand, 
perhaps taking into account Skp1 to explore the ligand binding and aid in the 
enhancement of the binding and efficacy of ZL-25. The ligand binding region of ZL-
25 occurs on Trp97 and Asp98, and this site exists only two residues before the N-
terminus end of the Skp2 2AST structure (Val95) and the rest of the N-terminal tail is 
unresolved.  
As was said previously, the missing residues of the N-terminal tail have not 
been crystalized before the Val95 residue, and none have been described to have any 
known secondary structure using any method currently available. Using various 
prediction tools indicated that there might be some small secondary features. For 
example, PsiPred indicated that there is a small helix from residues 40-43 and a larger 
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one from residues 52-58, and a very small coil in 80-83, but the confidence in this coil 
is very low (Figure 44).  
 
Figure 44. PsiPred prediction of secondary structure of Skp2 N-terminal tail. 2AST 
structure starts at residue 95. 
 
The most adequate of an F-box protein template that was found to have the F-
box domain and a longest region of the N-terminal tail was the 2OVP protein from 
Fbw7 (or FBXW7). This F-box protein had its additional 15-residue N-terminal tail 
existing both in a 2.5 turn (9 residue) helix and in a region closer to the LRR domain, 
and residing behind the H3 helix of Skp2, forming hydrophobic bonds between this 
tail and the Skp2 H3 helix (Figure 45). This 2OVP structure was initially used as the 
template on which to model a 15-residue extension of the N-terminal tail of Skp2.  
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Figure 45. Modeling of Skp2 N-terminal tail. 2AST structure (green) compared to 
2OVP structure (blue). 2OVP has additional residues crystalized and shown a position 
behind H3 helix. 
 
Five final tail models were selected based on their molpdf and DOPE scores, 
and each were diverse in their final positions relative to Skp2 (this was not a selection 
criteria). They were called mod6, mod9, mod11, mod18, and mod20 (colored yellow, 
light blue, red, and purple, respectively in Figure 46). The highest scoring model was 
in fact mod11 (Brown structure in Figure 46), which adopted a configuration in 
which the N-terminal tail occupied the ZL-25 binding site and forms extensive 
contacts in between the H1 and H2 helixes of the Skp2 F-box which is the primary 
binding site of both Skp1 and the Skp1-Skp2 inhibitor ZL-25). This mod11 
conformation might indicate that when a Skp2 N-terminal truncated mutant is 
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compared to WT Skp2, the mutant forms in the SCF complex almost 50% faster (data 
not shown). 
 
 
Figure 46. Highest scoring homology models of Skp2 tail. Four models showed on 
left have diverse structures (left). Mod11 (brown) is the only model that occupies 
Skp1 and ZL-25 binding site between H1 and H2 helixes (right).   
 
3.5 Homology Modeling of SCF Complex Results 
After further investigation into the entire SCF complex, it was determined that 
loop regions of Skp1 and Cul1 would have to be considered when modeling the N-
terminal tail of Skp2, and other structures were added to the 2AST structure. The full 
model of the SCF complex revealed that the 2OVP structure is in fact inappropriate 
for the N-terminal tail model, as it lies in a region which is occupied by Cul1 and 
clashes with multiple parts of this large protein (Figure 47).  
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Figure 47. Skp2 (green) with Cul1 structure (purple) shows large regions of steric 
clashes (red). Using the 2OVP template of the F-box protein, this model cannot adopt 
a conformation into the SCF complex without clashing with Cul1 residues. 
 
3.5.1 Active Recruitment Modeling of SCF Elements. 
It has been understood that there are post-translational events that occur in on 
the SCF complex that facilitate the recruitment of its constituents to the SCF complex. 
In order to help understand how these events impact Skp2 recruitment, they were 
recreated in the current SCF model. It was recently discovered that the Ser256 
residues in the LRR domain of Skp2 is important for Skp1 and Cul1 binding. 
(Ironically, SCFSkp2, after Akt phosphorylation, binds to FOXO1 and induces its 
ubiquitination at the same residue on FOXO1, Ser256 (280)). This Ser256 on Skp2 is 
located at the end of the 4th leucine-rich repeat (LRR4) opposite the side of where 
Cks1 binds and is oriented in a way that its side chain is pointing towards Cul1(Fig5). 
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This would indicate that, if Skp2 was able to “bend” towards Cul1, it would 
potentially interact with corresponding residues on Cul1. Merging the 2AST and 
1LDK structures, the Ser256 residue on Skp2 is closest to Asp216 and Leu225 on 
Cul1, with distances of 19.4Å and 26.4Å, respectively, requiring only a 31.7° bend in 
the Skp2 F-box domain in order to come within the distance where these residues 
could form extensive interactions. The 10 residue loop region that was generated 
between Asp216 and Leu225 (DDAFAKGPTL) by MODELLER extends the loop 
towards Skp2 and the Ser356 residue. The most notable residue of this loop region is 
Lys221 in the middle, which extends its side chain even closer to Skp2.  
 
Figure 48. Active recruitment of SCF complex members is enhanced by 
phosphorylation of key residues. Ser256 on Skp2 results in its enhancement of 
formation of the SCF complex.  Modeling of a key loop region on Cul1 shows that 
Lys221 on Cul1 can bind to Skp2 when the F-box domain bends only 31.7° (blue 
cartoon). The Cul1 Lys221A mutant displays similar rates of complex formation to a 
Skp2 Ser256A mutant. 
 When tested biologically, both residues are shown to impact the assembly of 
the SCF complex; mutation of Lys221 on Cul1 results in a SCF complex that is at 
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least 50% slower to assemble, and this mutation is similar to a Ser256 mutation on 
Skp2. 
 In terms of the post-translational modifications that result in active recruitment 
of the SCF complex, there have been multiple previous reports to this regard beyond 
those that take place on Skp2. For example, p27 is required to be ubiquitinated at the 
Thr187 and Ser10 residues (281). In Toxoplasma gondii, Skp1 has been shown to be 
glycosylated by five glycosyltransferases encoded by three genes on the Pro154 
residue in an evolutionarily conserved pathway that results in a pentasaccharide at this 
Pro residue (282). This residue corresponds to Glu147 in humans. The assembly of 
the Skp1/F-box protein heterodimer is shown to be more efficient when this 
glycosylation is present, based on interactome studies (283). The SCF model 
presented here shows that this residue is not only solvent exposed, but in a structural 
position completely unprotected in relation to the other elements in the SCF complex 
(Figure 49). Additionally, all Cullin proteins (including Cul1) have been found to be 
neddylated by the ubiquitin-like protein Nedd8/Rub1 and gave the first clue as to how 
these large proteins are regulated(284). In regards to the Cul1 protein specifically, it 
has been shown to be neddylated by Nedd8 on K720 in its winged-helix B (WH-B) 
domain (although the authors report the residue as K696), which results in enhanced 
activity towards p27 (285, 286). To remove the Nedd8 protein, the signalosome 
protein COP9 signalosome (CSN) is required, and this allows the binding of 
paralogous regulatory factor proteins called Cand1 and Cand2(287). When Cand1 
binds to Cul1, it results in a disruption of the F-box protein to bind to the Skp1 protein 
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and results in the inhibition of the conjugation of Nedd8(288). Additionally, Rbx1 
(another critical component of functional SCF ubiquitination) is found to be necessary 
to require neddylation and also enhances the E3 ligase activity of the SCF complex. 
This is partially explained by the fact that the location of K720 on Cul1 is proximal to 
Rbx1 in the 1U6G structure (only 5.6Å away). 
      
Figure 49. Post-translational events on other elements in SCF complex. A. Glu147 on 
Skp1 is glycosylated to enhance the binding of Skp1 to the SCF complex. 
The complete model of the SCF complex with the Skp2 tail and all loop 
regions reveals the complexity of the system and potential interplay among the 
elements and their resulting biological aspects (Figure 50). The first 16 residues of 
the N-terminal region of Cul1 have the potential to interact both with Skp1, and with 
the ZL-25 binding site on the interface between Skp1 and Skp2. The large 30 residue 
loop (Ser55 through Val84) is even closer to Skp1/Skp2 (including the LRR regions 
of Skp2) and has an even higher potential of interacting with the ZL-25 binding site. 
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Figure 50. Generation of full model of SCF complex. Using Modeller9.17, a 
homology model was generated that includes missing residues of Skp2 N-terminal 
region (green), Skp1 including missing loops (blue), and missing N-terminus/loops of 
Cul1 (magenta). Additionally, the ZL-25 ligand was added in its docked pose (green 
sticks). 
 
3.6 Molecular Dynamics of Skp2 Mutants Results 
Simulation of the Skp2 protein over a long period of time (182ns) shows the 
relative stability of its different regions (Figure 51). The F-box domain is highly 
destabilized compared to the highly stable LRR region, and, surprisingly, the seatbelt 
region that extends from the end of the 10th LRR and loops back to the F-box domain 
shown a higher stability difference than the F-box domain. 
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Figure 51. RMSD of backbone atoms from molecular dynamics simulations across 
182ns of Skp2 with a 15 residue N-terminal tail of various portions of Skp2 
represented. N-terminal tail and F-box show greatest amounts of variability, whereas 
the LRR and seatbelt regions are the most stable. The region in between the F-box and 
the LRR domain is very stable but has the potential to become destabilized for a short 
period of time. 
 
Simulations of WT Skp2 in comparison with R126A and W127A mutants 
support the known biological information of these isoforms. It has been shown that 
the R126A mutant loses its ability to bind to Skp1 in the F-box domain, whereas the 
W12A mutant is able to retain its binding to Skp1 (176). When RMSD plots are 
generated for these three isoforms of the F-box domain, the WT and W127A isoforms 
show similar results, where the R126A mutant shows a significantly higher F-box 
backbone destabilization relative to the other two (Figure 52).  
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Figure 52. RMSD backbone plots of MD simulations of F-box domains of 3 different 
Skp2 proteins. (Top graph): 3 different simulations were carried out of Skp2: Wild-
type (blue), W127A mutant (green), and R126A mutant (red). (Bottom): Average and 
standard deviation bar chart plot of the same data. 
 
Upon closer examination of the F-box domains of these mutants, the H3 helix 
is the most shifted during this simulation, pulling apart the H1 and H2 helixes. Also, 
at times the seat belt region (the final residues of Skp2 that have folded back from the 
LRR domain), have a greater interaction with the end of the H3 helix. 
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3.7 Molecular Dynamics of Skp2 of SCF Complex Results 
It has been widely understood that the flexibility of Skp2 occurs largely in its 
F-box domain, and in the linker region between the F-box and the first LRR region. 
This is flexibility is proven to be present upon examining MD simulations as well 
(Figure 53). This flexibility explains how it is reasonable to see how Skp2 and Cul1 
can interact via a phosphorylated Ser256 residue on Skp2. In fact, only a 31.5° 
movement of the “hinge” region between the F-box domain and the first LRR region 
of Skp2 moves Ser256 to within 7.3Å of Lys221 on Cul1. This rotation is certainly 
possible, as two other structures of Skp2, 1FQV and 1FS2, have a rotation angle in the 
same area of 61.6°. A small rotation of the side chain on Lys221 brings it within 
hydrogen bonding distance of Ser256 on Skp2. This movement in Skp2 is seen 
primarily in three residues: Ser135, Leu136, and Trp137, which lie just after the H3 
helix of the F-box and the first LRR region. This region is also able to move more 
freely as it is not significantly stabilized by the “seat-belt” region of Skp2 (residues 
415-419).  
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Figure 53. 11 superimposed snapshots of Skp2 after 182ns simulations. The 
simulation shows very little movement in the LRR and ‘seatbelt’ region (upper 
portion), whereas the F-box domain shows significant levels of dynamics (lower 
portion). 
There exist many post-translational modifications that are highly relevant for 
Skp2 that help us to understand the results presented here. The 95 residue N-terminal 
tail of Skp2 just before the F-box domain (also known as the nuclear localization 
signal, or NLS) is especially biologically highly significant for multiple reasons. The 
NLS lies within this N-terminal region, and Skp2 is acetylated at K68 and K71 by 
p300 (289). This acetylation stabilizes Skp2 via impairment of Cdh1-mediated 
proteolysis pathway, as well as promotes cytoplasmic retention. Multiple studies have 
shown that Akt binds to Skp2 in the N-terminal region (The substrate motif sequence 
of Akt is RXRXX(S/T), where X is any amino acid (290)), phosphorylating Skp2 on 
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Ser72 in a manner comparable to that of TSC2, a well-known Akt substrate. Other 
kinases (Akt2, SGK, or S6K) do not do this (214, 291, 292). It is understood that this 
event triggers SCF complex formation, E3 ligase activity, and triggered 14-3-3β-
dependent Skp2 cytosolic relocalization (291). It is worth mentioning that subsequent 
studies found information to the contrary; Ser72 phosphorylation does not control 
Skp2 binding to Skp1 and Cul1, does not influence SCF ubiquitin ligase activity with 
Skp2, and has no affect Skp2’s subcellular localization (293, 294). Therefore, when 
considering the effects of ZL-25 binding in the context of Skp2, one not only should 
consider the other elements of the SCF complex, but: the post-translational events that 
readily occur, the events that occasionally occur, and the resulting biological and 
structural implications of the interactions of these post-translational events in the 
context of all of the SCF complex. 
 
3.8 Molecular Dynamics of N-terminal tail Results 
The Skp2 N-terminal tail has been shown to have a high level of flexibility, 
but the other elements of the SCF limit the available space of the tail. When Skp1 
binds to Skp2, the tail loses about 20% of its available inhabitable region (if we 
assume that it has complete freedom compared to the Skp1/Skp2 complex vs Skp2 
alone). We know that, when tested biologically, the removal of the Skp2 tail greatly 
enhances the assembly of the SCF complex, so it is safe to assume that the N-terminal 
Skp2 tail can be in conformations where it prevents at least one of the other SCF 
members from binding. This is evident when we examine 4 snapshots of 1 simulation 
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of mod20 (one of the best performing tail models from the homology modeling of the 
tail residues of Skp2) over the course of 80ns. As the model progresses, it occupies 4 
very unique positions with roughly the same secondary structure throughout. It is 
worth noting that this is not the full length tail of Skp2; it is only an extra 20 residues 
and not the full 95 residues (Figure 54). 
 
 
Figure 54. Four snapshots of MD of Skp2 model with N-terminal tail portion. 4 
snapshots taken 20ns apart show very unique positions of the tail. Trp97 (green sticks) 
showing original 2AST structure. 
  
However, the addition of the much larger Cul1 (making a Skp1/Skp2/Cul1 
complex) restricts the position of the Skp2 N-terminal tail in a much more significant 
manner; it basically now has two primary positions that are 180°apart: one where the 
tail is extended away from the LRR domain of Skp2 (and away from the Cks1/p27 
binding site) and is highly solvent exposed, or one where it extends in the complete 
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opposite direction towards the LRR domain of Skp2 (these two configurations will be 
referred to henceforth as simply exposed and buried).  
The evidence that the exposed conformation is the most likely is to be found in 
the high number of post-translational events that occur on the N-terminal tail that 
require it to be solvent exposed. Akt1 (but not other kinases such as Akt2, SGK or 
S6k (214)) phosphorylate Skp2 on Ser72 (214, 291). Another study showed that the 
Ser72 phosphorylation event creates a priming site on Skp2 for subsequent 
phosphorylation by Casein Kinase I (CKI) on Ser75 which was detected by a cancer 
cell phosphoproteome (295). When both Ser72 and Ser75 are phosphorylated, 
association with Cdh1 is impaired, thus permitting Skp2 to avoid APC/Cdh1-
mediated ubiquitination and destruction(296). This is significant, as Skp2 itself is 
degraded via the APC/Cdh1 ubiquitin ligase, and binds to the N-terminal domain of 
Skp2 on residues 46-94.One notable neighboring phosphorylation site to Ser72 also 
with notable effects is Ser64 (214). Interestingly, this site is the most conserved site 
phylogenetically within the region of Cdh1 binding and is found in all Skp2 
orthologues, from vertebrates to insects, and also notable is the fact that this 
phosphorylation site is always located about 30 residues N-terminal to the F-box 
(292). One study found that mTORC1 also functions to regulate Skp2 by Ser64 
phosphorylation and this actually has the potential to represent an oncogenic event in 
gastric cancer, as the combination of p-Skp2 and p-mTOR (phosphorylation of 
mTOR) expression was a better predictor of survival than either factor alone (297).  
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Another recent discovery of the N-terminal tail of Skp2 is its inclusion of a 
“destruction box” (D-box) motif. The core sequence of this motif is an arginine 
followed by two residues, then ending in a leucine (RXXLXXXXN/D/E) (298), 
which starts on Arg84 on Skp2 and ends on residue 92. Proteins with a D-box have 
been shown to interact with another ubiquitin-protein ligase called the anaphase-
promoting complex or cyclosome (APC/C), and the first 90 residues of Skp2 are 
required for Skp2 degradation by APC/C in the G1 phase (299). This D-box domain 
on Skp2 is very close to the start of the F-box domain (residue 94). Considering all of 
these post-translational events and other protein elements that bind to the N-terminal 
tail of Skp2, it is highly unlikely that all these modifications and events occur when 
Skp2 is not bound to other SCF complex members or buried inside its other SCF 
partners. These facts indicate that the exposed form of the Skp2 N-terminal tail is the 
most likely conformation to exist biologically. 
 
3.9 Molecular Dynamics of ZL-25 Binding Results 
Simulations of the Skp1/Skp2 complex with the loop regions added to both 
proteins and with ZL-25 docked were performed. The regions that showed the 
greatest displacement were the two final helixes on the C-terminus of Skp1, and 
surprisingly the F-box domain of Skp2 showed only minor movements (Figure 55). 
Also interesting, was that ZL-25 actually flipped the relative locations of the 
benzothiazole group and the chromone core compared to the original starting docked 
structure at the relative start of the simulation, at about 16ns into a 32ns simulation. 
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This rotation was seen on at least 2 separate simulations (Figure 56). This is actually 
still reasonable, as the chromone core still has aromaticity and can still form pi-
stacking with Trp97 (albeit not as strong as the benzothiazole group), and the Asp98 
residue can potentially interact with the benzothiazole group. 
 
        
Figure 55. Results of MD simulation of ZL-25/Skp2 complex A. Backbone RMSD 
(blue) of Skp1/Skp2 in complex with ZL-25 of a 140ns simulation. B. RMSD color-
coded comparison of starting structure with final structure. Color goes from blue 
(small/no displacements) to red/grey (large displacements). ZL-25 shows a rotation 
across an axis perpendicular to main axis of Skp1/Skp2 structure. 
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Figure 56. Molecular Dynamics simulations of ZL-25 ligand in complete SCF 
complex with Skp2 N-terminal tail. From the starting structure (green), ZL-25 rotates 
its orientation relative to the starting structure after approximately 16ns (magenta). 
 
The average RMSD from the starting structure (Skp1/Skp2/ZL-25) to the end 
of the 140.3ns run was 2.95Å, but the maximum distance was 10.21Å. Additionally, 
comparing the per-residue RMSD of both the bound and unbound forms of Skp2 with 
ZL-25 show a destabilization in the F-box domain, whereas the other regions of Skp2 
remain basically unchanged (Figure 57).  
 
 
 
 
131 
 
 
 
Figure 57. Average RMSD per-residue of Skp2 in both bound (blue) and un-bound 
(red) states. Residues Asp373 and Asn403 are in highly variable regions of Skp2 F-
box shows highest destabilization effects upon ligand binding.  Asp373 and Asn403 
mark the end of the LLR domain, and the middle of the seat-belt region, respectively. 
 
This F-box destabilization is also indicated in the Ramachandran plots of the 
bound and unbound forms after a 42ns MD simulation. The majority of the residues 
that show changes in their dihedral angles lie in the F-box domain and there are in fact 
more than three times as many in the bound form vs the unbound state (7 vs. 25). The 
two major improper angles (red residues) in the starting structure and the lone 
improper angle in the bound form are either residues on the edges of the LRR domain, 
the end of the LRR transitioning into the seatbelt, or in the middle of the seat belt; 
residues that are highly solvent exposed or in regions where high torsion will 
naturally exist (Figure 58).  
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Figure 58. Ramachandran plot of (A) unbound and (B) bound forms of Skp2 with 
ZL-25 ligand after 42ns MD simulation. The majority of the shifted angles are from 
the F-box domain. 
It has been estimated that 85% of proteins undergo conformational changes 
upon binding to a ligand, and these changes can range from a simple rotamers (300) 
of key binding site residues to larger domain rearrangements (301). As ZL-25 is a 
protein-protein interaction disruptor, the results from the MD simulations here show 
that this inhibitor can destabilize Skp2 in its F-box domain in a manner that results in 
its ability to prevent its binding to Skp1. As Skp2 is the rate-limiting component of 
the SCF complex, its inability to bind to Skp1 results in a loss of ubiquitination 
activity for its ligands such as p27.  
 To summarize, in this section, we used homology modeling and molecular 
dynamics simulations to indicate that the intricacies of the SCF complex are not 
confined to just one protein and there are also post-translational events that must be 
considered when selecting models and evaluating results from these studies. 
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Chapter 4: Summary and Future Directions 
4.1 Summary of Hot Spots and their role in Drug Development 
 This study offers significant evidence that hot spot residue analysis offers the 
potential to expand the drug-target space by allowing researchers to examine PPIs as 
potential targets. PPIs have been proposed to be good candidates for drug targets, and 
notable cases include examples such as iNOS, LFA-1 and 14-3-3 pathways (302). 
Targeting PPIs have unique drug discovery challenges that will need to be overcome 
if they are to become a viable alternative to targeting enzymes or receptors like 
GPCRs. Standardized enzymatic turnover or kinetics can often not be used for some 
PPIs as a surrogate for the potency of hits, so design and execution of proper assays to 
measure responses that fit the proposed mechanism must be carried out. Also, 
accurate prediction as to how PPI disruptors/inhibitors alter the pathobiology and 
function of target proteins will be more difficult than enzyme/receptor predictions, as 
these traditional targets commonly have distinct residues/regions that are catalytic in 
nature and can be focused upon(303). Finally, proper library design must be utilized 
and as more PPI disruptors/inhibitors are uncovered, perhaps pharmacophores or 
moieties will be uncovered that are more likely to lead to their activity in certain 
features of PPIs. 
Alanine scanning mutagenesis, while costly and time consuming, can be 
carried out using the prediction tools carried out here, but care must be given as to the 
potential biases or weaknesses of each prediction method. When possible, ensemble 
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methods as well as simple structural analysis should be used to supplement these 
techniques to minimize false positives and false negatives.  
The theory and practice of using small molecule inhibitors to disrupt protein-
protein interactions of protein complexes is a novel one, and one that will require 
further exploration of the dynamics of proteins involved. While still in its relative 
infancy, proposed procedures and strategies have been outlined for using hot spots 
towards developing small molecule inhibitors of PPIs (304). This exploration is aided 
by the use of computational tools such as homology modeling and molecular 
dynamics. Advances in in silico high-throughput screening are also needed to identify 
active compounds and will speed the process of identifying hits. Multiple groups in 
both industry and academia are making use of high-performance clusters (HPCs, also 
called grid or distributed computing) that use multiple networked computers that can 
be set to perform intensive calculations (most notable are MD simulations and in 
silico virtual screens).  
Also of significance to the advancement of this field is the ever-increasing 
computing power and capacity of individual computers in both hardware and 
software. As computational speeds increase and molecular dynamics simulations 
increasingly become optimized in their scoring function accuracy and speed to take 
advantage of elements such as parallel computing and utilization of both next-
generation graphical processing units (GPUs) and CPU architecture(305), these 
simulations can be performed on timescales that will allow for the visualization and 
analysis of studies such as large, multi-subunit domain movements, assembly of large 
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protein complexes, and protein-ligand interactions such as the ones presented here, 
even the potential of simulations heading into the second timescale (as opposed to 
nanosecond or millisecond) are predicted to be capable based on current trends by the 
year 2022 (306-308) 
Hence, we believe that a well-developed structure-based modeling technique 
designed specifically for PPIs, e.g., structure-based virtual screening, is still in its 
infancy but holds the potential for increasing the drug-target space for cancer and can 
potentially be expanded towards other diseases. 
 
4.2 Skp2 and the Ubiquitin pathway as a Potential Clinical Target 
 Skp2 is a prime target for further development as a cancer target, as it clearly 
shows over expression (and not mutation or truncation/deletion) in multiple cancer 
types. Compared to bortezomib, the general proteasome inhibitor, targeting the E3 
ligase allows for tighter specificity and selectivity with less associated toxicity. There 
exist multiple endpoints for targeting the ubiquitin pathway, and this study gives 
strong evidence that there exist multiple mechanisms by which disruption of the SCF 
complex can be achieved: targeting the large interface of the Skp1/Skp2 interaction in 
the F-box domain of Skp2, as well as targeting the p27 binding site on the Cks1/Skp2 
interface. As we have shown with the inhibitors presented here, this specificity and 
selectivity can be achieve; other highly similar F-box proteins were not active towards 
ZL-25 (276 has not been tested against similar proteins at this time). As has been 
discussed previously, only two compounds (Lenalidomide and Pamalidomide) that 
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target elements of the ubiquitin pathway have been FDA approved (excluding the 
proteasome inhibitors). When one considers that there are approximately 40 E2 
(ubiquitin-conjugating enzymes) and over 600 E3 enzymes in humans (309), clearly 
there exist multiple opportunities to utilize PPI disruption (especially when 
considering hot spots) to rationally design small molecules to other elements of the 
ubiquitin pathway (Figure 59). 
 
Figure 59. Potential strategies for targeting the ubiquitin/proteasome pathway. This 
study presents two strategies for targeting the E3 ligase system of SCF/Skp2 (green). 
 To look for other potential projects on which small molecules could be 
designed for small molecule inhibition similar to the two studies that were performed 
on the two regions of Skp2, a literature and structure search was carried out for all 
other E3 ligase proteins, there exist a few potential targets that should be considered 
(Table 13). Most notable is FBXL10 and FBXW7, both have evidence of pathology 
to cancer, and have structures available. Some candidates do not currently have 
crystal structures available; for these either homology models could be built, or as 
crystallographers improve, these structures might be resolved at a later date.  
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Table 13. Potential F-box protein targets for future examination of small molecule 
inhibition. 
 
 The stabilization/restoration of p27 appears to be the driving force behind the 
effectiveness of both SCF complex inhibitors, and this has been demonstrated 
previously to be effective and achieved by other methods. One study has revealed two 
significant findings about dasatinib: first, that it enhances paclitaxel-associated 
apoptosis by increasing p27 expression, and second, that dasatinib induces nuclear 
p27 expression specifically by inhibiting its phosphorylation on Thr187 (which is 
necessary for it to bind to the Cks1/Skp2 complex and leads to its 26S proteasome 
degradation), as well as Ser10, and Thr157 (310). Each of these residue 
phosphorylation events have been reported to control the stability of p27 (reviewed in 
(311)). This second study also discusses the fact that anti-HER2 antibodies (such as 
trastuzumab) upregulate p27 protein levels in breast cancer cells that overexpress 
HER2 but decreasing Thr187 phosphorylation of p27 (312). This is in addition to the 
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at least six signaling targets and pathways that are modulated by trastuzumab. 
Another study proposed that the cisplatin analogue and DNA-damaging agent DAP is 
able to induce p27 via a novel mechanism. The authors propose that basal levels of 
p27 are recruited into two complexes: CDK4 and CDK2. The CDK2 complex results 
in phosphorylation that leads to rapid degradation of p27. They then propose that it is 
in fact p21 that is induced and is able to inhibit CDK2 and prevent p27 
phosphorylation, thereby stabilization of p27 via preventing its phosphorylation in a 
p53-dependant manner via DAP induction (313).  
 These studies reveal the paradigms of p27 induction, and when they are 
compared to the current study of using Skp2 inhibitors in two different regions, the 
differences are worth noting. First, there is direct binding of the compounds to Skp2, 
(indicated by the mutagenesis experiment) and there are no overt toxicities seen in the 
mouse xenograft studies. Second, as the ligands phenocopies the effects of Skp2 
genetic deficiency, cellular senescence is achieved in a p53-independent manner 
(176). This is significant as advanced cancers often develop resistance to treatments 
that induce p53-dependent apoptosis and senescence. 
 
4.3 Future Directions in ZL-25 Development  
Here we present novel inhibitors of two different regions targeting different 
components/regions of Skp2 and its role in the SCF complex. Both regions were 
analyzed using hot spot prediction techniques and the suggested hits were discovered 
via virtual screening and were later proven to have biological activity in line with the 
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described mechanism.  For the Skp1/Skp2 interface, an initial ligand set of over 
56,000 compounds was used, and from using two unique docking scoring functions, 
we were able to produce a list of 25 compounds that we predicted would have 
biological activity. Both sets of lead inhibitors are in the pre-clinical stage, and there 
is significant work and study that is needed in their development to advance them into 
clinical trials. While ZL-25 has been tested in mouse xenograft models and no overt 
toxicity was uncovered in their dosing, a full PK/PD profile should be generated, and 
work with medicinal chemists will help to refine the structure to find compounds that 
are more effective at lower doses. Also, the IC50 and affinity values for ZL-25 could 
certainly be better, and the suggested structures should be synthesized and tested not 
only against Skp2, but against other F-box proteins to ensure that specificity towards 
Skp2 is not lost. 
 For the ZM-276 inhibitor, it is certainly more potent than ZL-25, and it is 
more specific in targeting p27 to be restored in the nucleus, but at this point in its 
development, we don’t have as concrete of evidence that it is precisely binding in the 
mode that has been predicted (not as concrete as ZL-25). Therefore, mutagenesis 
studies should be carried out to remedy this, as well as crystallographic studies. 
  Skp2 is an oncogene in the ubiquitin pathway and this finding validates Skp2 
as a potential clinical target for which small-molecule inhibitors can be designed. 
These novel inhibitors are a first-in-class protein-protein interaction (PPI) inhibitors 
of the Skp1-Skp2 complex. Disruption of this complex halts function of the SCF 
complex and restores p21/p27. Preclinical work is ongoing to generate a more 
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efficient lead, and to identify a suitable cancer for development. This work also shows 
that targeting PPIs are a high-risk yet high-reward strategy that opens up a new 
domain of potential druggable targets. Computational techniques outlined here can 
help minimize this risk by using hot spot prediction to identify targetable regions on 
proteins. 
 As this study identifies two regions on which to target Skp2 with slightly 
different mechanisms of action (one disrupting the Skp1/Skp2 interaction, the other 
being disrupting the Cks1/Skp2/p27 interaction), it stands to reason that perhaps these 
two mechanisms and potential treatment might be synergistic when used as a 
combination, especially for cancers that show oncogenic addiction towards Skp2 and 
the SCF complex. Certainly, as bortezomib (Velcade) is currently being used for the 
treatment of multiple myeloma as a proteasome inhibitor, the inhibitors outlined here 
should be considered as a second-line of defense for cancers that are resistant to 
bortezomib. However, it should be noted that there is a possibility that resistance can 
be possible via a novel proteolytic processing pathway that is independent of 
ubiquitination and results in the abrogation of p27 function via the elimination of the 
critical cyclin-binding domain (314), and KPC (Kip1 ubiquitination-promoting 
complex, which consists of KPC1 and KPC2, a RING-finger  domain and a ubiquitin-
like domain, respectively) targets p27 for degradation in the G0 - G1 transition while 
Skp2/SCF complex targets it in the nucleus in the S and G2 phases (238); so it is 
possible that a compensation via KPC might make both inhibitors ineffective. Further 
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studies should be carried out to examine if these effects could be problematic for the 
development of Skp2 inhibition. 
 Further work would ideally involve resolving the crystal structure of any of 
the Skp2/inhibitor complex (or complexes) which would give a highly affirmative 
confirmation of the exact binding pose of these inhibitors, as well as show how Skp2 
and the F-box and Cks1 domains respond to binding. Additionally a resolved crystal 
structure of the Skp1/Skp2/ZL-25 complex as well as the complete SCF complex with 
ligands could indicate how ZL-25 is able to disrupt the preformed SCF complexes 
proteins. These structures could be used to conclusively suggest modifications for all 
inhibitors that would result in increased binding and efficacy. Additionally other 
means by which to measure inhibitor binding such ass ITC or Biacore studies to 
quantify the binding affinity and also be used for further design and QSAR studies.  
In addition to resolving the binding affinity experimentally, performing 
advanced QM/MM molecular dynamics of the complex to attempt to calculate a 
binding affinity of the inhibitor. This binding energy would then be compared to a 
series of similar compounds to the original (as well as compared relative to any 
ITC/Biocore data generated of the protein-ligand complex) and be used as a basis for 
qualitative structure-activity relationship (QSAR) studies.  
Use of new techniques in functional-genetic approaches can help answer 
questions about the best use and classification of these novel inhibitors. One approach 
is to examine the response of these inhibitors using a panel of tumor cell lines, and 
creating a signature of the sensitivity and resistance, similar to what is available in the 
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NCI-60 panel (315). Another approach is to analyze the global changes in the 
transcript that are inducted by a test ligand and compare that by known drugs or 
defined alterations in the genome (316-319). From this, common changes in 
expression are used to cluster small molecules that are similar. Finally, using an 
RNAi-based approach combined with machine learning technique can characterize 
therapeutic agents, especially in cancer (320). This allows the prediction of a 
mechanism of action based on the shRNA signature and can characterize a diverse 
range of the categories at high resolution.   
One other aspect of this work that should be explored is the question as to how 
ZL-25 specifically attenuates the proliferation and survival of cancer cells. It was 
shown that ZL-25 has multiple effects on conditions such as: apoptosis, aerobic 
glycolysis, and cellular senescence in a p53-independent manner (176), but it is 
unclear which of these effects leads most directly to the decreased proliferation and 
survival of cancer cells, and if these effects are different depending on the tumor type.  
From the NCI-60 data, it has been shown that leukemia cell lines seem to 
respond the highest to ZL-25. This would point to these types of cancers as potentially 
being a favorable indication to focus on. However, as the ZL-25-treated mouse 
xenograft data indicates, solid tumors also show good response rates. Identifying the 
precise cancer and cancer subtype are crucial towards maximizing the potential of ZL-
25 and the other inhibitors targeting Skp2. 
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Appendix 
1. Docking parameters 
For the precise parameters used in GOLD 5.0.1 (CCDC) for the virtual 
screening and docking, the primary scoring function used for the virtual screen was 
GoldScore, whereas GoldScore and occasionally ChemScore as well as ASP scoring 
functions were used to rescore selected ligands for docking analysis and QSAR work. 
Also for the virtual screen the setting of "allow early termination" and “soft 
potentials” were turned off, and a search efficiency set to 200% was employed to 
allow maximal exploration of the hits. For the rescoring and QSAR work, these two 
settings were set in the on state. 
Configuration file for HiPCDock (AutoDock) used for screening on 
Skp2/Skp1 interaction site on pocket1 (pocket 2 used grid_CenterCoordinates="-
1.962 -100.846 10.708"): 
[job] 
[dockingSoftware] 
dockingSoftwarePackage="AutoDock3" 
 
[autoDockReceptorPreProcessing] 
receptor="/scratch2/szhang/SKP2/AutoDock/skip2_2AST_with_H.pdb" 
 
[autoGridParameters] 
grid_Center="By Coordinates" 
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grid_CenterCoordinates="1.134 -114.378 -1.751" 
grid_Points="80 80 80" 
spacing="0.25" 
 
[autoDockLigandPreProcessing] 
database="/scratch2/lducuny/DataBase/ChemBridge/Chem_Lig" 
processLigand="Yes" 
autotorsFlags="-m -h -o -a -b -c -M -A +6.5" 
 
[autoDockSearchingParameters] 
searchingMethod="Genetic Algorithm" 
 
# geneticAlgorithmParameters 
numberOfGARuns="100" 
populationSize="100" 
maximumNumberOfEnergyEvaluations="500000" 
maximumNumberOfGenerations="27000" 
maximumNumberOfTopIndividualsThatAutomaticallySurvive="1" 
rateOfGeneMutation="0.02" 
rateOfCrossover="0.8" 
meanOfCauchyDistributionForGeneMutation="0.0" 
varianceOfCauchyDistributionForGeneMutation="1.0" 
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numberOfGenerationsForPickingWorstIndividual="10" 
 
# energyParameters 
externalGridEnergy="1000.0" 
maximumAllowableInitialEnrgy="0.0" 
maximumNumberOfRetries="10000" 
 
# stepSizeParameters 
translation="2.0" 
quaternion="50.0" 
torsion="50.0" 
 
# outputFormatParameters 
rmsClusterTolerance="0.5" 
performAClusterAnalysis="Yes" 
 
[outputOptions] 
selectionCriterion1Name="Ranking" 
selectionCriterion1="5" 
selectionCriterion2Name="Binding Affinity" 
selectionCriterion2="6" 
outputFormat="Text File" 
146 
 
Bibliography 
1. Overington, J. P., B. Al-Lazikani, and A. L. Hopkins. 2006. How many drug 
targets are there? Nat Rev Drug Discov 5: 993-996. 
2. Santos, R., O. Ursu, A. Gaulton, A. P. Bento, R. S. Donadi, C. G. Bologa, A. 
Karlsson, B. Al-Lazikani, A. Hersey, T. I. Oprea, and J. P. Overington. 2017. 
A comprehensive map of molecular drug targets. Nat Rev Drug Discov 16: 19-
34. 
3. Imming, P., C. Sinning, and A. Meyer. 2006. Drugs, their targets and the 
nature and number of drug targets. Nat Rev Drug Discov 5: 821-834. 
4. Golden, J. B. 2003. Prioritizing the human genome: knowledge management 
for drug discovery. Curr Opin Drug Discov Devel 6: 310-316. 
5. Gaulton, A., A. Hersey, M. Nowotka, A. P. Bento, J. Chambers, D. Mendez, 
P. Mutowo, F. Atkinson, L. J. Bellis, E. Cibrian-Uhalte, M. Davies, N. 
Dedman, A. Karlsson, M. P. Magarinos, J. P. Overington, G. Papadatos, I. 
Smit, and A. R. Leach. 2017. The ChEMBL database in 2017. Nucleic Acids 
Res 45: D945-D954. 
6. Varmus, H. 2006. The new era in cancer research. Science 312: 1162-1165. 
7. Gavin, A. C., M. Bosche, R. Krause, P. Grandi, M. Marzioch, A. Bauer, J. 
Schultz, J. M. Rick, A. M. Michon, C. M. Cruciat, M. Remor, C. Hofert, M. 
Schelder, M. Brajenovic, H. Ruffner, A. Merino, K. Klein, M. Hudak, D. 
Dickson, T. Rudi, V. Gnau, A. Bauch, S. Bastuck, B. Huhse, C. Leutwein, M. 
A. Heurtier, R. R. Copley, A. Edelmann, E. Querfurth, V. Rybin, G. Drewes, 
147 
 
M. Raida, T. Bouwmeester, P. Bork, B. Seraphin, B. Kuster, G. Neubauer, and 
G. Superti-Furga. 2002. Functional organization of the yeast proteome by 
systematic analysis of protein complexes. Nature 415: 141-147. 
8. Johnson, J. E. 1996. Functional implications of protein-protein interactions in 
icosahedral viruses. Proc Natl Acad Sci U S A 93: 27-33. 
9. Chothia, C., and J. Janin. 1975. Principles of protein-protein recognition. 
Nature 256: 705-708. 
10. Lawrence, M. C., and P. M. Colman. 1993. Shape complementarity at 
protein/protein interfaces. J Mol Biol 234: 946-950. 
11. Norel, R., S. L. Lin, H. J. Wolfson, and R. Nussinov. 1994. Shape 
complementarity at protein-protein interfaces. Biopolymers 34: 933-940. 
12. Lo Conte, L., C. Chothia, and J. Janin. 1999. The atomic structure of protein-
protein recognition sites. J Mol Biol 285: 2177-2198. 
13. Keskin, O., B. Ma, and R. Nussinov. 2005. Hot regions in protein--protein 
interactions: the organization and contribution of structurally conserved hot 
spot residues. J Mol Biol 345: 1281-1294. 
14. Janin, J. 1995. Elusive affinities. Proteins 21: 30-39. 
15. Janin, J. 1995. Protein-protein recognition. Prog Biophys Mol Biol 64: 145-
166. 
16. Jones, S., and J. M. Thornton. 1996. Principles of protein-protein interactions. 
Proc Natl Acad Sci U S A 93: 13-20. 
148 
 
17. Janin, J., and C. Chothia. 1990. The structure of protein-protein recognition 
sites. J Biol Chem 265: 16027-16030. 
18. Tsai, C. J., and R. Nussinov. 1997. Hydrophobic folding units at protein-
protein interfaces: implications to protein folding and to protein-protein 
association. Protein Sci 6: 1426-1437. 
19. Horton, N., and M. Lewis. 1992. Calculation of the free energy of association 
for protein complexes. Protein Sci 1: 169-181. 
20. Wells, J. A., and C. L. McClendon. 2007. Reaching for high-hanging fruit in 
drug discovery at protein-protein interfaces. Nature 450: 1001-1009. 
21. Verkhivker, G. M., D. Bouzida, D. K. Gehlhaar, P. A. Rejto, S. T. Freer, and 
P. W. Rose. 2003. Computational detection of the binding-site hot spot at the 
remodeled human growth hormone-receptor interface. Proteins 53: 201-219. 
22. Aqvist, J., V. B. Luzhkov, and B. O. Brandsdal. 2002. Ligand binding 
affinities from MD simulations. Acc Chem Res 35: 358-365. 
23. Marcotte, E. M., M. Pellegrini, H. L. Ng, D. W. Rice, T. O. Yeates, and D. 
Eisenberg. 1999. Detecting protein function and protein-protein interactions 
from genome sequences. Science 285: 751-753. 
24. Blazer, L. L., and R. R. Neubig. 2009. Small molecule protein-protein 
interaction inhibitors as CNS therapeutic agents: current progress and future 
hurdles. Neuropsychopharmacology 34: 126-141. 
149 
 
25. White, A. W., A. D. Westwell, and G. Brahemi. 2008. Protein-protein 
interactions as targets for small-molecule therapeutics in cancer. Expert Rev 
Mol Med 10: e8. 
26. Ajay, A., W. P. Walters, and M. A. Murcko. 1998. Can we learn to distinguish 
between "drug-like" and "nondrug-like" molecules? J Med Chem 41: 3314-
3324. 
27. Lipinski, C. A., F. Lombardo, B. W. Dominy, and P. J. Feeney. 2001. 
Experimental and computational approaches to estimate solubility and 
permeability in drug discovery and development settings. Adv Drug Deliv Rev 
46: 3-26. 
28. Siehler, S. 2008. Cell-based assays in GPCR drug discovery. Biotechnol J 3: 
471-483. 
29. Hopkins, A. L., and C. R. Groom. 2002. The druggable genome. Nat Rev Drug 
Discov 1: 727-730. 
30. Ofran, Y., M. Punta, R. Schneider, and B. Rost. 2005. Beyond annotation 
transfer by homology: novel protein-function prediction methods to assist drug 
discovery. Drug Discov Today 10: 1475-1482. 
31. Keskin, O., A. Gursoy, B. Ma, and R. Nussinov. 2007. Towards drugs 
targeting multiple proteins in a systems biology approach. Curr Top Med 
Chem 7: 943-951. 
32. Sharma, S. K., T. M. Ramsey, and K. W. Bair. 2002. Protein-protein 
interactions: lessons learned. Curr Med Chem Anticancer Agents 2: 311-330. 
150 
 
33. Clackson, T., and J. A. Wells. 1995. A hot spot of binding energy in a 
hormone-receptor interface. Science 267: 383-386. 
34. Bogan, A. A., and K. S. Thorn. 1998. Anatomy of hot spots in protein 
interfaces. J Mol Biol 280: 1-9. 
35. Wells, J. A. 1991. Systematic mutational analyses of protein-protein 
interfaces. Methods Enzymol 202: 390-411. 
36. Schreiber, G., and A. R. Fersht. 1995. Energetics of protein-protein 
interactions: analysis of the barnase-barstar interface by single mutations and 
double mutant cycles. J Mol Biol 248: 478-486. 
37. Stites, W. E. 1997. Proteinminus signProtein Interactions: Interface Structure, 
Binding Thermodynamics, and Mutational Analysis. Chem Rev 97: 1233-
1250. 
38. Clackson, T., M. H. Ultsch, J. A. Wells, and A. M. de Vos. 1998. Structural 
and functional analysis of the 1:1 growth hormone:receptor complex reveals 
the molecular basis for receptor affinity. J Mol Biol 277: 1111-1128. 
39. Hu, Z., B. Ma, H. Wolfson, and R. Nussinov. 2000. Conservation of polar 
residues as hot spots at protein interfaces. Proteins 39: 331-342. 
40. Kouadio, J. L., J. R. Horn, G. Pal, and A. A. Kossiakoff. 2005. Shotgun 
alanine scanning shows that growth hormone can bind productively to its 
receptor through a drastically minimized interface. J Biol Chem 280: 25524-
25532. 
151 
 
41. Thorn, K. S., and A. A. Bogan. 2001. ASEdb: a database of alanine mutations 
and their effects on the free energy of binding in protein interactions. 
Bioinformatics 17: 284-285. 
42. Moreira, I. S., P. A. Fernandes, and M. J. Ramos. 2007. Hot spots--a review of 
the protein-protein interface determinant amino-acid residues. Proteins 68: 
803-812. 
43. Lichtarge, O., H. R. Bourne, and F. E. Cohen. 1996. An evolutionary trace 
method defines binding surfaces common to protein families. J Mol Biol 257: 
342-358. 
44. Samanta, U., D. Pal, and P. Chakrabarti. 2000. Environment of tryptophan 
side chains in proteins. Proteins 38: 288-300. 
45. Fernandez, A. 2002. Desolvation shell of hydrogen bonds in folded proteins, 
protein complexes and folding pathways. FEBS Lett 527: 166-170. 
46. Tuncbag, N., O. Keskin, and A. Gursoy. 2010. HotPoint: hot spot prediction 
server for protein interfaces. Nucleic Acids Res 38: W402-406. 
47. Li, X., O. Keskin, B. Ma, R. Nussinov, and J. Liang. 2004. Protein-protein 
interactions: hot spots and structurally conserved residues often locate in 
complemented pockets that pre-organized in the unbound states: implications 
for docking. J Mol Biol 344: 781-795. 
48. Ma, B., T. Elkayam, H. Wolfson, and R. Nussinov. 2003. Protein-protein 
interactions: structurally conserved residues distinguish between binding sites 
and exposed protein surfaces. Proc Natl Acad Sci U S A 100: 5772-5777. 
152 
 
49. Lockless, S. W., and R. Ranganathan. 1999. Evolutionarily conserved 
pathways of energetic connectivity in protein families. Science 286: 295-299. 
50. Caffrey, D. R., S. Somaroo, J. D. Hughes, J. Mintseris, and E. S. Huang. 2004. 
Are protein-protein interfaces more conserved in sequence than the rest of the 
protein surface? Protein Sci 13: 190-202. 
51. Fraser, H. B., A. E. Hirsh, L. M. Steinmetz, C. Scharfe, and M. W. Feldman. 
2002. Evolutionary rate in the protein interaction network. Science 296: 750-
752. 
52. Panchenko, A. R., F. Kondrashov, and S. Bryant. 2004. Prediction of 
functional sites by analysis of sequence and structure conservation. Protein Sci 
13: 884-892. 
53. DeLano, W. L. 2002. Unraveling hot spots in binding interfaces: progress and 
challenges. Curr Opin Struct Biol 12: 14-20. 
54. Wells, J. A. 1996. Binding in the growth hormone receptor complex. Proc 
Natl Acad Sci U S A 93: 1-6. 
55. Wells, J. A., and A. M. de Vos. 1993. Structure and function of human growth 
hormone: implications for the hematopoietins. Annu Rev Biophys Biomol 
Struct 22: 329-351. 
56. Thanos, C. D., W. L. DeLano, and J. A. Wells. 2006. Hot-spot mimicry of a 
cytokine receptor by a small molecule. Proc Natl Acad Sci U S A 103: 15422-
15427. 
153 
 
57. Arkin, M. R., and J. A. Wells. 2004. Small-molecule inhibitors of protein-
protein interactions: progressing towards the dream. Nat Rev Drug Discov 3: 
301-317. 
58. Wrighton, N. C., F. X. Farrell, R. Chang, A. K. Kashyap, F. P. Barbone, L. S. 
Mulcahy, D. L. Johnson, R. W. Barrett, L. K. Jolliffe, and W. J. Dower. 1996. 
Small peptides as potent mimetics of the protein hormone erythropoietin. 
Science 273: 458-464. 
59. Sidhu, S. S., H. B. Lowman, B. C. Cunningham, and J. A. Wells. 2000. Phage 
display for selection of novel binding peptides. Methods Enzymol 328: 333-
363. 
60. Livnah, O., E. A. Stura, D. L. Johnson, S. A. Middleton, L. S. Mulcahy, N. C. 
Wrighton, W. J. Dower, L. K. Jolliffe, and I. A. Wilson. 1996. Functional 
mimicry of a protein hormone by a peptide agonist: the EPO receptor complex 
at 2.8 A. Science 273: 464-471. 
61. DeLano, W. L., M. H. Ultsch, A. M. de Vos, and J. A. Wells. 2000. 
Convergent solutions to binding at a protein-protein interface. Science 287: 
1279-1283. 
62. Li, R., V. Dowd, D. J. Stewart, S. J. Burton, and C. R. Lowe. 1998. Design, 
synthesis, and application of a protein A mimetic. Nat Biotechnol 16: 190-195. 
63. Tilley, J. W., L. Chen, D. C. Fry, S. D. Emerson, G. D. Powers, D. Biondi, T. 
Varnell, R. Trilles, R. Guthrie, F. Mennona, G. Kaplan, R. A. LeMahieu, M. 
Carson, R. J. Han, C. M. Liu, R. Palermo, and G. Ju. 1997. Identification of a 
154 
 
small molecule inhibitor of the IL-2/IL-2R alpha receptor interaction which 
binds to IL-2. Journal of the American Chemical Society 119: 7589-7590. 
64. Gonzalez-Ruiz, D., and H. Gohlke. 2006. Targeting protein-protein 
interactions with small molecules: challenges and perspectives for 
computational binding epitope detection and ligand finding. Curr Med Chem 
13: 2607-2625. 
65. Rajamani, D., S. Thiel, S. Vajda, and C. J. Camacho. 2004. Anchor residues in 
protein-protein interactions. Proc Natl Acad Sci U S A 101: 11287-11292. 
66. Acuner Ozbabacan, S. E., A. Gursoy, O. Keskin, and R. Nussinov. 2010. 
Conformational ensembles, signal transduction and residue hot spots: 
application to drug discovery. Curr Opin Drug Discov Devel 13: 527-537. 
67. Wells, J. A. 1990. Additivity of mutational effects in proteins. Biochemistry 
29: 8509-8517. 
68. Cunningham, B. C., and J. A. Wells. 1989. High-resolution epitope mapping 
of hGH-receptor interactions by alanine-scanning mutagenesis. Science 244: 
1081-1085. 
69. Skolnick, J., J. S. Fetrow, and A. Kolinski. 2000. Structural genomics and its 
importance for gene function analysis. Nat Biotechnol 18: 283-287. 
70. Morrison, K. L., and G. A. Weiss. 2001. Combinatorial alanine-scanning. 
Curr Opin Chem Biol 5: 302-307. 
155 
 
71. Dinner, A. R., A. Sali, L. J. Smith, C. M. Dobson, and M. Karplus. 2000. 
Understanding protein folding via free-energy surfaces from theory and 
experiment. Trends Biochem Sci 25: 331-339. 
72. Kumar, S., B. Ma, C. J. Tsai, N. Sinha, and R. Nussinov. 2000. Folding and 
binding cascades: dynamic landscapes and population shifts. Protein Sci 9: 10-
19. 
73. Fischer, T. B., K. V. Arunachalam, D. Bailey, V. Mangual, S. Bakhru, R. 
Russo, D. Huang, M. Paczkowski, V. Lalchandani, C. Ramachandra, B. 
Ellison, S. Galer, J. Shapley, E. Fuentes, and J. Tsai. 2003. The binding 
interface database (BID): a compilation of amino acid hot spots in protein 
interfaces. Bioinformatics 19: 1453-1454. 
74. Piehler, J., and G. Schreiber. 2001. Fast transient cytokine-receptor 
interactions monitored in real time by reflectometric interference 
spectroscopy. Anal Biochem 289: 173-186. 
75. Weiss, G. A., C. K. Watanabe, A. Zhong, A. Goddard, and S. S. Sidhu. 2000. 
Rapid mapping of protein functional epitopes by combinatorial alanine 
scanning. Proc Natl Acad Sci U S A 97: 8950-8954. 
76. Schymkowitz, J., J. Borg, F. Stricher, R. Nys, F. Rousseau, and L. Serrano. 
2005. The FoldX web server: an online force field. Nucleic Acids Res 33: 
W382-388. 
77. Kim, D. E., D. Chivian, and D. Baker. 2004. Protein structure prediction and 
analysis using the Robetta server. Nucleic Acids Res 32: W526-531. 
156 
 
78. Gao, Y., R. Wang, and L. Lai. 2004. Structure-based method for analyzing 
protein-protein interfaces. J Mol Model 10: 44-54. 
79. Brenke, R., D. Kozakov, G. Y. Chuang, D. Beglov, D. Hall, M. R. Landon, C. 
Mattos, and S. Vajda. 2009. Fragment-based identification of druggable 'hot 
spots' of proteins using Fourier domain correlation techniques. Bioinformatics 
25: 621-627. 
80. Kozakov, D., L. E. Grove, D. R. Hall, T. Bohnuud, S. E. Mottarella, L. Luo, 
B. Xia, D. Beglov, and S. Vajda. 2015. The FTMap family of web servers for 
determining and characterizing ligand-binding hot spots of proteins. Nat 
Protoc 10: 733-755. 
81. Assi, S. A., T. Tanaka, T. H. Rabbitts, and N. Fernandez-Fuentes. 2010. 
PCRPi: Presaging Critical Residues in Protein interfaces, a new computational 
tool to chart hot spots in protein interfaces. Nucleic Acids Res 38: e86. 
82. Segura Mora, J., S. A. Assi, and N. Fernandez-Fuentes. 2010. Presaging 
critical residues in protein interfaces-web server (PCRPi-W): a web server to 
chart hot spots in protein interfaces. PLoS One 5: e12352. 
83. Guharoy, M., and P. Chakrabarti. 2009. Empirical estimation of the energetic 
contribution of individual interface residues in structures of protein-protein 
complexes. J Comput Aided Mol Des 23: 645-654. 
84. Zhu, X., and J. C. Mitchell. 2011. KFC2: A knowledge-based hot spot 
prediction method based on interface solvation, atomic density, and plasticity 
features. Proteins 79: 2671-2683. 
157 
 
85. Cho, K. I., D. Kim, and D. Lee. 2009. A feature-based approach to modeling 
protein-protein interaction hot spots. Nucleic Acids Res 37: 2672-2687. 
86. Lise, S., C. Archambeau, M. Pontil, and D. T. Jones. 2009. Prediction of hot 
spot residues at protein-protein interfaces by combining machine learning and 
energy-based methods. BMC Bioinformatics 10: 365. 
87. Lise, S., D. Buchan, M. Pontil, and D. T. Jones. 2011. Predictions of hot spot 
residues at protein-protein interfaces using support vector machines. PLoS 
One 6: e16774. 
88. Higa, R. H., and C. L. Tozzi. 2009. Prediction of binding hot spot residues by 
using structural and evolutionary parameters. Genet Mol Biol 32: 626-633. 
89. Grosdidier, S., and J. Fernandez-Recio. 2008. Identification of hot-spot 
residues in protein-protein interactions by computational docking. BMC 
Bioinformatics 9: 447. 
90. Guney, E., N. Tuncbag, O. Keskin, and A. Gursoy. 2008. HotSprint: database 
of computational hot spots in protein interfaces. Nucleic Acids Res 36: D662-
666. 
91. Tuncbag, N., G. Kar, O. Keskin, A. Gursoy, and R. Nussinov. 2009. A survey 
of available tools and web servers for analysis of protein-protein interactions 
and interfaces. Brief Bioinform 10: 217-232. 
92. Guerois, R., J. E. Nielsen, and L. Serrano. 2002. Predicting changes in the 
stability of proteins and protein complexes: a study of more than 1000 
mutations. J Mol Biol 320: 369-387. 
158 
 
93. Kortemme, T., D. E. Kim, and D. Baker. 2004. Computational alanine 
scanning of protein-protein interfaces. Sci STKE 2004: pl2. 
94. Kortemme, T., and D. Baker. 2002. A simple physical model for binding 
energy hot spots in protein-protein complexes. Proc Natl Acad Sci U S A 99: 
14116-14121. 
95. Chen, J., and L. Lai. 2006. Pocket v.2: further developments on receptor-based 
pharmacophore modeling. J Chem Inf Model 46: 2684-2691. 
96. Mattos, C., and D. Ringe. 1996. Locating and characterizing binding sites on 
proteins. Nat Biotechnol 14: 595-599. 
97. Tuncbag, N., A. Gursoy, and O. Keskin. 2009. Identification of computational 
hot spots in protein interfaces: combining solvent accessibility and inter-
residue potentials improves the accuracy. Bioinformatics 25: 1513-1520. 
98. Berman, H. M., T. Battistuz, T. N. Bhat, W. F. Bluhm, P. E. Bourne, K. 
Burkhardt, Z. Feng, G. L. Gilliland, L. Iype, S. Jain, P. Fagan, J. Marvin, D. 
Padilla, V. Ravichandran, B. Schneider, N. Thanki, H. Weissig, J. D. 
Westbrook, and C. Zardecki. 2002. The Protein Data Bank. Acta Crystallogr 
D Biol Crystallogr 58: 899-907. 
99. Segura, J., and N. Fernandez-Fuentes. 2011. PCRPi-DB: a database of 
computationally annotated hot spots in protein interfaces. Nucleic Acids Res 
39: D755-760. 
159 
 
100. Yogurtcu, O. N., S. B. Erdemli, R. Nussinov, M. Turkay, and O. Keskin. 
2008. Restricted mobility of conserved residues in protein-protein interfaces in 
molecular simulations. Biophys J 94: 3475-3485. 
101. Kimura, S. R., R. C. Brower, S. Vajda, and C. J. Camacho. 2001. Dynamical 
view of the positions of key side chains in protein-protein recognition. Biophys 
J 80: 635-642. 
102. Huo, S., I. Massova, and P. A. Kollman. 2002. Computational alanine 
scanning of the 1:1 human growth hormone-receptor complex. J Comput 
Chem 23: 15-27. 
103. Massova, I., and P. A. Kollman. 1999. Computational Alanine Scanning To 
Probe Protein-Protein Interactions: A Novel Approach To Evaluate Binding 
Free Energies. J. Am. Chem Soc. 121: 8133-8143. 
104. Mitchell, J. C., R. Kerr, and L. F. Ten Eyck. 2001. Rapid atomic density 
methods for molecular shape characterization. J Mol Graph Model 19: 325-
330, 388-390. 
105. Darnell, S. J., L. LeGault, and J. C. Mitchell. 2008. KFC Server: interactive 
forecasting of protein interaction hot spots. Nucleic Acids Res 36: W265-269. 
106. Darnell, S. J., D. Page, and J. C. Mitchell. 2007. An automated decision-tree 
approach to predicting protein interaction hot spots. Proteins 68: 813-823. 
107. Wang, Y. T., Z. Y. Su, and C. L. Chen. 2009. Potential of mean force of the 
hepatitis C virus core protein-monoclonal 19D9D6 antibody interaction. 
Biophys Chem 145: 86-90. 
160 
 
108. Noble, W. S. 2006. What is a support vector machine? Nat Biotechnol 24: 
1565-1567. 
109. Halperin, I., H. Wolfson, and R. Nussinov. 2004. Protein-protein interactions; 
coupling of structurally conserved residues and of hot spots across interfaces. 
Implications for docking. Structure 12: 1027-1038. 
110. Fernandez-Recio, J., M. Totrov, and R. Abagyan. 2004. Identification of 
protein-protein interaction sites from docking energy landscapes. J Mol Biol 
335: 843-865. 
111. Keskin, O., I. Bahar, A. Y. Badretdinov, O. B. Ptitsyn, and R. L. Jernigan. 
1998. Empirical solvent-mediated potentials hold for both intra-molecular and 
inter-molecular inter-residue interactions. Protein Sci 7: 2578-2586. 
112. Eisenberg, D., and A. D. McLachlan. 1986. Solvation energy in protein 
folding and binding. Nature 319: 199-203. 
113. Hershko, A., and A. Ciechanover. 1998. The ubiquitin system. Annu Rev 
Biochem 67: 425-479. 
114. Hershko, A. 1983. Ubiquitin: roles in protein modification and breakdown. 
Cell 34: 11-12. 
115. Handley, P. M., M. Mueckler, N. R. Siegel, A. Ciechanover, and A. L. 
Schwartz. 1991. Molecular cloning, sequence, and tissue distribution of the 
human ubiquitin-activating enzyme E1. Proc Natl Acad Sci U S A 88: 258-
262. 
161 
 
116. Schulman, B. A., and J. W. Harper. 2009. Ubiquitin-like protein activation by 
E1 enzymes: the apex for downstream signalling pathways. Nat Rev Mol Cell 
Biol 10: 319-331. 
117. Jentsch, S. 1992. The ubiquitin-conjugation system. Annual review of genetics 
26: 179-207. 
118. Berndsen, C. E., and C. Wolberger. 2014. New insights into ubiquitin E3 
ligase mechanism. Nat Struct Mol Biol 21: 301-307. 
119. Nakayama, K. I., and K. Nakayama. 2006. Ubiquitin ligases: cell-cycle control 
and cancer. Nat Rev Cancer 6: 369-381. 
120. Hershko, A., and A. Ciechanover. 1992. The ubiquitin system for protein 
degradation. Annu Rev Biochem 61: 761-807. 
121. Ciechanover, A. 1994. The ubiquitin-proteasome proteolytic pathway. Cell 79: 
13-21. 
122. Rieser, E., S. M. Cordier, and H. Walczak. 2013. Linear ubiquitination: a 
newly discovered regulator of cell signalling. Trends Biochem Sci 38: 94-102. 
123. Komander, D., and M. Rape. 2012. The ubiquitin code. Annu Rev Biochem 81: 
203-229. 
124. Chen, Z. J., and L. J. Sun. 2009. Nonproteolytic functions of ubiquitin in cell 
signaling. Mol Cell 33: 275-286. 
125. Yang, W. L., X. Zhang, and H. K. Lin. 2010. Emerging role of Lys-63 
ubiquitination in protein kinase and phosphatase activation and cancer 
development. Oncogene 29: 4493-4503. 
162 
 
126. Bach, I., and H. P. Ostendorff. 2003. Orchestrating nuclear functions: 
ubiquitin sets the rhythm. Trends Biochem Sci 28: 189-195. 
127. Murray, A. W. 2004. Recycling the cell cycle: cyclins revisited. Cell 116: 221-
234. 
128. Weissman, A. M. 2001. Themes and variations on ubiquitylation. Nat Rev Mol 
Cell Biol 2: 169-178. 
129. Pickart, C. M. 2004. Back to the future with ubiquitin. Cell 116: 181-190. 
130. Glotzer, M., A. W. Murray, and M. W. Kirschner. 1991. Cyclin is degraded by 
the ubiquitin pathway. Nature 349: 132-138. 
131. Farhana, L., M. Dawson, A. K. Rishi, Y. Zhang, E. Van Buren, C. Trivedi, U. 
Reichert, G. Fang, M. W. Kirschner, and J. A. Fontana. 2002. Cyclin B and 
E2F-1 expression in prostate carcinoma cells treated with the novel retinoid 
CD437 are regulated by the ubiquitin-mediated pathway. Cancer research 62: 
3842-3849. 
132. Bhattacharya, S., J. Garriga, J. Calbo, T. Yong, D. S. Haines, and X. Grana. 
2003. SKP2 associates with p130 and accelerates p130 ubiquitylation and 
degradation in human cells. Oncogene 22: 2443-2451. 
133. Hoeller, D., and I. Dikic. 2009. Targeting the ubiquitin system in cancer 
therapy. Nature 458: 438-444. 
134. Lipkowitz, S., and A. M. Weissman. 2011. RINGs of good and evil: RING 
finger ubiquitin ligases at the crossroads of tumour suppression and 
oncogenesis. Nat Rev Cancer 11: 629-643. 
163 
 
135. Kirkin, V., and I. Dikic. 2011. Ubiquitin networks in cancer. Curr Opin Genet 
Dev 21: 21-28. 
136. Pal, A., M. A. Young, and N. J. Donato. 2014. Emerging potential of 
therapeutic targeting of ubiquitin-specific proteases in the treatment of cancer. 
Cancer Res 74: 4955-4966. 
137. Miranda, M., and A. Sorkin. 2007. Regulation of receptors and transporters by 
ubiquitination: new insights into surprisingly similar mechanisms. Mol Interv 
7: 157-167. 
138. Hicke, L., H. L. Schubert, and C. P. Hill. 2005. Ubiquitin-binding domains. 
Nat Rev Mol Cell Biol 6: 610-621. 
139. Pickart, C. M. 2001. Ubiquitin enters the new millennium. Mol Cell 8: 499-
504. 
140. Sigismund, S., S. Polo, and P. P. Di Fiore. 2004. Signaling through 
monoubiquitination. Curr Top Microbiol Immunol 286: 149-185. 
141. Hicke, L. 2001. Protein regulation by monoubiquitin. Nat Rev Mol Cell Biol 2: 
195-201. 
142. Adams, J., and M. Kauffman. 2004. Development of the proteasome inhibitor 
Velcade (Bortezomib). Cancer Invest 22: 304-311. 
143. Frankland-Searby, S., and S. R. Bhaumik. 2012. The 26S proteasome 
complex: an attractive target for cancer therapy. Biochim Biophys Acta 1825: 
64-76. 
164 
 
144. Kumar, S. K., S. V. Rajkumar, A. Dispenzieri, M. Q. Lacy, S. R. Hayman, F. 
K. Buadi, S. R. Zeldenrust, D. Dingli, S. J. Russell, J. A. Lust, P. R. Greipp, R. 
A. Kyle, and M. A. Gertz. 2008. Improved survival in multiple myeloma and 
the impact of novel therapies. Blood 111: 2516-2520. 
145. Bonvini, P., E. Zorzi, G. Basso, and A. Rosolen. 2007. Bortezomib-mediated 
26S proteasome inhibition causes cell-cycle arrest and induces apoptosis in 
CD-30+ anaplastic large cell lymphoma. Leukemia 21: 838-842. 
146. Groll, M., C. R. Berkers, H. L. Ploegh, and H. Ovaa. 2006. Crystal structure of 
the boronic acid-based proteasome inhibitor bortezomib in complex with the 
yeast 20S proteasome. Structure 14: 451-456. 
147. Hideshima, T., P. G. Richardson, and K. C. Anderson. 2011. Mechanism of 
action of proteasome inhibitors and deacetylase inhibitors and the biological 
basis of synergy in multiple myeloma. Mol Cancer Ther 10: 2034-2042. 
148. Gelman, J. S., J. Sironi, I. Berezniuk, S. Dasgupta, L. M. Castro, F. C. Gozzo, 
E. S. Ferro, and L. D. Fricker. 2013. Alterations of the intracellular peptidome 
in response to the proteasome inhibitor bortezomib. PLoS One 8: e53263. 
149. Mattern, M. R., J. Wu, and B. Nicholson. 2012. Ubiquitin-based anticancer 
therapy: carpet bombing with proteasome inhibitors vs surgical strikes with 
E1, E2, E3, or DUB inhibitors. Biochim Biophys Acta 1823: 2014-2021. 
150. Kubiczkova, L., L. Pour, L. Sedlarikova, R. Hajek, and S. Sevcikova. 2014. 
Proteasome inhibitors - molecular basis and current perspectives in multiple 
myeloma. J Cell Mol Med 18: 947-961. 
165 
 
151. Richardson, P. G., H. Briemberg, S. Jagannath, P. Y. Wen, B. Barlogie, J. 
Berenson, S. Singhal, D. S. Siegel, D. Irwin, M. Schuster, G. Srkalovic, R. 
Alexanian, S. V. Rajkumar, S. Limentani, M. Alsina, R. Z. Orlowski, K. 
Najarian, D. Esseltine, K. C. Anderson, and A. A. Amato. 2006. Frequency, 
characteristics, and reversibility of peripheral neuropathy during treatment of 
advanced multiple myeloma with bortezomib. J Clin Oncol 24: 3113-3120. 
152. Richardson, P. G., B. Barlogie, J. Berenson, S. Singhal, S. Jagannath, D. 
Irwin, S. V. Rajkumar, G. Srkalovic, M. Alsina, R. Alexanian, D. Siegel, R. Z. 
Orlowski, D. Kuter, S. A. Limentani, S. Lee, T. Hideshima, D. L. Esseltine, 
M. Kauffman, J. Adams, D. P. Schenkein, and K. C. Anderson. 2003. A phase 
2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348: 
2609-2617. 
153. Suzuki, E., S. Demo, E. Deu, J. Keats, S. Arastu-Kapur, P. L. Bergsagel, M. 
K. Bennett, and C. J. Kirk. 2011. Molecular mechanisms of bortezomib 
resistant adenocarcinoma cells. PLoS One 6: e27996. 
154. Vij, R., D. S. Siegel, S. Jagannath, A. J. Jakubowiak, A. K. Stewart, K. 
McDonagh, N. Bahlis, A. Belch, L. A. Kunkel, S. Wear, A. F. Wong, and M. 
Wang. 2012. An open-label, single-arm, phase 2 study of single-agent 
carfilzomib in patients with relapsed and/or refractory multiple myeloma who 
have been previously treated with bortezomib. Br J Haematol 158: 739-748. 
155. Vij, R., M. Wang, J. L. Kaufman, S. Lonial, A. J. Jakubowiak, A. K. Stewart, 
V. Kukreti, S. Jagannath, K. T. McDonagh, M. Alsina, N. J. Bahlis, F. J. Reu, 
166 
 
N. Y. Gabrail, A. Belch, J. V. Matous, P. Lee, P. Rosen, M. Sebag, D. H. 
Vesole, L. A. Kunkel, S. M. Wear, A. F. Wong, R. Z. Orlowski, and D. S. 
Siegel. 2012. An open-label, single-arm, phase 2 (PX-171-004) study of 
single-agent carfilzomib in bortezomib-naive patients with relapsed and/or 
refractory multiple myeloma. Blood 119: 5661-5670. 
156. Meng, L., R. Mohan, B. H. Kwok, M. Elofsson, N. Sin, and C. M. Crews. 
1999. Epoxomicin, a potent and selective proteasome inhibitor, exhibits in 
vivo antiinflammatory activity. Proc Natl Acad Sci U S A 96: 10403-10408. 
157. Potts, B. C., M. X. Albitar, K. C. Anderson, S. Baritaki, C. Berkers, B. 
Bonavida, J. Chandra, D. Chauhan, J. C. Cusack, Jr., W. Fenical, I. M. 
Ghobrial, M. Groll, P. R. Jensen, K. S. Lam, G. K. Lloyd, W. McBride, D. J. 
McConkey, C. P. Miller, S. T. Neuteboom, Y. Oki, H. Ovaa, F. Pajonk, P. G. 
Richardson, A. M. Roccaro, C. M. Sloss, M. A. Spear, E. Valashi, A. Younes, 
and M. A. Palladino. 2011. Marizomib, a proteasome inhibitor for all seasons: 
preclinical profile and a framework for clinical trials. Curr Cancer Drug 
Targets 11: 254-284. 
158. Kumar, S. K., J. G. Berdeja, R. Niesvizky, S. Lonial, J. P. Laubach, M. 
Hamadani, A. K. Stewart, P. Hari, V. Roy, R. Vescio, J. L. Kaufman, D. Berg, 
E. Liao, A. Di Bacco, J. Estevam, N. Gupta, A. M. Hui, V. Rajkumar, and P. 
G. Richardson. 2014. Safety and tolerability of ixazomib, an oral proteasome 
inhibitor, in combination with lenalidomide and dexamethasone in patients 
167 
 
with previously untreated multiple myeloma: an open-label phase 1/2 study. 
Lancet Oncol 15: 1503-1512. 
159. Piva, R., B. Ruggeri, M. Williams, G. Costa, I. Tamagno, D. Ferrero, V. Giai, 
M. Coscia, S. Peola, M. Massaia, G. Pezzoni, C. Allievi, N. Pescalli, M. 
Cassin, S. di Giovine, P. Nicoli, P. de Feudis, I. Strepponi, I. Roato, R. 
Ferracini, B. Bussolati, G. Camussi, S. Jones-Bolin, K. Hunter, H. Zhao, A. 
Neri, A. Palumbo, C. Berkers, H. Ovaa, A. Bernareggi, and G. Inghirami. 
2008. CEP-18770: A novel, orally active proteasome inhibitor with a tumor-
selective pharmacologic profile competitive with bortezomib. Blood 111: 
2765-2775. 
160. Tsukamoto, S., T. Takeuchi, H. Rotinsulu, R. E. Mangindaan, R. W. van 
Soest, K. Ukai, H. Kobayashi, M. Namikoshi, T. Ohta, and H. Yokosawa. 
2008. Leucettamol A: a new inhibitor of Ubc13-Uev1A interaction isolated 
from a marine sponge, Leucetta aff. microrhaphis. Bioorg Med Chem Lett 18: 
6319-6320. 
161. Dalisay, D. S., S. Tsukamoto, and T. F. Molinski. 2009. Absolute 
configuration of the alpha,omega-bifunctionalized sphingolipid leucettamol A 
from Leucetta microrhaphis by deconvoluted exciton coupled CD. J Nat Prod 
72: 353-359. 
162. Ceccarelli, D. F., X. Tang, B. Pelletier, S. Orlicky, W. Xie, V. Plantevin, D. 
Neculai, Y. C. Chou, A. Ogunjimi, A. Al-Hakim, X. Varelas, J. Koszela, G. A. 
Wasney, M. Vedadi, S. Dhe-Paganon, S. Cox, S. Xu, A. Lopez-Girona, F. 
168 
 
Mercurio, J. Wrana, D. Durocher, S. Meloche, D. R. Webb, M. Tyers, and F. 
Sicheri. 2011. An allosteric inhibitor of the human Cdc34 ubiquitin-
conjugating enzyme. Cell 145: 1075-1087. 
163. Ito, T., H. Ando, T. Suzuki, T. Ogura, K. Hotta, Y. Imamura, Y. Yamaguchi, 
and H. Handa. 2010. Identification of a primary target of thalidomide 
teratogenicity. Science 327: 1345-1350. 
164. Kim, Y., and I. G. Schmidt-Wolf. 2015. Lenalidomide in multiple myeloma. 
Expert Rev Anticancer Ther: 1-7. 
165. Lacy, M. Q., and S. V. Rajkumar. 2010. Pomalidomide: a new IMiD with 
remarkable activity in both multiple myeloma and myelofibrosis. Am J 
Hematol 85: 95-96. 
166. Vassilev, L. T., B. T. Vu, B. Graves, D. Carvajal, F. Podlaski, Z. Filipovic, N. 
Kong, U. Kammlott, C. Lukacs, C. Klein, N. Fotouhi, and E. A. Liu. 2004. In 
vivo activation of the p53 pathway by small-molecule antagonists of MDM2. 
Science 303: 844-848. 
167. Vassilev, L. T. 2007. MDM2 inhibitors for cancer therapy. Trends Mol Med 
13: 23-31. 
168. Vu, B., P. Wovkulich, G. Pizzolato, A. Lovey, Q. Ding, N. Jiang, J. J. Liu, C. 
Zhao, K. Glenn, Y. Wen, C. Tovar, K. Packman, L. Vassilev, and B. Graves. 
2013. Discovery of RG7112: A Small-Molecule MDM2 Inhibitor in Clinical 
Development. ACS Med Chem Lett 4: 466-469. 
169 
 
169. Chang, Y. S., B. Graves, V. Guerlavais, C. Tovar, K. Packman, K. H. To, K. 
A. Olson, K. Kesavan, P. Gangurde, A. Mukherjee, T. Baker, K. Darlak, C. 
Elkin, Z. Filipovic, F. Z. Qureshi, H. Cai, P. Berry, E. Feyfant, X. E. Shi, J. 
Horstick, D. A. Annis, A. M. Manning, N. Fotouhi, H. Nash, L. T. Vassilev, 
and T. K. Sawyer. 2013. Stapled alpha-helical peptide drug development: a 
potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer 
therapy. Proc Natl Acad Sci U S A 110: E3445-3454. 
170. Gembarska, A., F. Luciani, C. Fedele, E. A. Russell, M. Dewaele, S. Villar, A. 
Zwolinska, S. Haupt, J. de Lange, D. Yip, J. Goydos, J. J. Haigh, Y. Haupt, L. 
Larue, A. Jochemsen, H. Shi, G. Moriceau, R. S. Lo, G. Ghanem, M. 
Shackleton, F. Bernal, and J. C. Marine. 2012. MDM4 is a key therapeutic 
target in cutaneous melanoma. Nat Med 18: 1239-1247. 
171. Wang, H., X. Ma, S. Ren, J. K. Buolamwini, and C. Yan. 2011. A small-
molecule inhibitor of MDMX activates p53 and induces apoptosis. Mol 
Cancer Ther 10: 69-79. 
172. Ungermannova, D., J. Lee, G. Zhang, H. G. Dallmann, C. S. McHenry, and X. 
Liu. 2013. High-throughput screening AlphaScreen assay for identification of 
small-molecule inhibitors of ubiquitin E3 ligase SCFSkp2-Cks1. J Biomol 
Screen 18: 910-920. 
173. Orlicky, S., X. Tang, V. Neduva, N. Elowe, E. D. Brown, F. Sicheri, and M. 
Tyers. 2010. An allosteric inhibitor of substrate recognition by the SCF(Cdc4) 
ubiquitin ligase. Nat Biotechnol 28: 733-737. 
170 
 
174. Wu, L., A. V. Grigoryan, Y. Li, B. Hao, M. Pagano, and T. J. Cardozo. 2012. 
Specific small molecule inhibitors of Skp2-mediated p27 degradation. Chem 
Biol 19: 1515-1524. 
175. Chen, Q., W. Xie, D. J. Kuhn, P. M. Voorhees, A. Lopez-Girona, D. Mendy, 
L. G. Corral, V. P. Krenitsky, W. Xu, L. Moutouh-de Parseval, D. R. Webb, F. 
Mercurio, K. I. Nakayama, K. Nakayama, and R. Z. Orlowski. 2008. 
Targeting the p27 E3 ligase SCF(Skp2) results in p27- and Skp2-mediated 
cell-cycle arrest and activation of autophagy. Blood 111: 4690-4699. 
176. Chan, C. H., J. K. Morrow, C. F. Li, Y. Gao, G. Jin, A. Moten, L. J. Stagg, J. 
E. Ladbury, Z. Cai, D. Xu, C. J. Logothetis, M. C. Hung, S. Zhang, and H. K. 
Lin. 2013. Pharmacological inactivation of Skp2 SCF ubiquitin ligase restricts 
cancer stem cell traits and cancer progression. Cell 154: 556-568. 
177. Nakajima, H., H. Fujiwara, Y. Furuichi, K. Tanaka, and N. Shimbara. 2008. A 
novel small-molecule inhibitor of NF-kappaB signaling. Biochem Biophys Res 
Commun 368: 1007-1013. 
178. Blees, J. S., H. R. Bokesch, D. Rubsamen, K. Schulz, L. Milke, M. M. Bajer, 
K. R. Gustafson, C. J. Henrich, J. B. McMahon, N. H. Colburn, T. Schmid, 
and B. Brune. 2012. Erioflorin stabilizes the tumor suppressor Pdcd4 by 
inhibiting its interaction with the E3-ligase beta-TrCP1. PLoS One 7: e46567. 
179. Chauhan, D., L. Catley, G. Li, K. Podar, T. Hideshima, M. Velankar, C. 
Mitsiades, N. Mitsiades, H. Yasui, A. Letai, H. Ovaa, C. Berkers, B. 
Nicholson, T. H. Chao, S. T. Neuteboom, P. Richardson, M. A. Palladino, and 
171 
 
K. C. Anderson. 2005. A novel orally active proteasome inhibitor induces 
apoptosis in multiple myeloma cells with mechanisms distinct from 
Bortezomib. Cancer Cell 8: 407-419. 
180. Millward, M., T. Price, A. Townsend, C. Sweeney, A. Spencer, S. Sukumaran, 
A. Longenecker, L. Lee, A. Lay, G. Sharma, R. M. Gemmill, H. A. Drabkin, 
G. K. Lloyd, S. T. Neuteboom, D. J. McConkey, M. A. Palladino, and M. A. 
Spear. 2012. Phase 1 clinical trial of the novel proteasome inhibitor marizomib 
with the histone deacetylase inhibitor vorinostat in patients with melanoma, 
pancreatic and lung cancer based on in vitro assessments of the combination. 
Invest New Drugs 30: 2303-2317. 
181. Dick, L. R., and P. E. Fleming. 2010. Building on bortezomib: second-
generation proteasome inhibitors as anti-cancer therapy. Drug Discov Today 
15: 243-249. 
182. Kupperman, E., E. C. Lee, Y. Cao, B. Bannerman, M. Fitzgerald, A. Berger, J. 
Yu, Y. Yang, P. Hales, F. Bruzzese, J. Liu, J. Blank, K. Garcia, C. Tsu, L. 
Dick, P. Fleming, L. Yu, M. Manfredi, M. Rolfe, and J. Bolen. 2010. 
Evaluation of the proteasome inhibitor MLN9708 in preclinical models of 
human cancer. Cancer Res 70: 1970-1980. 
183. Ushiyama, S., H. Umaoka, H. Kato, Y. Suwa, H. Morioka, H. Rotinsulu, F. 
Losung, R. E. Mangindaan, N. J. de Voogd, H. Yokosawa, and S. Tsukamoto. 
2012. Manadosterols A and B, sulfonated sterol dimers inhibiting the Ubc13-
172 
 
Uev1A interaction, isolated from the marine sponge Lissodendryx fibrosa. J 
Nat Prod 75: 1495-1499. 
184. Metzger, M. B., V. A. Hristova, and A. M. Weissman. 2012. HECT and RING 
finger families of E3 ubiquitin ligases at a glance. J Cell Sci 125: 531-537. 
185. Nijman, S. M., M. P. Luna-Vargas, A. Velds, T. R. Brummelkamp, A. M. 
Dirac, T. K. Sixma, and R. Bernards. 2005. A genomic and functional 
inventory of deubiquitinating enzymes. Cell 123: 773-786. 
186. Skaar, J. R., J. K. Pagan, and M. Pagano. 2013. Mechanisms and function of 
substrate recruitment by F-box proteins. Nat Rev Mol Cell Biol 14: 369-381. 
187. Lu, G., R. E. Middleton, H. Sun, M. Naniong, C. J. Ott, C. S. Mitsiades, K. K. 
Wong, J. E. Bradner, and W. G. Kaelin, Jr. 2014. The myeloma drug 
lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. 
Science 343: 305-309. 
188. Fischer, E. S., K. Bohm, J. R. Lydeard, H. Yang, M. B. Stadler, S. Cavadini, J. 
Nagel, F. Serluca, V. Acker, G. M. Lingaraju, R. B. Tichkule, M. Schebesta, 
W. C. Forrester, M. Schirle, U. Hassiepen, J. Ottl, M. Hild, R. E. Beckwith, J. 
W. Harper, J. L. Jenkins, and N. H. Thoma. 2014. Structure of the DDB1-
CRBN E3 ubiquitin ligase in complex with thalidomide. Nature 512: 49-53. 
189. Lopez-Girona, A., D. Mendy, T. Ito, K. Miller, A. K. Gandhi, J. Kang, S. 
Karasawa, G. Carmel, P. Jackson, M. Abbasian, A. Mahmoudi, B. Cathers, E. 
Rychak, S. Gaidarova, R. Chen, P. H. Schafer, H. Handa, T. O. Daniel, J. F. 
Evans, and R. Chopra. 2012. Cereblon is a direct protein target for 
173 
 
immunomodulatory and antiproliferative activities of lenalidomide and 
pomalidomide. Leukemia 26: 2326-2335. 
190. Zhu, Y. X., E. Braggio, C. X. Shi, L. A. Bruins, J. E. Schmidt, S. Van Wier, 
X. B. Chang, C. C. Bjorklund, R. Fonseca, P. L. Bergsagel, R. Z. Orlowski, 
and A. K. Stewart. 2011. Cereblon expression is required for the antimyeloma 
activity of lenalidomide and pomalidomide. Blood 118: 4771-4779. 
191. Lee, J. T., and W. Gu. 2010. The multiple levels of regulation by p53 
ubiquitination. Cell Death Differ 17: 86-92. 
192. Haupt, Y., R. Maya, A. Kazaz, and M. Oren. 1997. Mdm2 promotes the rapid 
degradation of p53. Nature 387: 296-299. 
193. Honda, R., H. Tanaka, and H. Yasuda. 1997. Oncoprotein MDM2 is a 
ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett 420: 25-27. 
194. Fang, S., J. P. Jensen, R. L. Ludwig, K. H. Vousden, and A. M. Weissman. 
2000. Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and 
p53. J Biol Chem 275: 8945-8951. 
195. Tabernero, J., L. Dirix, P. Schoffski, A. Cervantes, J. A. Lopez-Martin, J. 
Capdevila, L. van Beijsterveldt, S. Platero, B. Hall, Z. Yuan, R. Knoblauch, 
and S. H. Zhuang. 2011. A phase I first-in-human pharmacokinetic and 
pharmacodynamic study of serdemetan in patients with advanced solid tumors. 
Clin Cancer Res 17: 6313-6321. 
196. Chargari, C., C. Leteur, E. Angevin, T. Bashir, B. Schoentjes, J. Arts, M. 
Janicot, J. Bourhis, and E. Deutsch. 2011. Preclinical assessment of JNJ-
174 
 
26854165 (Serdemetan), a novel tryptamine compound with radiosensitizing 
activity in vitro and in tumor xenografts. Cancer Lett 312: 209-218. 
197. Khoury, K., and A. Domling. 2012. P53 mdm2 inhibitors. Curr Pharm Des 
18: 4668-4678. 
198. Van Maerken, T., A. Rihani, A. Van Goethem, A. De Paepe, F. Speleman, and 
J. Vandesompele. 2014. Pharmacologic activation of wild-type p53 by nutlin 
therapy in childhood cancer. Cancer Lett 344: 157-165. 
199. Joseph, T. L., A. Madhumalar, C. J. Brown, D. P. Lane, and C. S. Verma. 
2010. Differential binding of p53 and nutlin to MDM2 and MDMX: 
computational studies. Cell Cycle 9: 1167-1181. 
200. Deshaies, R. J., and C. A. Joazeiro. 2009. RING domain E3 ubiquitin ligases. 
Annu Rev Biochem 78: 399-434. 
201. Petroski, M. D., and R. J. Deshaies. 2005. Function and regulation of cullin-
RING ubiquitin ligases. Nat Rev Mol Cell Biol 6: 9-20. 
202. Bielskiene, K., L. Bagdoniene, J. Mozuraitiene, B. Kazbariene, and E. 
Janulionis. 2015. E3 ubiquitin ligases as drug targets and prognostic 
biomarkers in melanoma. Medicina (Kaunas) 51: 1-9. 
203. Aghajan, M., N. Jonai, K. Flick, F. Fu, M. Luo, X. Cai, I. Ouni, N. Pierce, X. 
Tang, B. Lomenick, R. Damoiseaux, R. Hao, P. M. Del Moral, R. Verma, Y. 
Li, C. Li, K. N. Houk, M. E. Jung, N. Zheng, L. Huang, R. J. Deshaies, P. 
Kaiser, and J. Huang. 2010. Chemical genetics screen for enhancers of 
175 
 
rapamycin identifies a specific inhibitor of an SCF family E3 ubiquitin ligase. 
Nat Biotechnol 28: 738-742. 
204. Mallampalli, R. K., T. A. Coon, J. R. Glasser, C. Wang, S. R. Dunn, N. M. 
Weathington, J. Zhao, C. Zou, Y. Zhao, and B. B. Chen. 2013. Targeting F 
box protein Fbxo3 to control cytokine-driven inflammation. J Immunol 191: 
5247-5255. 
205. Chen, B. B., T. A. Coon, J. R. Glasser, B. J. McVerry, J. Zhao, Y. Zhao, C. 
Zou, B. Ellis, F. C. Sciurba, Y. Zhang, and R. K. Mallampalli. 2013. A 
combinatorial F box protein directed pathway controls TRAF adaptor stability 
to regulate inflammation. Nat Immunol 14: 470-479. 
206. Frescas, D., and M. Pagano. 2008. Deregulated proteolysis by the F-box 
proteins SKP2 and beta-TrCP: tipping the scales of cancer. Nat Rev Cancer 8: 
438-449. 
207. Skaar, J. R., J. K. Pagan, and M. Pagano. 2014. SCF ubiquitin ligase-targeted 
therapies. Nat Rev Drug Discov 13: 889-903. 
208. Klein, C., and L. T. Vassilev. 2004. Targeting the p53-MDM2 interaction to 
treat cancer. Br J Cancer 91: 1415-1419. 
209. Deshaies, R. J. 1999. SCF and Cullin/Ring H2-based ubiquitin ligases. Annual 
review of cell and developmental biology 15: 435-467. 
210. Koepp, D. M., J. W. Harper, and S. J. Elledge. 1999. How the cyclin became a 
cyclin: regulated proteolysis in the cell cycle. Cell 97: 431-434. 
176 
 
211. Miyamoto, T., A. Horiuchi, H. Kashima, A. Suzuki, T. Yamada, M. Kurai, I. 
Konishi, and T. Shiozawa. 2010. Inverse correlation between Skp2 and 
p27(Kip1) in normal endometrium and endometrial carcinoma. Gynecol 
Endocrinol 26: 220-229. 
212. Fukuchi, M., N. Masuda, M. Nakajima, Y. Fukai, T. Miyazaki, H. Kato, and 
H. Kuwano. 2004. Inverse correlation between expression levels of p27 and 
the ubiquitin ligase subunit Skp2 in early esophageal squamous cell 
carcinoma. Anticancer Res 24: 777-783. 
213. Li, Q., M. Murphy, J. Ross, C. Sheehan, and J. A. Carlson. 2004. Skp2 and 
p27kip1 expression in melanocytic nevi and melanoma: an inverse 
relationship. J Cutan Pathol 31: 633-642. 
214. Gao, D., H. Inuzuka, A. Tseng, R. Y. Chin, A. Toker, and W. Wei. 2009. 
Phosphorylation by Akt1 promotes cytoplasmic localization of Skp2 and 
impairs APCCdh1-mediated Skp2 destruction. Nat Cell Biol 11: 397-408. 
215. Cardozo, T., and M. Pagano. 2004. The SCF ubiquitin ligase: insights into a 
molecular machine. Nat Rev Mol Cell Biol 5: 739-751. 
216. Ganoth, D., G. Bornstein, T. K. Ko, B. Larsen, M. Tyers, M. Pagano, and A. 
Hershko. 2001. The cell-cycle regulatory protein Cks1 is required for 
SCF(Skp2)-mediated ubiquitinylation of p27. Nat Cell Biol 3: 321-324. 
217. Spruck, C., H. Strohmaier, M. Watson, A. P. Smith, A. Ryan, T. W. Krek, and 
S. I. Reed. 2001. A CDK-independent function of mammalian Cks1: targeting 
of SCF(Skp2) to the CDK inhibitor p27Kip1. Mol Cell 7: 639-650. 
177 
 
218. Dobashi, Y., H. Tsubochi, K. Minegishi, M. Kitagawa, S. Otani, and A. Ooi. 
2017. Regulation of p27 by ubiquitin ligases and its pathological significance 
in human lung carcinomas. Hum Pathol. 
219. Evans, L., L. Chen, G. Milazzo, S. Gherardi, G. Perini, E. Willmore, D. R. 
Newell, and D. A. Tweddle. 2015. SKP2 is a direct transcriptional target of 
MYCN and a potential therapeutic target in neuroblastoma. Cancer letters 
363: 37-45. 
220. Schiffer, D., P. Cavalla, V. Fiano, C. Ghimenti, and R. Piva. 2002. Inverse 
relationship between p27/Kip.1 and the F-box protein Skp2 in human 
astrocytic gliomas by immunohistochemistry and Western blot. Neurosci Lett 
328: 125-128. 
221. Lu, H., X. Cao, H. Zhang, G. Sun, G. Fan, L. Chen, and S. Wang. 2014. 
Imbalance between MMP-2, 9 and TIMP-1 promote the invasion and 
metastasis of renal cell carcinoma via SKP2 signaling pathways. Tumour Biol 
35: 9807-9813. 
222. Chen, H., X. Mo, J. Yu, S. Huang, Z. Huang, and L. Gao. 2014. Interference 
of Skp2 effectively inhibits the development and metastasis of colon 
carcinoma. Mol Med Rep 10: 1129-1135. 
223. Tian, Y. F., T. J. Chen, C. Y. Lin, L. T. Chen, L. C. Lin, C. H. Hsing, S. W. 
Lee, M. J. Sheu, H. H. Lee, Y. L. Shiue, H. Y. Huang, H. Y. Pan, C. F. Li, and 
S. H. Chen. 2013. SKP2 overexpression is associated with a poor prognosis of 
178 
 
rectal cancer treated with chemoradiotherapy and represents a therapeutic 
target with high potential. Tumour Biol 34: 1107-1117. 
224. Zhang, B., L. H. Ji, W. Liu, G. Zhao, and Z. Y. Wu. 2013. Skp2-RNAi 
suppresses proliferation and migration of gallbladder carcinoma cells by 
enhancing p27 expression. World J Gastroenterol 19: 4917-4924. 
225. Lv, A., Z. Li, X. Tian, X. Guan, M. Zhao, B. Dong, and C. Hao. 2013. SKP2 
high expression, KIT exon 11 deletions, and gastrointestinal bleeding as 
predictors of poor prognosis in primary gastrointestinal stromal tumors. PloS 
one 8: e62951. 
226. Liang, Y., X. Hou, Q. Cui, T. B. Kang, J. H. Fu, L. J. Zhang, R. Z. Luo, J. H. 
He, Y. X. Zeng, and H. X. Yang. 2012. Skp2 expression unfavorably impacts 
survival in resectable esophageal squamous cell carcinoma. J Transl Med 10: 
73. 
227. Kudo, Y., S. Kitajima, S. Sato, M. Miyauchi, I. Ogawa, and T. Takata. 2001. 
High expression of S-phase kinase-interacting protein 2, human F-box protein, 
correlates with poor prognosis in oral squamous cell carcinomas. Cancer Res 
61: 7044-7047. 
228. Ding, L., R. Li, X. Han, Y. Zhou, H. Zhang, Y. Cui, W. Wang, and J. Bai. 
2017. Inhibition of Skp2 suppresses the proliferation and invasion of 
osteosarcoma cells. Oncology reports 38: 933-940. 
229. Fu, H. C., Y. C. Yang, Y. J. Chen, H. Lin, Y. C. Ou, C. C. Chien, E. Y. 
Huang, H. Y. Huang, J. Lan, H. P. Chi, K. E. Huang, and H. Y. Kang. 2016. 
179 
 
Increased expression of SKP2 is an independent predictor of locoregional 
recurrence in cervical cancer via promoting DNA-damage response after 
irradiation. Oncotarget 7: 44047-44061. 
230. Yang, Q., J. Huang, Q. Wu, Y. Cai, L. Zhu, X. Lu, S. Chen, C. Chen, and Z. 
Wang. 2014. Acquisition of epithelial-mesenchymal transition is associated 
with Skp2 expression in paclitaxel-resistant breast cancer cells. Br J Cancer 
110: 1958-1967. 
231. Gao, H., M. Yang, and X. Zhang. 2018. Investigating a multigene prognostic 
assay based on significant pathways for Luminal A breast cancer through gene 
expression profile analysis. . Oncology Letters 0. 
232. Rose, A. E., G. Wang, D. Hanniford, S. Monni, T. Tu, R. L. Shapiro, R. S. 
Berman, A. C. Pavlick, M. Pagano, F. Darvishian, M. Mazumdar, E. 
Hernando, and I. Osman. 2011. Clinical relevance of SKP2 alterations in 
metastatic melanoma. Pigment Cell Melanoma Res 24: 197-206. 
233. Gao, J., B. A. Aksoy, U. Dogrusoz, G. Dresdner, B. Gross, S. O. Sumer, Y. 
Sun, A. Jacobsen, R. Sinha, E. Larsson, E. Cerami, C. Sander, and N. Schultz. 
2013. Integrative analysis of complex cancer genomics and clinical profiles 
using the cBioPortal. Sci Signal 6: pl1. 
234. Chan, C. H., C. F. Li, W. L. Yang, Y. Gao, S. W. Lee, Z. Feng, H. Y. Huang, 
K. K. Tsai, L. G. Flores, Y. Shao, J. D. Hazle, D. Yu, W. Wei, D. Sarbassov, 
M. C. Hung, K. I. Nakayama, and H. K. Lin. 2012. The Skp2-SCF E3 ligase 
180 
 
regulates Akt ubiquitination, glycolysis, herceptin sensitivity, and 
tumorigenesis. Cell 149: 1098-1111. 
235. Lee, S. W., C. F. Li, G. Jin, Z. Cai, F. Han, C. H. Chan, W. L. Yang, B. K. Li, 
A. H. Rezaeian, H. Y. Li, H. Y. Huang, and H. K. Lin. 2015. Skp2-Dependent 
Ubiquitination and Activation of LKB1 Is Essential for Cancer Cell Survival 
under Energy Stress. Mol Cell 57: 1022-1033. 
236. Bencivenga, D., I. Caldarelli, E. Stampone, F. P. Mancini, M. L. Balestrieri, F. 
Della Ragione, and A. Borriello. 2017. p27(Kip1) and human cancers: A 
reappraisal of a still enigmatic protein. Cancer Lett 403: 354-365. 
237. Zehir, A., R. Benayed, R. H. Shah, A. Syed, S. Middha, H. R. Kim, P. 
Srinivasan, J. Gao, D. Chakravarty, S. M. Devlin, M. D. Hellmann, D. A. 
Barron, A. M. Schram, M. Hameed, S. Dogan, D. S. Ross, J. F. Hechtman, D. 
F. DeLair, J. Yao, D. L. Mandelker, D. T. Cheng, R. Chandramohan, A. S. 
Mohanty, R. N. Ptashkin, G. Jayakumaran, M. Prasad, M. H. Syed, A. B. 
Rema, Z. Y. Liu, K. Nafa, L. Borsu, J. Sadowska, J. Casanova, R. Bacares, I. 
J. Kiecka, A. Razumova, J. B. Son, L. Stewart, T. Baldi, K. A. Mullaney, H. 
Al-Ahmadie, E. Vakiani, A. A. Abeshouse, A. V. Penson, P. Jonsson, N. 
Camacho, M. T. Chang, H. H. Won, B. E. Gross, R. Kundra, Z. J. Heins, H. 
W. Chen, S. Phillips, H. Zhang, J. Wang, A. Ochoa, J. Wills, M. Eubank, S. B. 
Thomas, S. M. Gardos, D. N. Reales, J. Galle, R. Durany, R. Cambria, W. 
Abida, A. Cercek, D. R. Feldman, M. M. Gounder, A. A. Hakimi, J. J. 
Harding, G. Iyer, Y. Y. Janjigian, E. J. Jordan, C. M. Kelly, M. A. Lowery, L. 
181 
 
G. T. Morris, A. M. Omuro, N. Raj, P. Razavi, A. N. Shoushtari, N. Shukla, T. 
E. Soumerai, A. M. Varghese, R. Yaeger, J. Coleman, B. Bochner, G. J. Riely, 
L. B. Saltz, H. I. Scher, P. J. Sabbatini, M. E. Robson, D. S. Klimstra, B. S. 
Taylor, J. Baselga, N. Schultz, D. M. Hyman, M. E. Arcila, D. B. Solit, M. 
Ladanyi, and M. F. Berger. 2017. Mutational landscape of metastatic cancer 
revealed from prospective clinical sequencing of 10,000 patients. Nat Med 23: 
703-713. 
238. Kamura, T., T. Hara, M. Matsumoto, N. Ishida, F. Okumura, S. Hatakeyama, 
M. Yoshida, K. Nakayama, and K. I. Nakayama. 2004. Cytoplasmic ubiquitin 
ligase KPC regulates proteolysis of p27(Kip1) at G1 phase. Nat Cell Biol 6: 
1229-1235. 
239. Ishida, N., T. Hara, T. Kamura, M. Yoshida, K. Nakayama, and K. I. 
Nakayama. 2002. Phosphorylation of p27Kip1 on serine 10 is required for its 
binding to CRM1 and nuclear export. J Biol Chem 277: 14355-14358. 
240. Denicourt, C., C. C. Saenz, B. Datnow, X. S. Cui, and S. F. Dowdy. 2007. 
Relocalized p27Kip1 tumor suppressor functions as a cytoplasmic metastatic 
oncogene in melanoma. Cancer Res 67: 9238-9243. 
241. 2006. DiverSet; ChemBridge Corp.: San Diego, CA. 
242. Hao, B., N. Zheng, B. A. Schulman, G. Wu, J. J. Miller, M. Pagano, and N. P. 
Pavletich. 2005. Structural basis of the Cks1-dependent recognition of 
p27(Kip1) by the SCF(Skp2) ubiquitin ligase. Mol Cell 20: 9-19. 
182 
 
243. Schulman, B. A., A. C. Carrano, P. D. Jeffrey, Z. Bowen, E. R. Kinnucan, M. 
S. Finnin, S. J. Elledge, J. W. Harper, M. Pagano, and N. P. Pavletich. 2000. 
Insights into SCF ubiquitin ligases from the structure of the Skp1-Skp2 
complex. Nature 408: 381-386. 
244. Morrow, J. K., and S. Zhang. 2012. Computational prediction of protein hot 
spot residues. Curr Pharm Des 18: 1255-1265. 
245. Zheng, N., B. A. Schulman, L. Song, J. J. Miller, P. D. Jeffrey, P. Wang, C. 
Chu, D. M. Koepp, S. J. Elledge, M. Pagano, R. C. Conaway, J. W. Conaway, 
J. W. Harper, and N. P. Pavletich. 2002. Structure of the Cul1-Rbx1-Skp1-F 
boxSkp2 SCF ubiquitin ligase complex. Nature 416: 703-709. 
246. Sussman, J. L., D. Lin, J. Jiang, N. O. Manning, J. Prilusky, O. Ritter, and E. 
E. Abola. 1998. Protein Data Bank (PDB): database of three-dimensional 
structural information of biological macromolecules. Acta Crystallogr D Biol 
Crystallogr 54: 1078-1084. 
247. 2009. The PyMOL Molecular Graphics System, Version 1.2r1, Schr”dinger, 
LLC. 
248. 2009. Molecular Operating Environment (MOE), developed and distributed by 
Chemical Computing Group  http://www.chemcomp.com/software-
moe2009.htm  
249. Zhang, S., and L. Du-Cuny. 2009. Development and evaluation of a new 
statistical model for structure-based high-throughput virtual screening. Int J 
Bioinform.Res Appl. 5: 269-279. 
183 
 
250. Zhang, S., K. Kumar, X. Jiang, A. Wallqvist, and J. Reifman. 2008. DOVIS: 
an implementation for high-throughput virtual screening using AutoDock. 
BMC.Bioinformatics. 9: 126. 
251. Verdonk, M. L., J. C. Cole, M. J. Hartshorn, C. W. Murray, and R. D. Taylor. 
2003. Improved protein-ligand docking using GOLD. Proteins 52: 609-623. 
252. Yang, W. L., J. Wang, C. H. Chan, S. W. Lee, A. D. Campos, B. Lamothe, L. 
Hur, B. C. Grabiner, X. Lin, B. G. Darnay, and H. K. Lin. 2009. The E3 ligase 
TRAF6 regulates Akt ubiquitination and activation. Science 325: 1134-1138. 
253. Li, T., N. P. Pavletich, B. A. Schulman, and N. Zheng. 2005. High-level 
expression and purification of recombinant SCF ubiquitin ligases. Methods 
Enzymol 398: 125-142. 
254. Wang, L., W. Zhang, Q. Gao, and C. Xiong. 2014. Prediction of hot spots in 
protein interfaces using extreme learning machines with the information of 
spatial neighbour residues. IET Syst Biol 8: 184-190. 
255. Hui-fang, L., S. Qing, Z. Jian, and F. Wei. 2010. Evaluation of various inverse 
docking schemes in multiple targets identification. J Mol Graph Model 29: 
326-330. 
256. Plewczynski, D., M. Lazniewski, R. Augustyniak, and K. Ginalski. 2011. Can 
we trust docking results? Evaluation of seven commonly used programs on 
PDBbind database. J Comput Chem 32: 742-755. 
184 
 
257. Li, X., Y. Li, T. Cheng, Z. Liu, and R. Wang. 2010. Evaluation of the 
performance of four molecular docking programs on a diverse set of protein-
ligand complexes. J Comput Chem 31: 2109-2125. 
258. Suzuki, H., T. Chiba, T. Suzuki, T. Fujita, T. Ikenoue, M. Omata, K. Furuichi, 
H. Shikama, and K. Tanaka. 2000. Homodimer of two F-box proteins 
betaTrCP1 or betaTrCP2 binds to IkappaBalpha for signal-dependent 
ubiquitination. J Biol Chem 275: 2877-2884. 
259. Wang, L., X. Ye, Y. Liu, W. Wei, and Z. Wang. 2014. Aberrant regulation of 
FBW7 in cancer. Oncotarget 5: 2000-2015. 
260. Sigrist, C. J., E. de Castro, L. Cerutti, B. A. Cuche, N. Hulo, A. Bridge, L. 
Bougueleret, and I. Xenarios. 2013. New and continuing developments at 
PROSITE. Nucleic Acids Res 41: D344-347. 
261. Huang, H. C., C. L. Lin, and J. K. Lin. 2011. 1,2,3,4,6-penta-O-galloyl-beta-
D-glucose, quercetin, curcumin and lycopene induce cell-cycle arrest in 
MDA-MB-231 and BT474 cells through downregulation of Skp2 protein. J 
Agric Food Chem 59: 6765-6775. 
262. Chen, X. M., Y. Bai, Y. J. Zhong, X. L. Xie, H. W. Long, Y. Y. Yang, S. G. 
Wu, Q. Jia, and X. H. Wang. 2013. Wogonin has multiple anti-cancer effects 
by regulating c-Myc/SKP2/Fbw7alpha and HDAC1/HDAC2 pathways and 
inducing apoptosis in human lung adenocarcinoma cell line A549. PLoS One 
8: e79201. 
185 
 
263. Zhao, K., L. Wei, H. Hui, Q. Dai, Q. D. You, Q. L. Guo, and N. Lu. 2014. 
Wogonin suppresses melanoma cell B16-F10 invasion and migration by 
inhibiting Ras-medicated pathways. PLoS One 9: e106458. 
264. Hong, M., H. Cheng, L. Song, W. Wang, Q. Wang, D. Xu, and W. Xing. 
2018. Wogonin Suppresses the Activity of Matrix Metalloproteinase-9 and 
Inhibits Migration and Invasion in Human Hepatocellular Carcinoma. 
Molecules 23. 
265. Meng, S., B. Wu, R. Singh, T. Yin, J. K. Morrow, S. Zhang, and M. Hu. 2012. 
SULT1A3-mediated regiospecific 7-O-sulfation of flavonoids in Caco-2 cells 
can be explained by the relevant molecular docking studies. Mol Pharm 9: 
862-873. 
266. Chen, J., H. Lin, and M. Hu. 2005. Absorption and metabolism of genistein 
and its five isoflavone analogs in the human intestinal Caco-2 model. Cancer 
Chemother Pharmacol 55: 159-169. 
267. Vervoorts, J., and B. Luscher. 2008. Post-translational regulation of the tumor 
suppressor p27(KIP1). Cell Mol Life Sci 65: 3255-3264. 
268. Cavasotto, C. N., and S. S. Phatak. 2009. Homology modeling in drug 
discovery: current trends and applications. Drug Discov Today 14: 676-683. 
269. Daga, P. R., R. Y. Patel, and R. J. Doerksen. 2010. Template-based protein 
modeling: recent methodological advances. Curr Top Med Chem 10: 84-94. 
270. Malmstrom, L., and D. R. Goodlett. 2010. Protein structure modeling. 
Methods Mol Biol 673: 63-72. 
186 
 
271. Grant, M. A. 2009. Protein structure prediction in structure-based ligand 
design and virtual screening. Comb Chem High Throughput Screen 12: 940-
960. 
272. Liu, X., D. Shi, S. Zhou, H. Liu, H. Liu, and X. Yao. 2018. Molecular 
dynamics simulations and novel drug discovery. Expert Opin Drug Discov 13: 
23-37. 
273. Hao, B., S. Oehlmann, M. E. Sowa, J. W. Harper, and N. P. Pavletich. 2007. 
Structure of a Fbw7-Skp1-cyclin E complex: multisite-phosphorylated 
substrate recognition by SCF ubiquitin ligases. Mol Cell 26: 131-143. 
274. Sali, A., and T. L. Blundell. 1993. Comparative protein modelling by 
satisfaction of spatial restraints. J Mol Biol 234: 779-815. 
275. Case, D. A., T. E. Cheatham, 3rd, T. Darden, H. Gohlke, R. Luo, K. M. Merz, 
Jr., A. Onufriev, C. Simmerling, B. Wang, and R. J. Woods. 2005. The Amber 
biomolecular simulation programs. J Comput Chem 26: 1668-1688. 
276. Maier, J. A., C. Martinez, K. Kasavajhala, L. Wickstrom, K. E. Hauser, and C. 
Simmerling. 2015. ff14SB: Improving the Accuracy of Protein Side Chain and 
Backbone Parameters from ff99SB. J Chem Theory Comput 11: 3696-3713. 
277. Mahoney, M. W., and W. L. Jorgensen. 2000. A five-site model for liquid 
water and the reproduction of the density anomaly by rigid, nonpolarizable 
potential functions. J Chem Phys 112: 8910-8922. 
187 
 
278. Roe, D. R., and T. E. Cheatham, 3rd. 2013. PTRAJ and CPPTRAJ: Software 
for Processing and Analysis of Molecular Dynamics Trajectory Data. J Chem 
Theory Comput 9: 3084-3095. 
279. Kim, S., P. A. Thiessen, E. E. Bolton, J. Chen, G. Fu, A. Gindulyte, L. Han, J. 
He, S. He, B. A. Shoemaker, J. Wang, B. Yu, J. Zhang, and S. H. Bryant. 
2016. PubChem Substance and Compound databases. Nucleic Acids Res 44: 
D1202-1213. 
280. Huang, H., K. M. Regan, F. Wang, D. Wang, D. I. Smith, J. M. van Deursen, 
and D. J. Tindall. 2005. Skp2 inhibits FOXO1 in tumor suppression through 
ubiquitin-mediated degradation. Proceedings of the National Academy of 
Sciences of the United States of America 102: 1649-1654. 
281. Hnit, S. S., C. Xie, M. Yao, J. Holst, A. Bensoussan, P. De Souza, Z. Li, and 
Q. Dong. 2015. p27(Kip1) signaling: Transcriptional and post-translational 
regulation. Int J Biochem Cell Biol 68: 9-14. 
282. Rahman, K., P. Zhao, M. Mandalasi, H. van der Wel, L. Wells, I. J. Blader, 
and C. M. West. 2016. The E3 Ubiquitin Ligase Adaptor Protein Skp1 Is 
Glycosylated by an Evolutionarily Conserved Pathway That Regulates Protist 
Growth and Development. J Biol Chem 291: 4268-4280. 
283. Sheikh, M. O., Y. Xu, H. van der Wel, P. Walden, S. D. Hartson, and C. M. 
West. 2015. Glycosylation of Skp1 promotes formation of Skp1-cullin-1-F-
box protein complexes in dictyostelium. Mol Cell Proteomics 14: 66-80. 
188 
 
284. Wada, H., E. T. Yeh, and T. Kamitani. 1999. Identification of NEDD8-
conjugation site in human cullin-2. Biochemical and biophysical research 
communications 257: 100-105. 
285. Morimoto, M., T. Nishida, R. Honda, and H. Yasuda. 2000. Modification of 
cullin-1 by ubiquitin-like protein Nedd8 enhances the activity of SCF(skp2) 
toward p27(kip1). Biochem Biophys Res Commun 270: 1093-1096. 
286. Enchev, R. I., B. A. Schulman, and M. Peter. 2015. Protein neddylation: 
beyond cullin-RING ligases. Nat Rev Mol Cell Biol 16: 30-44. 
287. Lydeard, J. R., B. A. Schulman, and J. W. Harper. 2013. Building and 
remodelling Cullin-RING E3 ubiquitin ligases. EMBO Rep 14: 1050-1061. 
288. Duda, D. M., D. C. Scott, M. F. Calabrese, E. S. Zimmerman, N. Zheng, and 
B. A. Schulman. 2011. Structural regulation of cullin-RING ubiquitin ligase 
complexes. Curr Opin Struct Biol 21: 257-264. 
289. Inuzuka, H., D. Gao, L. W. Finley, W. Yang, L. Wan, H. Fukushima, Y. R. 
Chin, B. Zhai, S. Shaik, A. W. Lau, Z. Wang, S. P. Gygi, K. Nakayama, J. 
Teruya-Feldstein, A. Toker, M. C. Haigis, P. P. Pandolfi, and W. Wei. 2012. 
Acetylation-dependent regulation of Skp2 function. Cell 150: 179-193. 
290. Obata, T., M. B. Yaffe, G. G. Leparc, E. T. Piro, H. Maegawa, A. Kashiwagi, 
R. Kikkawa, and L. C. Cantley. 2000. Peptide and protein library screening 
defines optimal substrate motifs for AKT/PKB. The Journal of biological 
chemistry 275: 36108-36115. 
189 
 
291. Lin, H. K., G. Wang, Z. Chen, J. Teruya-Feldstein, Y. Liu, C. H. Chan, W. L. 
Yang, H. Erdjument-Bromage, K. I. Nakayama, S. Nimer, P. Tempst, and P. 
P. Pandolfi. 2009. Phosphorylation-dependent regulation of cytosolic 
localization and oncogenic function of Skp2 by Akt/PKB. Nat Cell Biol 11: 
420-432. 
292. Rodier, G., P. Coulombe, P. L. Tanguay, C. Boutonnet, and S. Meloche. 2008. 
Phosphorylation of Skp2 regulated by CDK2 and Cdc14B protects it from 
degradation by APC(Cdh1) in G1 phase. The EMBO journal 27: 679-691. 
293. Bashir, T., J. K. Pagan, L. Busino, and M. Pagano. 2010. Phosphorylation of 
Ser72 is dispensable for Skp2 assembly into an active SCF ubiquitin ligase 
and its subcellular localization. Cell cycle 9: 971-974. 
294. Boutonnet, C., P. L. Tanguay, C. Julien, G. Rodier, P. Coulombe, and S. 
Meloche. 2010. Phosphorylation of Ser72 does not regulate the ubiquitin 
ligase activity and subcellular localization of Skp2. Cell cycle 9: 975-979. 
295. Zhou, H., S. Di Palma, C. Preisinger, M. Peng, A. N. Polat, A. J. Heck, and S. 
Mohammed. 2013. Toward a comprehensive characterization of a human 
cancer cell phosphoproteome. J Proteome Res 12: 260-271. 
296. Gao, D., H. Inuzuka, A. Tseng, and W. Wei. 2009. Akt finds its new path to 
regulate cell cycle through modulating Skp2 activity and its destruction by 
APC/Cdh1. Cell Div 4: 11. 
190 
 
297. Geng, Q., J. Liu, Z. Gong, S. Chen, S. Chen, X. Li, Y. Lu, X. Zhu, H. K. Lin, 
and D. Xu. 2017. Phosphorylation by mTORC1 stablizes Skp2 and regulates 
its oncogenic function in gastric cancer. Mol Cancer 16: 83. 
298. Zachariae, W., and K. Nasmyth. 1999. Whose end is destruction: cell division 
and the anaphase-promoting complex. Genes & development 13: 2039-2058. 
299. Wei, W., N. G. Ayad, Y. Wan, G. J. Zhang, M. W. Kirschner, and W. G. 
Kaelin, Jr. 2004. Degradation of the SCF component Skp2 in cell-cycle phase 
G1 by the anaphase-promoting complex. Nature 428: 194-198. 
300. Najmanovich, R., J. Kuttner, V. Sobolev, and M. Edelman. 2000. Side-chain 
flexibility in proteins upon ligand binding. Proteins 39: 261-268. 
301. Moras, D., and H. Gronemeyer. 1998. The nuclear receptor ligand-binding 
domain: structure and function. Current opinion in cell biology 10: 384-391. 
302. Skwarczynska, M., and C. Ottmann. 2015. Protein-protein interactions as drug 
targets. Future Med Chem 7: 2195-2219. 
303. Makley, L. N., and J. E. Gestwicki. 2013. Expanding the number of 
'druggable' targets: non-enzymes and protein-protein interactions. Chem Biol 
Drug Des 81: 22-32. 
304. Guo, W., J. A. Wisniewski, and H. Ji. 2014. Hot spot-based design of small-
molecule inhibitors for protein-protein interactions. Bioorg Med Chem Lett 24: 
2546-2554. 
305. Ge, H., Y. Wang, C. Li, N. Chen, Y. Xie, M. Xu, Y. He, X. Gu, R. Wu, Q. Gu, 
L. Zeng, and J. Xu. 2013. Molecular dynamics-based virtual screening: 
191 
 
accelerating the drug discovery process by high-performance computing. J 
Chem Inf Model 53: 2757-2764. 
306. Kutzner, C., S. Pall, M. Fechner, A. Esztermann, B. L. de Groot, and H. 
Grubmuller. 2015. Best bang for your buck: GPU nodes for GROMACS 
biomolecular simulations. J Comput Chem 36: 1990-2008. 
307. Purawat, S., P. U. Ieong, R. D. Malmstrom, G. J. Chan, A. K. Yeung, R. C. 
Walker, I. Altintas, and R. E. Amaro. 2017. A Kepler Workflow Tool for 
Reproducible AMBER GPU Molecular Dynamics. Biophys J 112: 2469-2474. 
308. Martinez-Rosell, G., T. Giorgino, M. J. Harvey, and G. de Fabritiis. 2017. 
Drug Discovery and Molecular Dynamics: Methods, Applications and 
Perspective Beyond the Second Timescale. Curr Top Med Chem 17: 2617-
2625. 
309. Rotin, D., and S. Kumar. 2009. Physiological functions of the HECT family of 
ubiquitin ligases. Nat Rev Mol Cell Biol 10: 398-409. 
310. Le, X. F., W. Mao, G. He, F. X. Claret, W. Xia, A. A. Ahmed, M. C. Hung, Z. 
H. Siddik, and R. C. Bast, Jr. 2011. The role of p27(Kip1) in dasatinib-
enhanced paclitaxel cytotoxicity in human ovarian cancer cells. J Natl Cancer 
Inst 103: 1403-1422. 
311. Le, X. F., F. Pruefer, and R. C. Bast, Jr. 2005. HER2-targeting antibodies 
modulate the cyclin-dependent kinase inhibitor p27Kip1 via multiple signaling 
pathways. Cell Cycle 4: 87-95. 
192 
 
312. Le, X. F., F. X. Claret, A. Lammayot, L. Tian, D. Deshpande, R. LaPushin, A. 
M. Tari, and R. C. Bast, Jr. 2003. The role of cyclin-dependent kinase 
inhibitor p27Kip1 in anti-HER2 antibody-induced G1 cell cycle arrest and 
tumor growth inhibition. J Biol Chem 278: 23441-23450. 
313. He, G., J. Kuang, Z. Huang, J. Koomen, R. Kobayashi, A. R. Khokhar, and Z. 
H. Siddik. 2006. Upregulation of p27 and its inhibition of CDK2/cyclin E 
activity following DNA damage by a novel platinum agent are dependent on 
the expression of p21. Br J Cancer 95: 1514-1524. 
314. Shirane, M., Y. Harumiya, N. Ishida, A. Hirai, C. Miyamoto, S. Hatakeyama, 
K. Nakayama, and M. Kitagawa. 1999. Down-regulation of p27(Kip1) by two 
mechanisms, ubiquitin-mediated degradation and proteolytic processing. J 
Biol Chem 274: 13886-13893. 
315. Shoemaker, R. H. 2006. The NCI60 human tumour cell line anticancer drug 
screen. Nat Rev Cancer 6: 813-823. 
316. Hughes, T. R., M. J. Marton, A. R. Jones, C. J. Roberts, R. Stoughton, C. D. 
Armour, H. A. Bennett, E. Coffey, H. Dai, Y. D. He, M. J. Kidd, A. M. King, 
M. R. Meyer, D. Slade, P. Y. Lum, S. B. Stepaniants, D. D. Shoemaker, D. 
Gachotte, K. Chakraburtty, J. Simon, M. Bard, and S. H. Friend. 2000. 
Functional discovery via a compendium of expression profiles. Cell 102: 109-
126. 
193 
 
317. Gardner, T. S., D. di Bernardo, D. Lorenz, and J. J. Collins. 2003. Inferring 
genetic networks and identifying compound mode of action via expression 
profiling. Science 301: 102-105. 
318. Lamb, J., E. D. Crawford, D. Peck, J. W. Modell, I. C. Blat, M. J. Wrobel, J. 
Lerner, J. P. Brunet, A. Subramanian, K. N. Ross, M. Reich, H. Hieronymus, 
G. Wei, S. A. Armstrong, S. J. Haggarty, P. A. Clemons, R. Wei, S. A. Carr, 
E. S. Lander, and T. R. Golub. 2006. The Connectivity Map: using gene-
expression signatures to connect small molecules, genes, and disease. Science 
313: 1929-1935. 
319. Hieronymus, H., J. Lamb, K. N. Ross, X. P. Peng, C. Clement, A. Rodina, M. 
Nieto, J. Du, K. Stegmaier, S. M. Raj, K. N. Maloney, J. Clardy, W. C. Hahn, 
G. Chiosis, and T. R. Golub. 2006. Gene expression signature-based chemical 
genomic prediction identifies a novel class of HSP90 pathway modulators. 
Cancer Cell 10: 321-330. 
320. Jiang, H., J. R. Pritchard, R. T. Williams, D. A. Lauffenburger, and M. T. 
Hemann. 2011. A mammalian functional-genetic approach to characterizing 
cancer therapeutics. Nat Chem Biol 7: 92-100. 
 
  
194 
 
Vita 
John Kenneth Morrow was born in Woodland, California, the son of Philip 
Ross Morrow and Jeanne Morrow. After completing his Bachelor of Science degree 
at University of California at Berkeley in 2007 in Molecular Toxicology, he obtained 
his Master’s degree from University of Texas MD Anderson Cancer Center UTHealth 
Graduate School of Biomedical Sciences at Houston in Experimental Therapeutics in 
2012. In September of 2012, he entered the Experimental Therapeutics Ph.D. program 
in the University Of Texas MD Anderson Cancer Center UTHealth Graduate School 
Of Biomedical Sciences at Houston. 
 
